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ABSTRACT
CHRONIC STRESS AND REPRODUCTIVE FUNCTION IN FEMALE
CHILDHOOD CANCER SURVIVORS
Theresa M. Hardy, BA, BSN
Marquette University, 2018
Reproductive dysfunction is reported as a major concern for childhood
cancer survivors (CCS) and is highly correlated with quality of life in this
population. Few predictors of post-treatment reproductive function in CCS have
been identified. CCS report high levels of psychological stress. Psychological
stress activates the hypothalamic-pituitary-adrenal axis, which can disrupt
reproductive function.
The purpose of this exploratory study was to explore the relationship
between perceived stress, biomarkers of hypothalamic-pituitary-adrenal activity,
gonadotropin levels, and anti-Müllerian hormone levels in female CCS.
This exploratory cross-sectional study included female cancer survivors
(ages 16-35) treated for pediatric cancer at the Royal Hospital for Sick Children
in Edinburgh, Scotland. Perceived stress was measured using the Perceived
Stress Scale (PSS-10). Hypothalamic-pituitary-adrenal activity (HPA) was
measured using salivary and hair cortisol levels. Ovarian function was measured
using serum gonadotropin levels and serum anti-Müllerian hormone levels.
Latent growth curve modeling was used to determine diurnal cortisol slope and
intercept. Bayesian structural equation modeling was used to explore the
relationship between perceived stress, biomarkers of HPA activity and ovarian
function.
Twenty-four female (mean age 21.79 ± 5.68) CCS were included in the
study. We found an inverse association between perceived stress and ovarian
function and a positive association between biomarkers of HPA activity and
ovarian function.
The findings from this study suggest that perceived stress is negatively
associated with ovarian function and that threshold cortisol levels are required for
healthy ovarian function in female childhood cancer survivors.
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Chapter 1. Introduction
Significance
An estimated one in 1000 adults under the age of 35 is a survivor of
childhood cancer (Blumenfeld, 2012). Due to significant advances in the
treatment of pediatric cancer, the five year survival rate now exceeds 80% in the
United States (Barton et al., 2013) with similar statistics worldwide (Reinmuth et
al., 2013). With an increasing number of survivors, there has been growing
recognition of the potential late effects of cancer treatment (Kremer et al., 2013).
Reproductive dysfunction is one such major concern for cancer survivors, and is
highly correlated with quality of life in this population (Cherven, Mertens,
Wasilewski-Masker, Williamson, & Meacham, 2015; Knopman, Papadopoulos,
Grifo, Fino, & Noyes, 2010; Letourneau, Chan, & Rosen, 2013). Among female
childhood cancer survivors (CCS), 6.3% suffer from acute ovarian failure and
another 22.6% suffer from a significant reduction in ovarian function (Salih et al.,
2015). Premenopausal female CCS are at risk for persistent chemotherapyrelated amenorrhea and early menopause; however, not all experience these
effects (Abusief, Missmer, Ginsburg, Weeks, & Partridge, 2012).
The American Society for Clinical Oncology has recommended that
options for fertility preservation be discussed with cancer patients at the earliest
opportunity; however, it remains challenging for healthcare providers to predict
individual risk of post-treatment reproductive dysfunction because of the limited
knowledge of factors associated with this late effect (Knight et al., 2015;
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Letourneau et al., 2013). While the etiology of reproductive dysfunction in cancer
survivors has been examined (El-Shalakany, Ali, Abdelmaksoud, Abd El-Ghany,
& Hasan, 2013; Letourneau et al., 2013), few predictors of this effect of treatment
have been identified (Dewailly, et al., 2014, Anderson et al., 2015). Further
research is warranted to provide reliable biomarkers to help clinicians accurately
identify cancer survivors at increased risk for reproductive dysfunction (Abusief et
al., 2012).
In clinical practice, a woman’s level of ovarian function is currently
determined with measures of FSH, LH, and the presence or absence of menses.
However, neither FSH nor menstrual cyclicity post-cancer treatment are reliable
predictors of future fertility (Knight et al., 2015). A more reliable measure of the
risk for premature ovarian failure and subsequent infertility is the size of the
ovarian follicle pool (ovarian reserve). A biomarker which more closely reflects
the number of remaining follicles in the ovary would have significant clinical
potential.
A biomarker is defined as ‘‘a characteristic that is objectively measured
and evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic intervention’’ (National
Institute of Health Biomarker Definition Working Group, 2001, p. 91). A recently
identified biomarker of ovarian reserve is anti-Müllerian hormone (AMH). Plasma
levels of AMH reflect the continuous non-cyclic growth of small follicles, and
therefore mirror the size of the remaining follicle pool (Jeppesen, Anderson,
Kelsey, Christiansen, Kristensen, Jayaprakasan, Campbell, et al., 2013). Kelsey
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et al. developed and validated the first model of AMH, mapping out the
chronological trajectory of the hormone from conception to menopause (Kelsey,
Wright, Nelson, Anderson, & Wallace, 2011). La Marca et al. went on to establish
normative age-ranges to aid in the clinical interpretation of AMH values (La
Marca et al., 2012).
Ovarian reserve declines naturally with age; however, recent research
demonstrates that chronological age alone is not an accurate indicator of
reproductive age and that other factors affect the depletion of the ovarian
follicular pool over time (Dolleman et al., 2013). Identifying factors that contribute
to the decline of the ovarian reserve may aid in the prevention and early
detection of follicle depletion, premature ovarian insufficiency and impaired
fertility. AMH is prematurely reduced in CCS (Anderson & Wallace, 2013;
Charpentier et al., 2014; Miyoshi et al., 2013), and may be an early marker of
significant gonadotoxicity post treatment (Brougham et al., 2012; Lie Fong et al.,
2009). Several studies have demonstrated the utility of pre-treatment AMH
concentrations to predict risk of post treatment ovarian dysfunction in cancer
survivors (Anderson & Wallace, 2013; Lunsford, Whelan, McCormick, & McLaren,
2014). However, the predictive value of AMH in cancer survivors is limited due to
incomplete knowledge of factors that influence AMH concentrations (Abusief et
al., 2012; van Dorp et al., 2014). There is also limited information on how
changes in AMH relate to changes in serum gonadotropin levels (e.g. follicle
stimulating hormone) affecting fertility in women, and the predictive value of AMH
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in assessing reproductive potential in young cancer survivors (Lunsford et al.,
2014).
One of the primary regulators of reproductive function is the hypothalamicpituitary-adrenal (HPA) axis. Precise levels of glucocorticoids are required for
proper ovarian function (Whirledge & Cidlowski, 2010). At homeostatic levels,
cortisol contributes to steroid biosynthesis and maintenance of gonadotropin
release; at elevated levels, it suppresses gonadotropin-releasing hormone
(GnRH) secretion, reduces pulsatile LH secretion, and increases rates of follicle
atresia (Breen & Mellon, 2014; Kalantaridou et al., 2010; Whirledge & Cidlowski,
2010; Whirledge & Cidlowski, 2013). It is well established that psychological
stress impairs reproductive function by activating the HPA axis (Louis et al.,
2011; Lynch, Sundaram, Maisog, Sweeney, & Buck Louis, 2014). Stress is also
associated with increased concentrations of pro-inflammatory cytokines, such as
interleukin-6 (IL-6), which may reflect reduced sensitivity to the anti-inflammatory
effects of cortisol (Rohleder, Aringer, & Boentert, 2012; Sribanditmongkol, Neal,
Patrick, Szalacha, & McCarthy, 2014). Increased IL-6 levels diminish aromatase
activity within ovarian follicles, inhibiting steroidogenesis and follicle maturation
(Taghavi et al., 2014).
Cancer survivors experience high rates of psychological stress and HPA
dysregulation (Oancea et al., 2014; Taylor, Absolom, Snowden, & Eiser, 2012;
Zeltzer et al., 2009). As both higher rates of psychological stress and
reproductive dysfunction are observed in cancer survivors, this study explored
the relationship between psychological stress and biomarkers of ovarian function
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in young cancer survivors. The purpose of this study was to explore
relationships between perceived stress, HPA activity, and ovarian function
in a sample of female survivors of childhood cancer.
Specific Aims
Aim 1: To describe the relationship between perceived stress and HPA activity in
female childhood cancer survivors.
Aim 2: To explore the relationship between perceived stress, biomarkers of HPA
activity, gonadotropin levels, and AMH in female childhood cancer survivors.
Significance to vulnerable populations
“The term ‘vulnerability’ is used to identify individuals and groups at risk of
harm” (Spiers, 2000, p. 715). Thus, vulnerable individuals or groups are defined
based on a real or perceived likelihood of experiencing an adverse outcome due
to the nature of their circumstances. The definition of a cancer survivor starts
from the time of diagnosis; accordingly, in the United States, there are more than
420,000 survivors of cancer diagnosed before the age of 21, which is
approximately one in every 750 individuals (Tonorezos et al., 2015). The number
of cancer survivors is growing because there have been improvements in the
early detection and treatment of cancer. However, the cure is not an end to
health concerns; many survivors face lifelong challenges to their health due to
the late effects of cancer treatment. Over two thirds of survivors exhibit at least
one chronic health condition 5 to 14 years after diagnosis (Phillips et al., 2015).
At risk of numerous adverse health outcomes, cancer survivors make up a

6
vulnerable population, with distinct and highly variable needs based on cancer
diagnosis, treatment, and duration.
CCS often do not receive adequate risk-based survivorship care as they
transition from pediatric oncology to adult care. Despite the growth of
survivorship clinics, a recent study by Zheng et al. (2015) found that the majority
of CCS (72.2%) did not attend a clinic even at 10 years post-diagnosis.
Researchers offer potential explanations for this discrepancy; CCS do not
receive adequate education regarding the risks of treatment, providers lack
sufficient knowledge of risks and fail to recommend proper long-term
surveillance, and the transfer to adult care lacks standardization (Kremer et al.,
2013; Phillips et al., 2015; Szalda et al., 2016; Zheng, Sint, Mitchell, & KadanLottick, 2015).
As a response, survivorship research has emphasized the importance of
developing personalized follow-up care plans based on individual risk so as to
prevent chronic disease and improve quality of life in this population (Salz et al.,
2015). In order to provide appropriate individualized follow-up for cancer
survivors, clinicians need tools to help them to stratify risk. However, in order to
develop effective risk models for the prediction of late-effects, it is necessary to
have sufficient knowledge of each variable included in the models (Salz et al.,
2015).
One effect of cancer treatment that is particularly concerning for cancer
survivors is reproductive dysfunction. Female cancer survivors are at increased
risk of premature ovarian insufficiency and fertility problems, and this effect of
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treatment is associated with significant psychological distress, negatively
impacting quality of life in this population (Terenziani et al., 2014). And yet,
studies consistently demonstrate that cancer survivors receive inadequate fertility
care, which consists of a thorough evaluation of infertility risk and counseling on
options for the preservation of fertility and the treatment of infertility (Barton et al.,
2013; Noyes, Knopman, Long, Coletta, & Abu-Rustum, 2011; Salih et al., 2015).
Barton et al. (2013) found that compared to sibling controls, cancer survivors
were approximately half as likely to be treated for infertility. Kim et al. (2016)
found that survivors who received fertility counseling prior to treatment were
more likely to pursue fertility care post treatment. However, the majority (73%)
did not recall receiving sufficient information regarding risks of cancer treatment
on future fertility or options for fertility preservation (Kim et al., 2016). One of the
primary reasons for this disparity is the difficulty in quantifying risk of reproductive
dysfunction after cancer treatment due to the lack of a sensitive biological marker
of ovarian function (Barton et al., 2013).
This study contributes to our knowledge of AMH as a biomarker of ovarian
reserve in a population at high risk for reproductive dysfunction. Existing
biomarkers of reproductive function, such as FSH, may not change until infertility
is advanced. AMH levels may be important in predicting risk for infertility post
treatment early enough that interventions to promote fertility are likely to be
successful (Gordon, Kanaoka, & Nelson, 2015).
Cancer survivors also report increased levels of perceived stress and
demonstrate alterations in HPA activity. The effects of chronic stress on ovarian
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reserve are poorly understood. This study therefore sought to increase the value
of AMH as a biomarker of ovarian reserve by exploring the association between
stress, gonadotropins, and AMH in a population of female survivors of childhood
cancer. The study’s findings will be used to inform future research to improve
clinical decision-making based on an individual’s vulnerability to the effect of
cancer treatment on reproductive function.
Significance to nursing knowledge development
The late effects of cancer and survivorship care reflect 8 of the top 20
ranked priorities in oncology nursing research (LoBiondo-Wood et al., 2014).The
goal of survivorship care is to individualize care to maximize quality of life. The
ability to tailor treatment plans depends on the availability of accurate biomarkers
that can reliably predict vulnerabilities to the late effects of cancer (Knobf et al.,
2014). Cancer survivors are at increased risk of infertility and reproductive
dysfunction; however the mechanism underlying this late effect is not well
understood (Barton et al., 2013). Fertility is a high priority for survivors of
childhood cancer and is correlated with quality of life in this population (McLaren
& Bates, 2012).
Further research is needed to increase knowledge of factors contributing
to reproductive dysfunction to improve prediction models for the risk of this late
effect of cancer and its treatment. The knowledge gained in this study will allow
patients, researchers and clinicians to collaborate in addressing the complex and
multi-factorial etiology of reproductive dysfunction in female cancer survivors
(Bhatia et al., 2015; Woodruff, 2013). Targeted interventions to prevent a
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premature decline in ovarian functioning will decrease the prevalence of
reproductive dysfunction and its associated financial and psychological burden to
patients.
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Chapter 2. Review of the Literature
Chapter 2 consists of two parts. Part I includes a description of life history
theory and how it will be used to structure the study’s main concepts and explore
relationships between them. Part II will review the research on AMH as a
biomarker of the ovarian reserve, its current uses in reproductive medicine, and
its promising potential as a predictor of fertility post treatment in cancer survivors.
Part I: Theoretical Framework:
Life History Theory
The theoretical framework used to guide this study is life history (Ellis,
2013; Whirledge & Cidlowski, 2013). Rooted in evolutionary biology, life history
theory was developed to explain variation in life history strategies, which are
resource allocation strategies adopted by organisms to optimize survival and
reproduction throughout the life course and across varying environmental
conditions. The task of all organisms is essentially the same, to distribute
material and energy resources to competing life functions: bodily maintenance,
growth and reproduction. Because resources are limited, an organism must
make trade-offs, prioritizing their use in one domain at the expense of other
competing domains (Ellis, Figueredo, Brumbach, & Schlomer, 2009). Life
history traits, characteristics that determine rates of bodily maintenance,
reproduction, and growth, are the primary units of analysis in life history theory.
Both individually and collectively, life history traits provide a window into an
organism’s life history strategy and the developmental continuum that results
from a chain of resource allocation decisions (trade-offs). The main life history
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traits are age and size at maturity, reproductive investment, reproductive
lifespan, and aging (Stearns, 2000).
Influences on Life History Strategies
Life history traits are influenced by an organism’s genetic characteristics
and environmental conditions. These traits form the organism’s life history
trajectory or continuum. Based on the availability of extrinsic and intrinsic
resources, the organism will coordinate tradeoffs so as to optimize its overall
fitness. “A synchronized optimization of tradeoffs is therefore at the heart of what
constitutes a coherent and coordinated [life history] strategy” (Ellis et al., 2009, p.
212). While life history strategies are varied, general patterns, or continua, can
be observed. These continua have been described as taking either a ‘slow’ or
‘fast’ course, dependent on environmental conditions.
Ellis describes two types of environmental influence that can shape an
organism’s life history strategy: environmental harshness and environmental
unpredictability. “Environmental harshness indexes the rates at which external
factors cause disability and death at each age in a population” (Ellis et al., 2009,
p. 206). While classical life history theory defines harshness as the rate of
mortality in a population, Ellis expanded the concept to include non-fatal injury,
disease, and other sources of stress, as these can also significantly impact
reproductive success, and therefore the optimal allocation of resources to
growth, survival and reproduction. Environmental unpredictability is defined as
“the rates at which environmental harshness varies over time and space” (Ellis et
al., 2009, p. 207). While environmental harshness will likely favor some life
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history strategies over others (selective evolution), environmental unpredictability
limits any one strategy from having an advantage over another since these
conditions are largely unavoidable.
In addition to environmental influence on resource allocation decisions,
individual characteristics (i.e. genetic and biological factors) impact an
organism’s life history strategy. As would be anticipated, this results in
considerable variability, and for this reason, life history trajectories cannot be
easily divided into slow and fast tracks. Instead, an organism’s life history
strategy is often a mixture of slow and fast traits. However, identifying general
patterns that give rise to “clusters of correlated traits” (Ellis et al., 2009, p. 212)
may improve prediction of future traits as well as increase understanding of
current ones.
HPA axis: Regulator of Life History Strategies
Early evolutionary biologists were able to demonstrate that organisms
make tradeoffs in response to changing environmental conditions and that these
tradeoffs influence the life course of an organism, but they struggled to identify
the biological mechanisms that allow organisms to make tradeoffs. Identifying
these mechanisms is vital to understanding the sources of variation in life history
strategies (Stearns, 2000). One of the primary mechanisms by which an
organism responds to changing environmental conditions is the hypothalamicpituitary-adrenal (HPA) axis (Ellis, 2013). Environmental challenges or stressors
activate the HPA axis and increase glucocorticoid secretion, directing resources
to vital physiological activities such as energy mobilization, cardiac output, and
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cognition, and away from less vital functions. Because reproduction is
energetically costly, when resources are limited, an organism is likely to prioritize
survival over reproduction, delaying fertility until environmental conditions are
more ideal. The HPA axis, as a primary mediator of resource allocation
decisions, plays an important role in determining an organism’s life history traits.
The HPA axis plays a prominent role in the regulation of the hypothalamicpituitary-gonadal (HPG) axis through glucocorticoids, which have both supportive
and suppressive effects on reproductive function. This complex and
synchronized neuroendocrine cross talk between the HPA and HPG axes allows
tradeoffs to occur. At homeostatic levels, glucocorticoids contribute to steroid
biosynthesis and maintenance of gonadotropin release. During acute stress,
endogenous glucocorticoids counteract the suppressive effects of prostaglandins
on reproductive function, thus protecting gonadotropin secretion. This suggests
that threshold glucocorticoid levels are necessary to maintain adequate
gonadotropin release (Whirledge & Cidlowski, 2010). Elevated glucocorticoid
levels suppress reproduction at multiple levels along the HPG axis. Increasing
glucocorticoid levels down-regulate gonadotropin releasing hormone (GnRH)
synthesis and decrease GnRH pulsatility, inhibiting the LH surge and delaying
ovulation, and increasing the rate of ovarian follicle atresia (Whirledge &
Cidlowski, 2010, 2013).
Strengths and Weaknesses of Life History Theory
Life History theory examines an organism’s life history strategy as a
dynamic process. The capacity of organisms to adapt to changing environments
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and adjust life history traits to enhance overall fitness is referred to as
developmental plasticity (Ellis & Del Giudice, 2014). Developmental plasticity is
beneficial from an evolutionary perspective. It acknowledges that a single life
history strategy is unlikely to afford an organism maximal fitness in every
environment. The ‘best’ strategy for survival and reproduction varies as a
function of one’s environment and thus a strategy that promotes success in some
environmental contexts may lead to failure in others (Ellis & Del Giudice, 2014).
Life history theory contrasts with other prevailing models of toxic stress
and allostatic load in that it takes into account individual differences in
developmental adaptation. Ellis and Del Giudice describe models of toxic stress
as falling short in addressing the variation in life history strategies, since they
operate on the assumption that chronic stress is fundamentally maladaptive. This
paradigm, while compelling in the examination and prediction of chronic illness,
fails to capture the ability of stress response systems to adaptively regulate
development (Ellis & Del Giudice, 2014). Overall, life history theory offers an
advantage over other models in its balanced perspective of stress within the
context of environment and human development.
Life history theory offers an adequate framework for examining an
organism’s resource allocations in response to competing physiological demands
(i.e. survival and reproduction) in the face of changing environmental conditions.
However, life history theory does not comprehensively explain variation in human
life history traits. It offers a primarily biological framework for examining
phenotypic variation, as a complex interplay of biological, environmental, and
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genetic influences on the human organism. Stearns, the father of life history
theory, examined phenotypic variation within the context of plant and animal life.
Ellis and Giudice expanded Stearns’ work by applying life history principles to
human biology. Their work generated a series of testable hypotheses regarding
the effects of varying environmental conditions on human life history traits. Life
history theory does not take into account the effect of social context and personal
choice on biological processes. While human fertility is contingent upon
biological, environmental and genetic factors, it cannot be fully explained by
these influences.
In order to examine the effects of higher level influences such as social
context and personal choice on human fertility, biological and environmental
influences need to be better understood. Despite the limitation of life history
theory as a biobehavioral framework, it is well suited for the current exploratory
study examining associations between biobehavioral measures of stress and
ovarian function. Life history theory has been successfully employed in other
studies to explore variability in reproductive function and lifespan (Bleil et al.,
2012).
Application of Life History Theory to Study’s Main Concepts
Life history theory provides an ideal framework for exploring factors that
affect life history traits such as reproductive lifespan. A description of how the
main life history constructs will be conceptualized and measured in the current
study follows. A complete description of measures will be presented in Chapter 3.
As stated above, the purpose of this study was to explore relationships
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between perceived stress, HPA activity, and ovarian function in a sample of
female survivors of childhood cancer.
1. The life history trait that was the main outcome of interest for this study
was ovarian function. As a concept, it was examined both as current and
“potential” ovarian function. Current ovarian function was measured using
serum gonadotropin levels (LH and FSH), serum reproductive hormones
(estrogen), and menstrual cycle characteristics (regularity, age at
menarche). Because an organism allocates resources for both current and
predicted future environments, “potential” ovarian function was also
measured using ovarian reserve (AMH). This concept is described in
greater detail in the second part of this chapter.
2. The resource allocation strategy was conceptualized as HPA activity and
measured using salivary cortisol and IL-6 and hair cortisol. The HPA axis
is the mechanism by which an organism takes in information regarding
environmental conditions and makes tradeoffs to meet current demands
while also attempting to predict and prepare for future environments.
3. Environmental influences on ovarian function were conceptualized as
cancer specific influences and perceived stress. Cancer specific
influences included cancer diagnosis and treatment type. Stress is “a state
of threatened or perceived as threatened homeostasis” (Nicolaides,
Kyratzi, Lamprokostopoulou, Chrousos, & Charmandari, 2015). Perceived
stress will be measured using the Perceived Stress Scale (Cohen,
Kamarck, & Mermelstein, 1983).
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Figure 1: Conceptual-Theoretical-Empirical Model for the Study

Contribution of this study to Life History Theory
While it is well established that psychological stress interrupts normal
reproductive functioning (An, Sun, Li, Zhang, & Ji, 2013; Kalantaridou et al.,
2010; O’Connor et al., 2011; Whirledge & Cidlowski, 2013), the biological
mechanisms underlying this effect are poorly understood (Bleil et al., 2012;
Lynch, Sundaram, Buck Louis, Lum, & Pyper, 2012). In this study, we explored
the influence of chronic stress on ovarian function with the goal of improving our
understanding of variation in life history strategies (Stearns, 2000). The findings
expand our knowledge of anti-Müllerian hormone (AMH), a biomarker of ovarian
reserve. Biomarkers provide insight into life history traits, and give us a window
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into the resource allocation decisions that constitute an organism’s life history
trajectory. This study contributes to life history theory by furthering our
understanding of AMH, a biomarker of ovarian reserve. This knowledge may be
used to improve the biomarker’s ability to reliably predict the development of
reproductive life history traits among female CCS.
Philosophical Underpinnings
A philosophical framework informs the researcher’s understanding of
reality (ontology), what can be known about reality and how knowledge of reality
is attained (epistemology). While all scientific inquiry makes implicit claims about
the nature of reality, unless these philosophical foundations are made explicit,
research risks superficiality and incongruity. A solid philosophical foundation
informs the conduct of research, ensuring that the right questions are asked and
promoting coherence in the research aims, methodology and interpretation of the
findings (Walsh & Evans, 2014).
This study was based on a post-positivist philosophical framework.
Positivist epistemology is the philosophical framework that informs modern
science. Positivist inquiry assumes the existence of an objective reality, which
can be observed and directly perceived through the senses. In this framework,
knowledge gained about reality is always true and generalizable, and truth is
dependent not on belief but on knowable facts present in external reality (Clark,
1998). Positivism rejects the existence and influence of unobservable
phenomena. The positivist researcher therefore is able to assume an atheoretical
and unbiased perspective in the research process. While an appealing
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philosophical framework for the conduct of empirical research, positivism is
unrealistic in its conceptualization of uncertainty.
There is an increasing shift to the post-positivist philosophical framework
in scientific inquiry. Post-positivism shares the positivistic view that metaphysical
realities are outside the realm of science, but differs from positivism in that it
adopts a realist perspective of science, recognizing that unobservable
phenomena, aspects of reality not directly perceivable or measurable, may
explain observable phenomena (Clark, 1998). Post-positivist inquiry permits
theoretical explanations of reality. Thus, in addition to the positivist requirement
for precision in the measurement of observable phenomena, post-positivist
inquiry incorporates evidence that can be inferred about unobservable
phenomena (e.g. evidence obtained through self-report, questionnaires, etc…).
The post-positivist framework assumes that the “researching human, with or
without instruments, must shape the research process” (Clark, 1998, p. 1246).
Post-positivism not only acknowledges but also adjusts for uncertainty in the
research process, allowing for greater realism in the conduct of scientific inquiry
and the interpretation of findings. As a consequence, knowledge gained through
post-positivistic inquiry is contextually bounded and not generalizable to all
cases.
Post-positivism aligns well with the truths sought in biological nursing
research (Letourneau & Allen, 1999). The post-positivist framework supports the
view that truth is unknowable and that the aim of scientific inquiry is to make
“warranted assertions”, which represent probabilities about human behavior
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rather than universal laws governing behavior. Scientific claims are warranted
when there is sufficient objective evidence about the phenomena under study,
and when these claims demonstrate coherence and consistency through time
and critical evaluation. In addition to permitting greater realism in the conduct of
research, post-positivism also supports critical multiplism, recognizing that there
is no correct or perfect method and that research questions can and should be
approached through multiple perspectives.
The post-positivist framework best reflects the mode of inquiry used to
conduct this study. First, the study’s purpose was informed by life history theory,
which provided an explanatory framework for examining the relationship between
the study’s main variables (stress, HPA activity, ovarian function). Second, the
study was exploratory, permitting uncertainty regarding the nature of the
relationship between the variables. And finally, the statistical methodology
(discussed in chapter 3) selected for this study was Bayesian structural equation
modeling (SEM) because it integrates uncertainty about the model parameters,
appropriate for exploring the relationship between stress and ovarian function in
a small sample of female cancer survivors.
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Part II: Literature Review
The Ovarian Reserve
The Ovarian Reserve and Anti-Müllerian Hormone
The woman’s reproductive lifespan is determined by the size of the
primordial follicle pool, or the ovarian reserve. The ovarian reserve is established
during fetal life when germ cells populate the ovary and form primordial follicles
(Dunlop & Anderson, 2014). These follicles consist of oocytes surrounded by a
single layer of squamous granulosa cells, and remain in the phase of the first
meiotic division until puberty. At birth, the number of primordial follicles is
estimated at 1 million. This number decreases steadily during a female’s lifespan
and is reduced to approximately 300,000 at menarche. Throughout a female’s
reproductive years, follicles are recruited from the primordial pool and progress
through the various stages of follicle growth. At the start of each menstrual cycle,
one dominant follicle is selected for ovulation (Visser, de Jong, Laven, &
Themmen, 2006).
At present, there are is no way to directly assess the ovarian reserve;
however, there are several biomarkers that provide an indirect measurement of
its size based on the assumption that the number of growing follicles is correlated
with the non-growing primordial follicle pool (Dunlop & Anderson, 2014). The
association between these indirect measures and the number of non-growing
follicles has been confirmed in histological studies (Hansen, Hodnett, Knowlton,
& Craig, 2011; Kevenaar et al., 2006).
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One biomarker that has shown considerable promise in the field of
reproductive medicine is anti-Müllerian hormone (Dewailly et al., 2014). AntiMüllerian hormone (AMH) is a dimeric glycoprotein and a member of the
transforming growth factor β family of growth and differentiation factors (Dewailly
et al., 2014). Initially, AMH, also known as Müllerian inhibiting substance (MIS),
was studied within the context of male sexual differentiation (Dewailly et al.,
2014; Visser et al., 2006). AMH is produced by the Sertoli cells of the testes, and
induces regression of the Müllerian ducts, the initial clustering of embryonic cells
from which the female reproductive tract develops (Visser et al., 2006). However,
AMH also plays a role in ovarian follicle growth, specifically in regulating the pace
of follicle recruitment and selection. AMH is expressed in granulosa cells of small
growing follicles with its strongest expression in preantral and small antral
follicles between 5-8mm in diameter (Jeppesen, Anderson, Kelsey, Christiansen,
Kristensen, Jayaprakasan, Campbell, et al., 2013). AMH is no longer expressed
by granulosa cells during FSH-dependent stages of follicle growth or by atretic
follicles, degenerated follicles that do not ovulate during the menstrual cycle
(Broekmans et al., 2008; Dewailly et al., 2014).
The role of AMH in follicle growth was first characterized in studies of
AMH-deficient mice (Visser et al., 2007). These studies demonstrated that AMH
acts as an inhibitor of primordial follicle recruitment (Durlinger et al., 1999, 2002).
AMH deficient mice had more growing follicles and an increased rate of oocyte
degeneration and follicle atresia (Visser et al., 2007), indicating that in the
absence of AMH, primordial follicles are recruited at a faster rate, leading to a

23
premature depletion of the follicle pool. Another consequence of AMH absence is
an increased sensitivity of growing follicles to FSH. AMH has an inhibitory effect
on FSH and therefore plays an important role in the selection of the dominant
follicle (Durlinger et al., 2001; Sacchi et al., 2016; Visser & Themmen, 2014;
Visser, de Jong, Laven, & Themmen, 2006).
AMH: Validated Measurement and Normative Age Ranges
Until recently, FSH and inhibin B were the gold standard measures of the
ovarian reserve. However, changes in FSH and inhibin B levels are not
detectable in serum until there is a significant reduction in the follicle pool
(Steiner, 2013), making timely detection and intervention challenging. AMH levels
decline before other biomarkers of the ovarian reserve, and are therefore one of
the earliest detectable changes in the process of ovarian aging (Sills, Alper, &
Walsh, 2009). Several prospective longitudinal studies involving normo-ovulatory
women have found that declining AMH concentrations predict with reasonable
accuracy the onset of menopause (Broer et al., 2011; van Disseldorp et al.,
2008). The hormone is ideal as a research and clinical measure because
concentrations do not fluctuate significantly across the menstrual cycle, and are
independent of FSH, LH, and E2 levels (Hehenkamp et al., 2006; La Marca et al.,
2010; Shaw et al., 2011). AMH assays have been developed and serum levels
correlate with the number of developing follicles in the ovary (Didier Dewailly et
al., 2014).
Kelsey et al. (2011) generated the first validated model of AMH in healthy
females from conception until menopause. Their findings demonstrate that AMH
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rises steadily until its peak at mean age of 24.5 years, at which point it declines
until menopause. The model was generated utilizing data from studies of women
without a diagnosis of infertility or chronic illness. According to their model, 34%
of the variation in AMH is due to age alone (Kelsey, Wright, Nelson, Anderson, &
Wallace, 2011). La Marca et al. (2010) established normative AMH ranges based
on age. In order for AMH values to be clinically interpreted, an established
nomogram with normative age ranges is vital. La Marca et al. (2010)
acknowledge the need for more studies to refine these ranges and establish
standardized values for use in research and clinical/diagnostic assessment.
Current Uses of AMH in Reproductive Medicine
AMH has already demonstrated considerable clinical potential, most
significantly in the field of assisted reproductive technology. Since ovarian
reserve correlates with the size of the remaining follicular pool, it is thought to be
associated with reproductive potential. The variable response to in vitro
fertilization (IVF) treatment is thought to be related to variability in the ovarian
reserve (Reijnders et al., 2016). Diminished ovarian reserve is predictive of poor
response to gonadotropin therapy, therefore limiting the possibility of pregnancy
(Iliodromiti, Kelsey, Wu, Anderson, & Nelson, 2014). AMH concentrations are
also useful for predicting ovarian hyperstimulation syndrome, which is a
potentially life-threatening condition (Dewailly et al., 2014). Currently there is
insufficient evidence to base treatment decisions within assisted reproductive
technology solely on a test of ovarian reserve (Iliodromiti et al., 2014). However,
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tests of ovarian reserve have proven useful for tailoring treatment and pre-IVF
treatment counseling (Nelson, 2013).
Since AMH regulates the pace of follicle growth by inhibiting initial
recruitment from the primordial follicle pool and dominant follicle selection, it also
may have potential application in understanding the pathophysiology of ovarian
dysfunction (Broekmans et al., 2008). One area of particular interest is polycystic
ovary syndrome (PCOS). PCOS is the most common female reproductive
disorder and occurs in up to 10% of all women. The three diagnostic hallmarks of
the syndrome include oligo/amenorhhea, clinical or biological signs of
hyperandrogenemia, and polycystic ovaries assessed by transvaginal ultrasound
(Broekmans et al., 2008). Polycystic ovarian morphology is characterized by an
increased number of intermediate-sized follicles. This suggests an increased rate
of initial follicle recruitment coupled with arrested follicle maturation. Several
studies have demonstrated that serum AMH concentrations are markedly
increased in PCOS patients, which is consistent with the increase of AMHproducing preantral and small antral follicles (Broekmans et al., 2008). Thus,
AMH may serve as a serological biomarker of PCOS (Iliodromiti et al., 2013).
Factors Associated with AMH Concentrations
While ovarian reserve naturally declines with age, age alone is not
predictive of ovarian age or reproductive status. The decline of ovarian reserve is
primarily due to apoptotic loss of oocytes (programmed cell death) rather than
ovulation (Tremellen, Kolo, Gilmore, & Lekamge, 2005). Thirty-four percent of the
variation in AMH concentrations is due to age, meaning that the remaining 66%
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is due to other factors (Kelsey et al., 2011). Identifying these factors may help to
elucidate predictors of reproductive dysfunction and disease. Understanding
factors that influence AMH levels in normo-ovulatory women may also help to
establish reliable normative age ranges for use in clinical practice and research.
Several studies have explored the influence of both reproductive and
lifestyle determinants of AMH concentrations (Dolleman et al., 2013; Freeman et
al., 2007; La Marca et al., 2010; La Marca, Stabile, Artenisio, & Volpe, 2006;
Malhotra, Bahadur, Singh, Kalaivani, & Mittal, 2013; Nelson, Stewart, Fleming, &
Freeman, 2010; Steiner, Stanczyk, Patel, & Edelman, 2010; Tsepelidis et al.,
2007). Oral contraceptive use is associated with lower AMH concentrations
(Dolleman et al., 2013; Kristensen et al., 2012; Shaw et al., 2011). However,
some studies have reported no association between oral contraceptive use and
AMH concentrations (Steiner et al., 2010). Some studies have demonstrated a
negative correlation between body mass index (BMI) and AMH (Freeman et al.,
2007; Steiner et al., 2010), but again this association has not been consistently
demonstrated (Dewailly et al., 2014; Dolleman et al., 2013). Pregnancy is
associated with lower AMH concentrations (Dolleman et al., 2013; Nelson et al.,
2010). Smoking is associated with lower AMH concentrations (Dafopoulos et al.,
2010; Hawkins Bressler et al., 2016).
Several studies have also demonstrated an association between AMH
concentrations and menstrual cycle irregularity (Dolleman et al., 2013; Kristensen
et al., 2012). AMH has been studied extensively within the context of advanced
reproductive technologies and various pathological conditions, but little is known
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about the factors associated with variation of AMH concentrations observed in
normo-ovulatory women (Dolleman et al., 2013). The first manuscript in this
dissertation, entitled, “An Integrative Review of Modifiable Biobehavioral Factors
Associated with Anti-Müllerian Hormone Concentrations” provides an integrative
review of the biobehavioral predictors of AMH concentrations in normo-ovulatory
women (Appendix A).
The relationship between AMH concentrations and reproductive outcomes
is disputed in the literature. AMH is considered a useful biomarker of
reproductive potential in infertile women undergoing assisted reproductive
technology (Burks et al., 2015; Reijnders et al., 2016). However, its value as a
predictor of natural fertility is still uncertain (Hagen, Vestergaard, et al., 2012;
Steiner et al., 2011, 2017; Zarek et al., 2015). This is an important distinction as
AMH concentrations are applied and interpreted in clinical practice. The
diagnostic and prognostic value of AMH continues to expand, however more
research is needed to examine its association with reproductive outcomes in
healthy populations.
Stress and the Ovarian Reserve
This study explored the effect of chronic stress on ovarian reserve.
Allsworth et al. (2001) were among the first to investigate the effect of chronic
stress on the ovarian reserve. They examined whether ovarian hormone levels
(FSH and estradiol [E2]) indicative of menopausal changes were observed at an
earlier age among 732 women (ages 36-44) who experienced physical or sexual
violence compared with women who reported no exposure to violence. More
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extreme levels of both FSH and E2 in relation to abuse history among
premenopausal women 41-45 years of age were observed, whereas little
difference was seen for younger women. Allsworth et al. offer a potential
explanation for the association between abuse history and ovarian function.
Stress activates the HPA axis and stimulates glucocorticoid secretion, which in
turn inhibits the synthesis and release of GnRH, LH, and FSH. However, the
authors did not include a biomarker of stress in the study and as a result, were
unable to examine this proposed biological mechanism (Allsworth, Zierler,
Krieger, & Harlow, 2001).
Pal et al. (2010) expanded the work of Allsworth et al., examining
associations between acute (serum cortisol) and chronic (history of abuse and/or
drug use) psychosocial stress and biomarkers of ovarian reserve (FSH and
Müllerian-Inhibiting-Substance (MIS), now referred to as AMH) in 89 premenopausal infertile women <42 years of age. Women were considered to have
diminished ovarian reserve (DOR) if they either demonstrated early follicular
phase (days 1–3) FSH levels >10 mIU/ml and/or poor ovarian response during
attempts at ovarian hyperstimulation. Those with chronic stress demonstrated
reduced ovarian reserve parameters: higher FSH (p = 0.051) and significantly
lower MIS levels (p = 0.034), and were three times more likely to be diagnosed
with DOR (p = 0.025). However, no association was observed between serum
cortisol levels and DOR. The authors concluded that chronic, but not current
stress, was associated with DOR. They proposed inappropriate HPA activation
as a plausible explanation for this association (Pal, Bevilacqua, & Santoro, 2010).
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Because a biomarker of chronic stress was not included in the study, they were
unable to provide evidence supporting this theory.
Cancer and Reproductive Dysfunction
Cancer survivors are at increased risk of reproductive dysfunction (Barton
et al., 2013). Cancer treatments cause damage to the ovaries and impair
reproductive potential through accelerated follicle loss (Lie Fong et al., 2009).
The proposed mechanism is apoptotic cell death in growing follicles, accelerating
the movement of follicles from the primordial pool to replace those lost to atresia
(Letourneau et al., 2013; Lie Fong et al., 2009). Increased follicle atresia
coincides with a decrease in quantity and quality of oocytes, increasing the risk of
infertility and spontaneous abortion (Knopman et al., 2010). The degree of risk of
impaired fertility depends on age at cancer diagnosis (El-Shalakany et al., 2013)
and the treatment regimen (Anderson & Wallace, 2013; Knopman et al., 2010).
Many chemotherapeutic agents are known to have cytotoxic effects on the
ovary, and are associated with premature ovarian failure and chemotherapyrelated amenorrhea (Oktem & Oktay, 2009). Chemotherapy exerts its
gonadotoxic effects by activating apoptotic machinery in the oocyte and
enclosing granulosa cells (Oktem & Oktay, 2009). This leads to premature
depletion of the ovarian follicle pool with a subsequent decline of the ovarian
reserve (McLaren & Bates, 2012). The highest risk is associated with alkylating
agents (Barton et al., 2013), and with pelvic radiation (Reinmuth et al., 2013).
However, the quantification of risk of infertility remains challenging for healthcare
providers (Barton et al., 2013) due in large part to an incomplete understanding
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of the factors contributing to long-term reproductive function in this population
(Abusief et al., 2012).
AMH in Female Cancer Survivors
Reproductive potential has been identified as a factor significantly
associated with quality of life in cancer survivors (Kondapalli et al., 2014). AMH
has shown considerable promise in predicting post-treatment risk for infertility in
female cancer survivors (Anderson, Rosendahl, Kelsey, & Cameron, 2013).
Recent studies have demonstrated associations between pre- and posttreatment AMH concentrations (Anderson & Cameron, 2011; Anderson et al.,
2013; Brougham et al., 2012). Lower pre-treatment AMH concentrations are
predictive of long term loss of ovarian function (Anderson et al., 2013; Brougham
et al., 2012).
Ovarian reserve is decreased in female survivors of childhood cancer
(Charpentier et al., 2014). Several studies have examined the influence of
treatment-related and biobehavioral factors on AMH concentrations posttreatment. Treatment-related factors include the therapeutic regimen
(Charpentier et al., 2014), the length of exposure (El-Shalakany et al., 2013;
Reinmuth et al., 2013), and the age of the patient at the time of treatment (Barton
et al., 2013; El-Shalakany et al., 2013). There is also evidence to suggest that
cancer pathology may contribute to prematurely reduced AMH concentrations.
Van Dorp et al. found that compared to healthy age-matched controls, girls newly
diagnosed with cancer presented with significantly lower serum AMH levels (p <
0.001) (van Dorp et al., 2014). Biobehavioral factors include obesity (van Dorp et
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al., 2013) and age at menarche (El-Shalakany et al., 2013). Pre-treatment
planning and the ability to provide individualized fertility prognoses depends on
increased understanding of factors associated with the ovarian reserve in female
childhood cancer survivors. This information can then be used to assist decisionmaking regarding treatment options and fertility preservation (Anderson et al.,
2013; Knopman et al., 2010).
Gaps in the Literature
The study of ovarian aging as a biological process spanning many years
has proven challenging. Premature ovarian aging increases risk for infertility and
early menopause. In addition to reproductive dysfunction, premature menopause
is associated with increased risk of osteoporosis and cardiovascular disease
(Letourneau et al., 2013; Salih et al., 2015). There is great need for a reliable
biomarker of the ovarian reserve to assist in the early detection of infertility. While
the number of studies examining AMH as a biomarker of the ovarian reserve has
increased considerably in the last fifteen years, significant gaps in the literature
remain. First, the value of AMH as an age-independent predictor of fecundity has
not yet been established (La Marca et al., 2010). In the context of assisted
reproduction, AMH provides useful information regarding reproductive potential
and ovarian responsiveness to hormonal stimulation, but its predictive accuracy
of live birth is poor (Iliodromiti et al., 2014). In the context of unassisted
reproduction, only a small number of studies have examined the association
between AMH and fecundability (Hagen, Aksglaede, et al., 2012; Steiner et al.,
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2017b; Zarek et al., 2015), and these failed to find an association between
having a low ovarian reserve and a longer time to pregnancy.
Second, most of the studies that have examined the predictive value of
AMH have been based on single measurements. Freeman et al. (2012) found
that the rate of change in AMH levels improved the precision of estimates of time
to menopause (Freeman, Sammel, Lin, Boorman, & Gracia, 2012). Longitudinal
studies are needed to determine if the rate of change in AMH levels also
improves prediction of fertility outcomes. Third, more studies are needed to
identify the biobehavioral factors that influence serum AMH concentrations in
order to account for these effects in prediction models (Dolleman et al., 2013).
And finally, because AMH alone is unlikely to provide enough information to
predict reproductive potential, more studies are needed to develop and test
models based on multiple predictors (Venturella et al., 2015). This study
contributes to the literature by improving our understanding of chronic stress on
the ovarian reserve in female cancer survivors, a population at high risk of
prematurely diminished ovarian reserve.
Preliminary Work
In June 2010, the author conducted a pilot study at the Hatfield Clinical
Research Center at the National Institutes of Health. The study sample was
obtained using an existing database that included urine cortisol levels from 36
reproductive age females with and without chronic abdominal pain (CAP).
Laboratory staff assisted with the analysis of frozen serum samples for AMH
concentrations using a commercially available assay (AMH GEN II ELISA,
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Beckman Coulter). Women with CAP had significantly lower 5-hour urinary
cortisol, a finding that is consistent with literature reporting hypocortisolemia in
individuals with chronic pain (Generaal et al., 2014). Using contingency table
analysis, we found that women with clinically abnormal (high or low) AMH levels
had significantly lower 5-hour urinary cortisol (p = 0.04) compared to women with
normal AMH levels (Hardy, McCarthy, Fourie, & Henderson, 2016). These
findings suggest that HPA dysregulation may contribute to the variation of AMH
levels warranting further exploration of this relationship.
In the summer of 2017, the author examined patterns of cardiometabolic,
psychological and reproductive parameters of health in postpartum women and
examined the ovarian reserve within these patterns (Hardy, Garnier-Villarreal,
McCarthy, Anderson, Reynolds, unpublished manuscript) (Appendix B). Latent
class analysis (LCA) was used to classify the subjects of the whole sample
(heterogeneous) into smaller homogeneous groups in which members are similar
to each other and different from subjects in other groups. The objective is to
identify groups underlying the data, when the number of underlying groups is
unknown (DiStefano, 2012; Kaplan, 2014). The LCA model included the following
variables: fasting lipids (triglycerides, cholesterol, and HDL), fasting glucose,
fasting cortisol, lean/obese, breastfeeding status, anxiety, depression, FSH, LH,
E2, and AMH levels. The best fitting LCA model included 3 classes. For the 3
class LCA, 32.2% (n=22) of the sample was in Class 1, 43.4% (n=30) of the
sample was in Class 2, and 24.3% (n=17) of the sample was in Class 3. We
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found that women (class 3) who had lower ovarian reserve also had less
favorable cardiometabolic and psychological profiles.
These findings suggest that cardiometabolic and psychological factors
may contribute to the process of ovarian aging. While numerous studies have
examined these factors in association with AMH (Dolleman et al., 2013; La
Marca et al., 2012), few have explored patterns within and between women as a
means of identifying subgroups. Accurate group classification would facilitate risk
stratification and early detection in the context of ovarian aging (Pal et al., 2010).
The findings from this study provided preliminary evidence to support the
hypothesis that there are modifiable biobehavioral factors that contribute to
variation in the process of ovarian aging.
Study Aims, Research Questions, and Hypotheses
Aim 1: To describe the relationship between perceived stress and HPA activity in
female childhood cancer survivors.
Research question 1: Is perceived stress associated with HPA activity in female
childhood cancer survivors?
Hypothesis: Higher levels of perceived stress will be associated with
dysregulated HPA activity.
Research question 2: Is the diurnal pattern of HPA activity (salivary cortisol and
IL-6) associated with long-term average cortisol secretion (hair cortisol)?
Hypothesis: Flatter diurnal patterns will be associated with lower long-term
average cortisol secretion.
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Aim 2: To explore relationships between perceived stress, biomarkers of HPA
activity, gonadotropin levels, and AMH in female childhood cancer survivors.
Research question 1: Is perceived stress associated with ovarian function
(gonadotropin and AMH levels) in female childhood cancer survivors?
Research question 2: Is dyregulated HPA activity associated with ovarian
function (gonadotropin and AMH levels) in female childhood cancer survivors?
Hypothesis: Increased levels of perceived stress and dysregulated HPA activity
will be associated with abnormal gonadotropin levels and diminished ovarian
reserve.
Study Assumptions
This study was based on several assumptions. The first was that stress, a
complex and multifaceted construct, could be measured through a combination
of biological and self-report measures. It was assumed that chronic stress could
be accurately measured with self-report of perceived stress levels over the past
month, diurnal cortisol patterns (intercept and slope), and hair cortisol levels
which reflect the average cortisol level over a month or more. Second, the study
assumed that participants were reliable and trustworthy sources of information
regarding their medical history and that the participants’ treatment team kept
accurate medical records regarding their diagnoses and treatments. Third, the
study assumed that the laboratory testing of hair cortisol, serum gonadotropin
levels and serum AMH levels was completed and recorded precisely and
accurately.
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Chapter 3. Research Design and Methods
Sample and Settings
The sample for this descriptive, cross-sectional cohort study consisted of
24 female subjects between the ages of 16 and 35 who were previously treated
for cancer (including leukemia and brain tumors) at the Edinburgh Children’s
Cancer Centre, Royal Hospital for Sick Children (RHSC). Sample size and power
estimates are challenging in an exploratory model of predictors, due to the fact
that one is not aware of predictor effects and cannot put forth anticipated effect
sizes.
Rules-of-thumb regarding appropriate sample sizes were used to best
estimate the necessary sample size. The subject to variable (SV) ratio has been
an attempt to ensure that the sample is “large enough” to minimize “parameter
inflation” and improve “replicability”. While numerous rules-of-thumb exist (Green,
1991), it has been shown that the power for a test of Cohen’s (1988) effects sizes
(medium: f2 = 0.15 [R2 = 0.13] to large: f2 = 0.35 {R2 = 0.26]) for partial correlation
(regression parameters) at approximately 1- b = .80 (Alpha = 0.05) is achieved
based on Harris’ (1975) rule that N >= 50 + 8m for medium effects, where m =
the number of predictors. This approximates Cohen’s estimates. Assuming a
maximum number of predictors around six, to achieve power (0.80, alpha = 0.05,
two-tailed) a sampling of approximately 41 individuals for six predictors was
required. Thus in order to achieve a power to detect regression effects slightly
less than a large effect size, a sample of approximately 50 individuals was
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needed. Due to several recruitment challenges, obtaining this target sample size
was not as feasible as originally anticipated. These challenges will be discussed
in detail in the results and discussion.
Cancer survivors are seen annually for follow up at the Royal Hospital for
Sick Children (RHSC) (Wallace, Smith, Kelsey, Edgar, & Anderson, 2014). The
inclusion criteria were: female patients treated for cancer (including leukemia and
brain tumors) at the Edinburgh Children’s Cancer Centre, younger than 18 years
of age at cancer diagnosis and between 16-35 years of age at the time of the
study visit, at least one year following the conclusion of treatment, and signed
written informed consent. This age range was selected because subjects are
likely to be post-pubertal and in the most fertile window of their reproductive
lifespan. Cancer survivors seen for long-term follow-up at the Royal Hospital for
Sick Children (RHSC) in Edinburgh, Scotland were selected because of Dr.
Anderson’s current research on reproductive function and fertility preservation in
cancer survivors (Wallace et al., 2014). This collaboration minimized burden to
subjects. In the UK, research subjects aged 16 and older are able to provide
informed consent. The exclusion criteria were a positive pregnancy test, ovarian
surgery in the past 6 months, hormonal therapy in the preceding 3 months
(GnRH agonists, recFSH), alcohol or drug abuse/dependence according to ICD10 criteria, and investigational drug received in the past 3 months (90 days).
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Recruitment and Retention Strategies
One day a month, the RHSC medical staff hold annual review
appointments for cancer survivors in long-term follow-up. This monthly clinic
promotes a multi-disciplinary approach to care and encourages long-term followup. Recruitment letters (Appendix 2) were sent to potential study participants two
weeks prior to their annual review appointment to inform them of the study and to
invite them to consider participating. Subjects could either send their reply slip by
mail or inform medical staff of their decision at the monthly clinic.
Research Sites
All data collection occurred at the RHSC. Laboratory analyses were
conducted at the Queens Medical Research Institute (QMRI). Data analyses
were conducted at Marquette University.
Instruments
Ovarian function: assessment of ovarian function included serum
gonadotropin levels (luteinizing hormone (LH), follicle-stimulating hormone
(FSH)) and AMH. Serum levels of these hormones are routinely measured during
the annual follow-up appointment as part of standard care at NHS affiliated
clinics and at regular intervals during in the parent study in Ireland. The
laboratory results were retrieved from subjects’ medical records. Serum AMH
levels were analyzed using the Beckman Coulter AMH GEN II ELISA (Beckman
Coulter Inc., Brea, CA). The AMH Gen II ELISA has a sensitivity of 0.57 pmol/l.
The validated model of serum anti-Müllerian hormone by Kelsey et al. (2011) and
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the nomogram with normative values for age published by LaMarca et al. (2012)
will be used to interpret AMH levels (Kelsey et al., 2011a; La Marca et al., 2012).
Psychosocial stress was determined using the Perceived Stress Scale
(PSS-10). Perceived stress is a concept that incorporates an understanding of
stress as a “cognitively mediated emotional response to an event, not the object
of the event itself” (Cohen, Kamarck, & Mermelstein, 1983). Perceived stress
was measured using the Perceived Stress Scale, PSS-10, a self-report
instrument which measures the degree to which situations in one’s life are
appraised as stressful over the past month (Cohen, Kamarck, & Mermelstein,
1983).
Validation of the PSS-14
Cohen et al. (1983) developed the PSS to determine to what extent the
respondents found their lives to be “unpredictable, uncontrollable, and
overloaded”, as these had been consistently found to be central components of
the experience of stress (Cohen & Williamson, 1988). The items were designed
for use with community samples with at least a junior high school education.
Responses to each item range from “never” to “very often” on a 5-point Likert
scale and a higher score indicates greater stress (Cohen et al., 1983).
The measure was validated using two samples of college students and
one sample of adults enrolled in a smoking-cessation program. Cohen et al.
(1983) first calculated the mean and variance of the PSS-14 scores in each
sample to determine if there were significant differences between gender and
age. While mean scores were slightly higher in females than in males, the
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difference was not statistically significant. They also reported that age was
unrelated to scores.
Reliability of the PSS-14
Reliability of the measure was tested in each sample using Cronbach’s
alpha and test-retest correlations. Cronbach’s alpha, a measure of internal
consistency, was .84, .85, and .86 respectively. Test-retest correlations were
calculated at two different intervals. In the college students, the time between the
first and second administration was two days, whereas in the smoking-cessation
sample, the interval was six weeks. The test-retest correlations were .85 and .55
for the two-day and the six-week interval respectively. Participants were asked to
strive for accuracy rather than consistency across time. In this way, the authors
demonstrated that while the test reliably examines perceived stress, test-retest
correlations weaken as the time between test administration increases.
Validity of the PSS-14
Validity was examined using tests of concurrent and predictive validity. To
test concurrent validity, the CSLES (College Student Life Event Scale) and the
life-event scale (for the smoking-cessation sample) were used. The authors
anticipated that perceived stress scores would increase with the number of
stressful events reported in the life event scales (LES) and that the correlations
between the scores would be even higher when the impact scores of the events
were included. As predicted, there was a small to moderate correlation between
LES and the PSS scores (r = .35-.49) and the correlations increased when
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including the impact scores. While the authors considered the LES to be the best
available self-report measure for testing concurrent validity, the authors
recommend the possibility of using a biomarker of stress such as cortisol for
future validity testing (Cohen, Kamarck, & Mermelstein, 1983).
To examine predictive validity, Cohen et al. (1983) administered a
depression scale (CES-D), an anxiety scale (SADS), a physical symptom
checklist (CHIPS), and monitored utilization of health services several months
before and after the testing session. They predicted that the PSS would be a
better predictor of depression and anxiety, physical symptomatology, and
utilization of health services. As anticipated, the PSS was a better predictor of
depression (r = .65-.76), anxiety (r= .37-.48), utilization of health services (r = .11.20), and physical symptomology (r = .52-.70) than the life events scores.
PSS-10
Cohen & Williamson (1988) tested the validity and reliability of the PSS-14
in a large sample of adults (n = 2,387) in the United States. The authors
conducted a factor analysis using a principle components method with varimax
rotation. The analysis revealed a two-factor structure accounting for 41.6% of the
variance. The PSS-10, a shorter version, was derived by eliminating the four
items with the lowest factor loadings. The authors conducted a second factor
analysis with the PSS-10, which resulted in an improvement in both the total
explained variance (48.9%) and internal reliability (alpha coefficient = .78).
To examine construct validity of the PSS-10, Cohen & Williamson (1988)
examined relations between the PSS scores and other stress measures, health,
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health service utilization, health behaviors, life satisfaction, and help seeking.
Similar to the PSS-14, the PSS-10 was moderately correlated with the life event
scale (r = .32). The PSS scores were weakly correlated with self-reported health
behaviors, weakly or moderately correlated with self-reported physical illness,
and moderately correlated with scores on the life satisfaction scale (r = .47). The
authors conclude that the PSS-10 is as reliable and valid a measure of perceived
stress as the PSS-14. The PSS-10 also had a tighter factor structure and a
slightly better internal reliability. They therefore recommend the PSS-10 for use
in research.
Utilization of PSS-10 in research
The PSS-10 is one of the most widely used measures of psychological
stress (E.-H. Lee, 2012). It has been validated for use in numerous populations
and is currently translated into 25 languages other than English (E.-H. Lee,
2012). The PSS-10 has been utilized as a measure of perceived stress to
examine the association between stress and reproductive outcomes (Bleil et al.,
2012; Li, Newell-Price, Jones, Ledger, & Li, 2012; Lynch, Sundaram, Maisog,
Sweeney, & Buck Louis, 2014b; Schliep et al., 2015), to quantify stress levels in
cancer survivors (Keir, Swartz, & Friedman, 2007), and to examine the
effectiveness of interventions to reduce stress in cancer survivors (Loprinzi,
Prasad, Schroeder, & Sood, 2011). For example, Loprinzi et al. (2011) assessed
the effect of a SMART (Stress Management and Resiliency Training) program for
increasing resiliency and decreasing stress and anxiety among breast cancer
survivors. A total of twelve patients completed the intervention, and eight patients
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were in the control group. No significant differences in any of the measures were
noted in the control group. In the intervention group, the PSS score decreased
from 22.1 ± 5.9 initially to 12.8 ± 6.6 (p = .003). The change in PSS score was
equivalent in magnitude to other concurrent measures of anxiety and resilience.
Based on previous use, the PSS-10 is an appropriate measure of stress in
female cancer survivors.
HPA Activity
HPA activity was determined using measures of salivary cortisol, salivary
IL-6 and hair cortisol. Analysis of salivary cortisol and IL-6 were performed in Dr.
Anderson’s lab under the guidance of the Queen’s Medical Research Institute
(QMRI) staff and in Dr. Bryan Hennessy’s lab under the guidance of the Royal
College of Surgeons in Ireland (RCSI) staff. Hair (1 cm) will be processed for
extraction of cortisol in the laboratory of Clemens-Kirschbaum in Dresden,
Germany as previously described (Kirschbaum, Tietze, Skoluda, & Dettenborn,
2009).
Salivary cortisol
Cortisol is the main glucocorticoid hormone produced in the adrenal
cortex. Approximately 90% of cortisol in blood is bound to plasma proteins
(corticosteroid-binding globulin and albumin), leaving only about 5-10% unbound
(Kahn, Rubinow, Davis, Kling, & Post, 1988; Kirschbaum & Hellhammer, 1989).
This latter fraction, which is reflected in salivary cortisol, reflects the biologically
active corticosteroid that is capable of acting on target tissues (Kirschbaum &
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Hellhammer, 1989). Cortisol is not secreted continuously, but rather in pulses
influenced by circadian rhythmicity, evident in its well-characterized diurnal
pattern with levels highest in the early morning hours and lowest around midnight
(Kirschbaum & Hellhammer, 1989).
Advantages
Salivary cortisol has many advantages over prior measures used to
examine HPA activity. In comparison to serum cortisol, salivary cortisol is
noninvasive, providing an accurate measure of HPA activity without the risk of
provoking the stress response and potentially compromising the findings (Raff,
2009). It is easy to collect, making it convenient in both the clinical and research
settings, especially in cases when repeated sampling is required. Studies have
reported high compliance with home collection of salivary cortisol with minimal
burden to participants (Bergen et al., 2012).
Validity and Reliability
Validity of salivary cortisol has been established by examining correlations
with plasma cortisol levels. The linear correlations between salivary and plasma
cortisol are high, ranging from r = 0.54 to r = 0.97, with most investigators
reporting correlation coefficients of r ≥ 0.90. The lower correlations were reported
in studies comparing salivary cortisol levels with total plasma cortisol levels
(Kirschbaum & Hellhammer, 1989). Since salivary cortisol levels reflect unbound
cortisol, correlations with total plasma cortisol levels would yield much lower
coefficients (Inder, Dimeski, & Russell, 2012). Reliability is assay-dependent. A
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commercially available Enzyme-Linked Immuno-Sorbent Assay (ELISA) kit was
used for the quantification of cortisol in saliva (Salimetrics, Suffolk, UK KIT 13002). This cortisol assay kit has a lower detection limit of 7 ng/dl. The mean
intra-assay coefficient is 5.7% and the mean inter-assay coefficient is 10%.
Influences on cortisol levels
Saliva flow rate and viscosity do not significantly affect salivary cortisol
levels, making the measure robust in a variety of clinical and research conditions
(Kirschbaum & Hellhammer, 1989). While there is considerable variation, most
studies recommend participants not eat, drink, or brush their teeth prior to
sample collection. There is evidence that habitual smoking increases salivary
cortisol levels as well as exercising within 30 minutes of collection (Kirschbaum &
Hellhammer, 1989). During pregnancy, cortisol levels are elevated due to the
estrogen-induced rise in cortisol binding globulin and up-regulation of the
maternal HPA axis (Jung et al., 2011). Similarly, cortisol binding globulin levels
are elevated in women taking estrogen-containing oral contraceptives (Raff,
2009). Salivary cortisol is not sex-dependent, however concentrations may
decline with age (Inder et al., 2012). Because cortisol is a stable molecule, saliva
samples can be stored in a home refrigerator at 4-8° for up to 7 days, after which
they can be frozen and stored at -20° or -80° for up to 12 months without
depreciation of concentrations (Inder et al., 2012).

46
Use in research
Salivary cortisol has been used in numerous studies as a reliable measure
of the stress response and HPA activity (An et al., 2015). Chronic stress is
associated with alterations in the cortisol awakening response (Dedovic & Ngiam,
2015; Révész et al., 2013), and blunting of the morning-evening diurnal slope
(Carvalho et al., 2015; Garland, Beck, Lipschitz, & Nakamura, 2014; Ho, Fong,
Chan, & Chan, 2013; Schrepf et al., 2015). It has been used to measure HPA
activity in cancer survivors and other populations (Du et al., 2013; Ho et al.,
2013; Sephton et al., 2013).
Salivary IL-6
Interleukin-6 (IL-6) is one of the major cytokines that stimulates HPA
activity in response to inflammatory stress and is thought to play a role in the
mechanisms linking psychosocial stress with increased risk of chronic disease
(Sjögren, Leanderson, Kristenson, & Ernerudh, 2006). Chronic stress is
associated with elevated levels of pro-inflammatory cytokines, which may reflect
reduced sensitivity to the inhibitory effects of cortisol (Sribanditmongkol et al.,
2014).
Validity and Reliability
Unlike salivary cortisol, salivary IL-6 has not been shown to correlate with
serum/plasma levels of IL-6. Salivary IL-6 is thought to reflect localized rather
than systemic inflammation (Izawa, Sugaya, et al., 2013). However, Izawa et al.
demonstrated elevated salivary IL-6 concentrations post-TSST (Trier Social
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Stress Test) when compared to baseline concentrations (p < .01), indicating a
close association between salivary IL-6 and psychosocial stress. They also
demonstrated significant correlations between salivary IL-6 and salivary cortisol
(p < .05) post-TSST. This association was not seen at baseline, suggesting that
the correlation between the inflammatory response and HPA activity is specific to
stressful conditions (Izawa, Sugaya, et al., 2013).
Izawa et al. also described the relationship between IL-6 and cortisol as
dependent on proximity to and duration of the stressor. Following an acute
stressor, both IL-6 and cortisol remain elevated for approximately 30-60 minutes.
Cortisol then suppresses IL-6 production, changing their relationship from a
positive to an inverse correlation. However, in chronic stress, hypocortisolism
may occur causing salivary IL-6 to remain elevated (DeSantis et al., 2012;
Nikkheslat et al., 2015). Thus, salivary IL-6 is particularly useful in helping to
distinguish between acute and chronic stress when collected in conjunction with
salivary cortisol (Izawa, Sugaya, et al., 2013). Salivary IL-6 has a diurnal pattern
similar to that of cortisol, peaking in the morning immediately after awakening
and then gradually declining into the afternoon and evening. However, unlike
salivary cortisol, salivary IL-6 peaks again at midnight before going to bed
(Izawa, Miki, Liu, & Ogawa, 2013).
A commercially available Enzyme-Linked Immuno-Sorbent Assay (ELISA)
kit was used for the quantification of salivary IL-6 (Salimetrics, Suffolk, UK KIT 13602). This IL-6 assay kit has a lower detection limit of 7 ng/dl, intra-assay
coefficient of 4.8% and mean inter-assay coefficient of 6.6%.
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Hair cortisol
Psychosocial stress has also been associated with elevated levels of
cortisol in hair (Russell et al., 2012; Wells et al., 2014). Hair has a predictable
growth rate of 1 cm/month; the most proximal 1 cm segment to the scalp
approximates the last month’s cortisol production, the second most proximal
segment the month prior to that, and so on (Russell et al., 2012). Hair cortisol
provides several advantages over current measures of cortisol. It permits a
retrospective analysis of cortisol secretion, allowing researchers to examine
cortisol secretion before an event occurred (Stalder & Kirschbaum, 2012). Hair is
also easy and non-invasive to collect; a sample of hair is cut from the vertex
posterior region of the scalp as close to the skin with scissors (Raul, Cirimele,
Ludes, & Kintz, 2004). Only a small amount (about 10mg) is needed to extract
cortisol concentrations. Sample storage is convenient; hair cortisol can be stored
at room temperature in aluminum foil for extended periods of time (Raul et al.,
2004).
Protocol for hair cortisol analysis
To extract cortisol from hair, the sample is weighed and then cut into
segments correlating with the time period of interest. Then, the hair is finely
minced with scissors, and incubated overnight in a solvent such as methanol.
The resulting solution is evaporated until the sample is dry and methanol is
removed from the sample. Then the sample is reconstituted in a solution such as
phosphate buffered saline (PBS). Following the extraction, an ELISA is used for
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cortisol quantification (Raul et al., 2004; Russell et al., 2012; Sauvé, Koren,
Walsh, Tokmakejian, & Van Uum, 2007).
Validation of hair cortisol assay
Cortisol was first measured in human hair by Raul et al. (2004) using liquid
chromatography-mass spectrometry analysis and then further validated by Sauve
et al. (2007) using an ELISA. The methodology and results of both studies will be
summarized.
Measurement range
Raul et al. (2004) performed liquid chromatography-mass spectrometry
analysis on 44 hair samples from 17 men and 27 women. Ages ranged from 2 to
90 years old (mean 36 years old). Four hair color categories were distinguished;
black, brown, grey and blond (Raul et al., 2004). None of the analyzed samples’
concentrations were below the limit of quantification of 5 pg/mg, defined as the
“lowest reported quantitative value, within the established acceptable error of the
essay” (Rifai, Gillette, & Carr, 2006). The limit of detection, defined as “the lowest
value that exceeds the measurand value obtained with a blank sample” (Rifai et
al., 2006), was 1 pg/mg. Linearity, which “refers to the range of measurand
values over which there exists a constant relationship between observed and
expected values” (Rifai et al., 2006), was between 1 and 500 pg/mg. Cortisol
concentrations ranged from 5.2 to 91 pg/mg with a mean value of 19 pg/mg.
Concentrations of cortisol were not different based on groups (age, natural hair
color).
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Sauve et al. (2007) were the first to use a modified saliva ELISA to
measure cortisol concentrations in human hair (Sauvé et al., 2007). They used a
sample of 39 non-obese subjects, 19 male and 20 female, to develop and
validate an assay for the measurement of cortisol in human hair. For each
subject, hair, urine, saliva and serum samples were collected for cortisol
analysis. Sauve et al. (2007) also examined the effect of hair color (n=12) and
sample location (n=14) (e.g. posterior vertex) on cortisol concentrations, as well
as the difference between hair cortisol concentrations in hair that had been dyed
(n=14) and hair that was untreated (n=25).
Hair cortisol levels were not normally distributed, but after log
transformation, the distribution was normal. The reference range for cortisol
levels in hair of healthy non-obese individuals was 17.7-153.2 pg/mg of hair with
a median of 46.1 pg/mg. Hair cortisol concentrations did not differ significantly
based on natural hair color. However, hair that was dyed before sample
collection (n=14) had lower cortisol levels (p < .05) than hair that was untreated
(n=25) (Sauvé et al., 2007).
Accuracy and Precision
Accuracy is the “closeness of agreement between the value of a
measurement and the true concentration of the measurand in the sample” (Rifai
et al., 2006). Raul et al. (2004) examined accuracy using calibration curves. To
obtain calibration curves for cortisol concentrations under 20 pg/mg, the authors
could not use blank hair (physiological concentrations being sometimes below 20
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pg/mg). For this reason, they used melanin to obtain a “blank” hair as close as
possible to human hair (Raul et al., 2004).
Sauve et al. (2007) determined accuracy by examining recovery,
calculated by adding various concentrations of cortisol to the hair sample and
comparing the measured amount with the added amount (Rifai et al., 2006). The
mean extraction recovery of 80 ng/ml and 2 ng/ml cortisol standards (n=5) from
PBS was 87.4% and 83.6% respectively. When hair samples were spiked with
100 ng/ml, 50 ng/ml and 2 ng/ml (n=6) cortisol standards, incubated and
extracted, the mean extraction recoveries were 87.9%, 88.9% and 87.4%,
respectively (Sauvé et al., 2007).
Precision is the “closeness of agreement between independent test results
obtained under stipulated conditions” (Andreasson et al., 2015, p. 3). Raul et al.
(2004) examined precision through repeatability. Intra-day repeatability (CV
value) was 11% for cortisol (at 7 pg/mg). Sauve et al. examined the precision of
the ELISA assay using two hair samples with an average (about 60 pg/mg) and a
high cortisol level (about 600 pg/mg). The intra-assay coefficients of variation for
these samples were 7.2% and 6.0%, respectively. Inter-day precision had a
coefficient of variation of 10.6% for the sample of average concentration and
7.6% for the sample of high cortisol content (Sauvé et al., 2007). The mean
coefficient of variation of hair cortisol levels from samples obtained from the
vertex posterior of 14 individuals was 15.6%. The mean coefficient of variation for
cortisol levels from hair samples taken from various parts of the head was 30.5%.
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Based on these results, Sauve et al. (2007) recommend hair samples be taken
from the vertex superior in order to obtain consistent results.
Validity
Sauve et al (2007) established validity of the hair cortisol ELISA assay by
examining correlations between hair cortisol concentrations and concentrations
of cortisol in urine, saliva, and serum. There was a correlation between hair
cortisol levels and 24-hr urine cortisol (r=0.33; P=0.041) and between serum and
salivary cortisol (r=0.58; P=0.0016). The strong correlation between saliva and
serum cortisol can be explained because both matrices reflect short-term cortisol
secretion. One explanation for the weaker correlation between hair cortisol and
urinary cortisol is the difference in the time frames that are reflected by the
measurements: urine represents cortisol secretion during one day, whereas hair
cortisol levels represent levels during 1-2 months (Sauvé et al., 2007).
Stability reliability
Stalder et al. (2012) examined patterns of intra-individual stability in hair
cortisol levels in two independent study groups. In study I, hair was collected
from 45 participants at two time points one year apart from each other. In study
II, 64 participants provided hair samples at three time points occurring at twomonth intervals. In both studies, relevant psychosocial variables and hair-related
variables were also assessed. Results of both studies consistently revealed
strong test-retest associations for repeated hair cortisol measurements (‘r’s
between 0.68 and 0.79, ‘p’s <0.0001). The authors concluded that hair cortisol
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concentrations demonstrate a considerable degree of intra-individual stability
(Stalder et al., 2012).
Validity in known hypercortisolemic conditions
Several studies have demonstrated validity of hair cortisol by examining
cortisol concentrations in individuals with known hypercortisolemic conditions.
D’Anna-Hernandez et al. (2011) examined associations between hair and
salivary cortisol throughout pregnancy and in the first three months postpartum.
Cortisol levels are known to increase throughout pregnancy (D’Anna-Hernandez,
Ross, Natvig, & Laudenslager, 2011). Findings demonstrated a significant effect
of pregnancy phase on hair cortisol levels (p = 0.003), with levels higher in the
third trimester relative to the first trimester (p < 0.001). Overall mean salivary and
hair cortisol levels calculated across all time points were significantly correlated
(p = 0.047).
Association between hair cortisol and self-report measures
Several studies have also examined the association between hair cortisol
and self-report measures of stress, with variable results. Wells et al. (2014) used
a pooled database from diverse community samples to examine associations
between hair cortisol concentrations and self-reported measures of stress as well
as mental health measures. Two centimeters of hair (reflecting the last two
months) were collected from participants for analysis of cortisol. Stress was
measured using the PSS-10 and the Chronic Stress Scale. To measure mental
health, the following data was collected: depression and anxiety (using screening
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questions taken from the DSM-IV); drug, alcohol and antidepressant use;
smoking status; WHO Disability Assessment (WHO-DAS II) (to assess limitations
in activities and daily functioning); and intimate partner aggression.
Hair cortisol concentrations (HCC) were significantly related to the use of
antidepressants, hazardous drinking, smoking, disability and aggression by
partner, after controlling for confounders. Correlations of HCC with self-reported
chronic stress and perceived stress were small and both were non-significant
after controlling for confounders. The authors provide several possible
explanations for the lack of association between HCC and self-report measures
of stress. The first explanation they offer is that HCC and self-report measures of
stress such as the PSS-10 do not reflect the same time frame. Second, they offer
the explanation that the relationship between hair cortisol and self-report
measures of stress may not be linear. They explored alternate models, and found
that HCC increased at higher levels of perceived stress but decreased at the
highest levels of stress, suggesting an inverse U relationship (Wells et al., 2014).
Conclusions
The Perceived Stress Scale-10 is a valid and reliable measure of stress of
an individual’s perceived stress over the past month. Salivary cortisol and IL-6
are measures of current HPA activity whereas hair cortisol reflects integrated
cortisol secretion over the past month. Together they can be used to measure
biological and behavioral levels of stress, providing a more complete picture of
the stress response. These measures were used in this study to examine the
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associations between chronic stress and ovarian function in female cancer
survivors.
Data Collection Schedule and Procedures
Recruitment began by sending letters of invitation to female cancer
survivors in long-term follow-up, two weeks prior to their annual review
appointment. Letters included a Patient Information Sheet and a reply slip
(Appendix E). By returning the reply slip, patients agreed to be contacted by the
research team. This manner of recruitment prevented patients from feeling any
obligation to participate. After consenting to be contacted, patients were
interviewed over the phone to determine eligibility to participate in the study. If
eligibility requirements were met and the patient agreed to participate, a 30minute study visit at the RHSC was scheduled at a mutually agreed upon time.
The study visit was scheduled within a week of the subject’s annual review visit.
Written consent was obtained from subjects at the study visit. Each subject was
assigned a unique study ID and data was entered into an SPSS file on an
encrypted computer in a locked office.
Procedure Data Collection
Data was collected in this order: saliva, demographic and PSS-10
questionnaires, hair. Salivette collecting devices and detailed instructions for
collection of samples were provided to participants at their annual review
appointment. Subjects were instructed not to eat, consume caffeine or exercise
for 30 minutes prior to sample collection (Schrepf et al., 2015). Subjects were
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instructed to record the date/time of saliva collection and to refrigerate samples
immediately following collection to preserve sample integrity. Subjects provided
four timed saliva samples: the first sample was collected before going to bed on
the night prior to the study visit, the second immediately upon awakening the
morning of their visit before getting out of bed, and the third and fourth were
collected 30 minutes after the second sample. Subjects were instructed to bring
the four saliva samples to the study visit. Samples were labeled with a unique
subject study ID. Saliva samples were stored at the RHSC at -20 C. Dr.
Anderson’s research nurse picked them up within a week of collection and
brought them to the QMRI, where they were centrifuged and stored at -80 C.
During the study visit, subjects provided demographic information
including age, ethnicity/race, years of formal education, marital status,
employment status, number of pregnancies and live births, and income status
(Appendix D). Subjects then completed the PSS-10, a 10-item questionnaire,
which measures perceived stress over the past month (Cohen et al., 1983).
Lastly, subjects provided a sample of hair for measurement of hair cortisol. A
small sample of hair, 20mg (100-150 strands), was taken from the vertex
posterior of the participant’s scalp using a new pair of thinning shears (Hoffman,
Karban, Benitez, Goodteacher, & Laudenslager, 2014; Van Uum et al., 2008).
Hair length was recorded and proximal ends of the hair samples were marked.
Hair samples were stored in aluminum foil for protection before processing
(Hoffman et al., 2014) and labeled with a unique subject study ID. Wells et al.
(2014) reported that 95% of 247 women consented to hair sampling conducted in
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this manner. To minimize variation in sample collection, research nurses were
trained on how to collect and store hair samples.
The following clinical characteristics were retrieved from subjects’ medical
records: age at cancer diagnosis, cancer type, treatment type and duration, age
at completion of treatment, comorbidities, prescription medications, and
reproductive history (age at menarche, last menstrual period, menstrual cycle
regularity, and parity). Reproductive hormone levels (AMH, FSH, LH and E2),
measured as part of routine care at the annual review visit, were also retrieved
from subjects’ medical records. This data was used to describe the sample
characteristics and explore subgroup effects on associations between variables
(aim 1).
Amendment to Data Collection Procedures
During data collection, it was discovered that many subjects travel a great
distance to the hospital for clinic visits. Therefore, to reduce the burden of
participation, subjects were given the option to receive a research packet in the
mail if they were unable to return to the Royal Hospital for Sick Children for a
separate study visit because of the travel distance. Since the current methods
already required subjects to collect saliva samples at home, the main change
was that subjects who decided to receive a research packet in the mail also selfcollected a hair sample. In a study of 70 multi-ethnic breast cancer survivors,
Ramirez et al. examined the feasibility of self-collection of hair samples and
demonstrated that it was a reliable and non-invasive way to measure cortisol
(Ramirez et al., 2017). Participants were instructed on how to collect the hair
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sample after consenting to participate in the study. They were also asked to
complete the PSS-10 at home. Biological samples and questionnaires were
labeled with the subject’s study ID so as to ensure confidentiality. No identifying
information was included in or on the research packet. The research packet
included prepaid return packaging and an ice pack so that subjects could return
samples and questionnaires to the Royal Hospital for Sick Children for
processing. Clements & Parker (1998) demonstrated that salivary cortisol
concentrations of samples frozen immediately after collection and samples sent
on ice were highly correlated (Clements & Parker, 1998).
Data Analysis and Interpretation
Means and standard deviations or frequency distributions, as appropriate,
for all demographic and clinical variables were reported to describe the sample
and reveal distributional characteristics.
Latent Growth Curve Modeling was used to examine diurnal cortisol
patterns. Bayesian Structural Equation Modeling was used to explore the
relationship between perceived stress and HPA activity and to explore
relationships between perceived stress, biomarkers of HPA activity, gonadotropin
levels, and AMH.
Latent Growth Curve Modeling
Latent Growth Curve Modeling was used to define diurnal cortisol change
over time (three time points). Growth curve modeling (GCM) examines change
as a trajectory and assumes that trajectories vary across participants (Barker,
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Rancourt, & Jelalian, 2013). This method was selected since chronic stress is
characterized by a persistent and unstable trajectory of HPA activity
(Hellhammer, Wüst, & Kudielka, 2009). Change processes are determined by
combining the underlying pattern of growth (slope) with the initial or baseline
measurement (intercept). The intercept and slope of this trajectory were then
incorporated into the structural equation model as independent predictors of
ovarian function. GCM was selected instead of more commonly utilized methods
of analyzing diurnal cortisol (e.g. area under the curve, cortisol awakening
response) because it permits a robust examination of change in small samples.
GCM was evaluated as yit = λintηint + λslpηslp + et, where yit represents the
observations for each subject i at each time t. λint represents the vector of fixed
values that define the latent intercept, this is λint = [1,1,1], while λslp represents the
vector of fixed values that define the linear slope, this is λslp = [0, 9.3, 9.8]. This
represents the average time between the first observation to the second (9.3
hours), and from the first observation to the third observation (9.8 hours). ηint
represents the latent intercepts, while ηslp represents the latent slope, for which
we estimate the respective mean and variance. The means represent the
average starting point and average change over time, while the respective
variance represents how much the subjects vary from the respective mean.
Lastly, et represents the residual variance at each time point t, this indicates that
the GCM is estimated without the assumption of homogeneity of variance over
time, the residual variance is allowed to differ over time.
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Bayesian analysis
In Bayesian analysis, statistical inferences are drawn from parameter
values that could give rise to the observed data (Scheines, Hoijtink, & Boomsma,
1999). The term prior is used to refer to the expected parameter distribution
based on theory or previous research. The posterior distribution is the parameter
distribution that results from multiplying the prior distribution by the likelihood (as
observed in the sample data). The posterior distribution describes the behavior of
the parameters conditional on the data. Because the Bayesian framework makes
inferences from the posterior distribution, it allows researchers to make direct
inferences about the parameters given the observed data. The posterior
distribution describes both the best estimate given the data, and the level of
uncertainty about the respective parameter by the width of it, typically
represented by the credible interval (Yuan & MacKinnon, 2009).
The Bayesian framework is an appropriate method for small sample sizes.
Frequentist methods rely on the asymptotically correct estimation methods,
basing the inference in function of the null hypothesis (Wagenmakers et al.,
2008). Bayesian inference bases the inference on the observed data, which
allows estimation of parameters with small samples in conditions where
frequentist estimation fails (Lee & Song, 2004).
The Bayesian approach requires specification of prior distributions for
each of the model parameters (Palomo, Dunson, & Bollen, 2007). The selection
of the prior distribution is important because the posterior distribution is informed
by the prior distribution and the likelihood of the data (Palomo et al., 2007). The
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prior distribution incorporates information drawn from previous empirical studies
or theory regarding the model parameters. Given the exploratory nature of this
study, we first examined the model parameters using weakly informed priors.
Weakly informed priors are not intended to guide the parameters, but instead
provide information to delimitate the most likely data space for the parameters.
Means/intercepts have a prior µ~N(0,100); the standard deviations have a prior
δ~half-cauchy(0,2.5); the regressions have a prior β~N(0,50); and the
correlations have a prior ρ~U(-1,1).
Strong hypotheses are tested by model comparison. A model without
constraints was compared to a model with constraints in the regressions (β),
constraining if the β is positive or negative (according to theory). These
constraints are set by specifying the respective β prior as a truncated normal
(e.g: β~N(0,50)T(0,)) not allowing β to be above/below 0. Model comparison
allowed us to evaluate if the model with directional constraints fit the data better
than the unconstrained model. If the directional constraint model fit better, it is
evidence that the β should be directional. The models were compared with
Information Criteria Leave-One-Out (LOO), and Widely Applicable (WAIC)
(Vehtari, Gelman, and Gabry, 2016; Gelman et al., 2013; Raftery, 1993; Kass,
and Raftery, 1995). The theoretical model including the hypothesized
directionality of the associations is presented in Figure 1.
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Bayesian Structural Equation Modeling
Structural Equation Modeling (SEM) provides a broad framework for
modeling relationships with multivariate outcomes (Palomo et al., 2007). The
purpose of SEM is to test a theory by specifying a model that represents
predictions about the theory’s constructs measured with appropriate observed
variables (Kline, 2016, p. 10). The outcome of SEM is a set of model parameters
for hypothesized effects given the data. From these parameters, a set of logical
implications result about the nature of the relationship or non-relationship
between the variables (Kline, 2016, p. 10). While SEM typically includes an
approximation of unobserved or latent constructs as well as an estimation of the
structure of the relationships among these observed constructs, in this study we
used a special case of SEM called path analysis. In path analysis, every variable
in the model is directly measured or observed (Bryan, Schmiege, & Broaddus,
2007). While latent variables account for unreliability of measures and
uncertainty in the model, they can also complicate a model, especially when the
sample size is small. Path analysis was selected instead of multiple linear
regression because it allowed us to test multiple relationships between variables,
with multiple outcomes, conforming to the hypothesized model in this study.
Establishing relationships including multiple paths and outcomes allowed us to
test the presence of relationships accounting for the relationships with other
variables of interest (Kline, 2015).
Bayesian SEM was selected because it facilitates greater precision in
estimating the posterior distribution of the parameters for small samples.
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Additionally, Bayesian SEM offers the advantage of incorporating previous
knowledge about the model’s parameters through the use of priors. Thus,
Bayesian SEM provided an excellent framework for exploring the relationships
between this study’s variables, allowing for an appropriate degree of uncertainty
when estimating the model’s parameters (Scheines et al., 1999). We ran a series
of path analysis models with salivary cortisol intercept and slope, PSS, Hair
cortisol, BMI, Age, Age at diagnosis, and Age at menarche as predictors and with
AMH, E2, FSH, and LH, as outcomes.
Because the aim of the study was to explore relationships between
variables, the analysis was not strictly confirmatory. If the data did not fit the
model specified, alternative models were tested. The purpose of exploring
various models was to provide additional information about the plausible
relationships between the variables of interest and make recommendations for
future model testing. Data augmentation was used to account for missing data.
Missing data was treated simultaneously as a parameter and data, filling any
missing data points with the most likely value given the posterior distribution. At
each iteration of the estimation, likely values were imputed for the missing data.
These likely values were drawn from the posterior distribution estimated at that
point in the iterations. In later steps of the estimation, the likely values were used
as data in the path analysis, and this process continued until the model had
converged (Merkle, 2011).
Data analysis was conducted in R (R Core Team, 2017). Bayesian path
analysis was run with the R package blavaan (Merkle & Rosseel, 2016), which
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estimates the model with the general Bayesian software JAGS (Plummer, 2003).
Convergence of the Markov chains was determined using the potential scale
reduction factor (PSRF), also known as univariate R-hat (see Gelman & Rubin,
1992). It was determined that the model converged when R-hat was lower than
1.10 for every parameter (Brooks & Gelman, 1998). The models were run with 3
chains, keeping the last 5000 iterations from each chain to build the posterior
distributions. Model comparison with LOO and WAIC were done with loo R
package (Vehtari, Gelman, and Gabry, 2016b); smaller values for LOO and
WAIC represent a better fit.
Protection of Human Subjects
Human Subjects Involvement and Characteristics, and Design
The goal of the proposed study was to explore relationships between
perceived stress, biomarkers of (hypothalamic-pituitary-adrenal) HPA activity,
and ovarian function in female survivors of childhood cancer. This population was
selected because female survivors of childhood cancer are at increased risk of
experiencing a premature decline in ovarian function. Additionally, cancer
survivors have higher levels of stress and HPA dysregulation. The association
between HPA dsyregulation and ovarian function in cancer survivors has not
been examined. The present study sought to fill this research gap so as to better
understand factors associated with this late effect of cancer treatment.
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Ethics approval in Scotland
The South East Scotland Research Ethics Committee approved the
study. Approval included recruitment materials and methods, consent forms, and
data collection protocols. The South East Scotland Research Ethics Committee
approved any changes made to the study protocol before they were
implemented.
IRB Oversight
Marquette University’s Institutional Review Board (IRB) reviews and
approves research involving the use of human subjects under the jurisdiction of
Marquette University. The IRB is charged with the responsibility of ensuring the
adequacy of the research plan, to minimize risks and to maximize the potential
benefits for human subjects who participate in research, based on federal and
state regulations as well as institutional policies. The proposed study was
approved by Marquette University’s IRB.
Data Management
Data management was compliant with the most current guidelines of the
Complete Health Insurance Portability and Accountability Act (HIPAA) of 1996
and in full conformance with the principles of the “Declaration of Helsinki”, in
accordance with the principles laid down in the Convention of the Council of
Europe for the protection of human rights and dignity of the human being with
regard to the application of biology and medicine.
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Original patient names and hospital barcodes were de-identified by using
a new, independent numbering system for all study related documentation (ie
pseudo-anonymisation). A link-list was established and kept separate from other
study documentation. The link-list was only accessible by the Principal
Investigator (Theresa Hardy), Dr. Anderson, Dr. Wallace, and Rachel McAndrew
(oncology research nurse). Theresa Hardy was granted an NHS Lothian visiting
researcher passport giving her access to clinical data once participants
consented to participate in the study.
Data Protection
All personal information was kept separate from the research record.
Consent forms (Appendix F) were stored in locked filing cabinets in locked NHS
premises at the Department of Pediatric Oncology, RHSC. Consent forms were
stored on the NHS premises until the completion of the study. No identifying
information will be stored on secure University computers, with all relevant files
accessed only by the researchers and protected by passwords. Computer-stored
data will be on password-protected computers/servers without identifying
information.
Potential Risks
The risks to subjects are minimal. The time required to collect saliva
samples at home as well as involvement in the study may be an inconvenience
to subjects. The collection of hair samples may cause some discomfort to
subjects. However, previous researchers have found taking a small hair sample
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from the vertex to be very acceptable (personal communication from Dr. Jodi
Ford, Ohio State University, Columbus, Ohio, July 2015). The PSS-10 is a
measure of stress perceived over the past month. As subjects recall stress, they
may experience some distress.
Adequacy of Protection Against Risk
Recruitment and Informed Consent
All recruitment materials and procedures were reviewed and approved by
the South East Scotland Research Ethics Committee and the Marquette
University IRB prior to initiating data collection. The letter of invitation (Appendix )
sent to potential subjects included a description of the study, what was involved if
they agreed to take part, and an explanation of risks. Written informed consent
was obtained at the annual review appointment. Potential subjects had the
opportunity to ask questions before providing consent. Participants were allowed
to withdraw from the study at any point. Any patients identified as participating in
ongoing interventional research were not recruited.
Protection Against Risk
The primary risk of the proposed study was risk of disclosure of personal
data, which was minimized by the data management and security measures
described above. Risk of harm associated with biological specimen collection
was minimized by adhering closely to study procedures and allowing subjects to
withdraw from the study at any point. NHS staff were available to treat any
adverse effects due to study collection procedures, and any subject that
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expressed emotional distress as a result of recalling perceived stress were
referred to a member of the interdisciplinary care team.
Potential Benefits of the Proposed Research to Human Subjects
Any relevant clinical information obtained during the course of the study
was made available to participants during routine care.
Importance of the Knowledge to be Gained
The findings from this study will be used to improve knowledge of factors
associated with fertility and ovarian function in female survivors of childhood
cancer, which may inform decision-making prior to and after treatment of cancer
in young women. Reproductive potential is a major concern for cancer survivors.
The knowledge gained from this study will directly contribute to quality of life for
female cancer survivors. Potential risks to subjects are minimal and reasonable
in relation to the importance of the knowledge that will be obtained.
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Chapter 4: Results

The findings from this study are presented in the manuscript entitled,
“Chronic Stress and Reproductive Function in Female Childhood Cancer
Survivors” and can be found in Appendix C.
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Chapter 5: Discussion, Implications, and Conclusion
In this chapter, the main findings from this dissertation will be summarized.
The strengths and limitations of the study and the implications for nursing
practice, education and research will be discussed.
Chronic Stress and Reproductive Function in Female Childhood Cancer
Survivors
In this study, we examined the association between chronic stress and
ovarian function in childhood cancer survivors. The hypothalamic-pituitaryadrenal (HPA) axis is one of the primary regulators of reproductive function
(Shannon Whirledge & Cidlowski, 2013b). As high levels of psychological stress
and HPA dysregulation have been observed in childhood cancer survivors
(Oancea et al., 2014; Taylor et al., 2012; Zeltzer et al., 2009), we hypothesized
that increased psychological stress and HPA dysregulation would be associated
with lower levels of gonadotropins and anti-Müllerian hormone (AMH), a
biomarker of the ovarian reserve. We found that perceived stress was negatively
associated with ovarian function, and that biomarkers of HPA activity were
positively associated with ovarian function in female childhood cancer survivors.
The findings from this study provide preliminary evidence supporting the
hypothesis that chronic stress negatively impacts ovarian function and may
contribute to infertility in female childhood cancer survivors.
While many cancer survivors encounter impaired fertility after treatment,
few studies have examined predictors of the ovarian reserve in childhood cancer
survivors other than diagnosis and treatment-related factors. Pre-treatment
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planning and the ability to provide individualized fertility prognoses depends on
increased understanding of factors associated with the ovarian reserve in this
population (Anderson et al., 2013; Knopman et al., 2010). The findings from this
study provide the foundation for further research examining factors that
contribute to risk for post-treatment reproductive dysfunction in female childhood
cancer survivors.
Strengths of the study
This exploratory study has several strengths. First, this study involved
interdisciplinary collaboration, bringing together expertise from oncology,
reproductive endocrinology and nursing to examine factors associated with posttreatment reproductive function with the aim of improving quality of life for
childhood cancer survivors (Kremer et al., 2013). Second, we used Bayesian
structural equation modeling to address the study’s aims, a useful approach for
small sample sizes. Bayesian inference is based on the observed data,
permitting estimation of parameters with small samples in conditions where
frequentist estimation fails (Lee & Song, 2004). Third, while the sample size was
small, the association between chronic stress, measured as both perceived
stress and HPA activity, and ovarian function has not been previously examined
in childhood cancer survivors. As this population is at higher risk of infertility, the
findings from this study provide the foundation for further hypothesis testing.
And last, this study demonstrates the feasibility of examining factors that
contribute to reproductive function in this population. Of those asked to
participate in the study, all but one consented. The participants expressed
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interest in contributing to research in this area. Contrary to our concern that
cancer survivors might be reluctant to provide a hair sample, no one refused to
participate for this reason. Hair cortisol has not been utilized as a measure of
chronic stress in childhood cancer survivors; this study demonstrates that this
measure may be a useful non-invasive biomarker of chronic stress in this
population.
Limitations of the study
Several aspects of data collection may have impacted the study’s internal
validity. Clinical and demographic information was collected using self-report. To
reduce the potential for recall bias, we verified information using medical records.
The Perceived Stress Scale (PSS-10) also relies on subject recall. However, the
PSS-10 is the most widely used measure of perceived stress and has
demonstrated good to excellent reliability in varied populations (Sheldon Cohen
et al., 1983). The measure has also been utilized to reliably measure stress
appraisal in cancer survivors (Golden-Kreutz, Browne, Frierson, & Andersen,
2009).
As the Royal Hospital for Sick Children was far away for many patients,
participants were given the choice to self-collect hair and saliva samples at home
rather than returning to the hospital for a study visit. Participants were provided
with a prepaid packet and an ice pack to return the samples; postal
transportation of samples may have affected sample integrity. However,
Clements & Parker (1998) demonstrated that salivary cortisol concentrations of
samples frozen immediately after collection and samples sent on ice were highly
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correlated (Clements & Parker, 1998). In addition, the amendment allowed
participants to self-collect hair samples. In a study of 70 multi-ethnic breast
cancer survivors, Ramirez et al. examined the feasibility of self-collection of hair
samples and demonstrated that it was a reliable and non-invasive way to
measure cortisol (Ramirez et al., 2017). And finally, the majority of samples had
undetectable IL-6 levels, so we were unable to include this measure in the
analysis. IL-6 is less stable, and sample integrity may have been affected by
collection procedures (Izawa, Miki, et al., 2013).
There are also several factors that may have impacted the study’s
external validity. The study design was cross-sectional and relied on a
convenience sample. Due to the small sample, we were unable to adjust for
hormonal contraceptive use in the overall model. Hormonal contraceptive use is
associated with increased production of corticotropin-binding-globulin and
subsequent decreases in unbound cortisol levels (Stephens, Mahon, McCaul, &
Wand, 2016). In addition, due to the wide variety of pediatric cancer diagnoses in
the sample, we could not adjust for cancer diagnosis and treatment-related
factors in the model. Several studies have found a significant effect of diagnosis
and treatment-related factors on post-treatment ovarian function, including the
cancer pathology itself (Van Dorp et al., 2014), the therapeutic regimen
(Charpentier et al., 2014) and the length of exposure (El-Shalakany et al., 2013;
Reinmuth et al., 2013). Another limitation is that due to the great distance that
many of the participants needed to travel, we were unable to time study visits to
coincide with a specific menstrual cycle phase. For this reason, we were unable
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to adjust gonadotropin and reproductive hormone levels to account for menstrual
cycle phase.
Integrative Review
The majority of the studies examining AMH as a biomarker of the ovarian
reserve have been conducted in women diagnosed with infertility or polycystic
ovary syndrome. AMH has been proposed as a biomarker of the ovarian reserve
for use in reproductive medicine; in order to improve its accuracy as a reliable
biomarker, more studies examining AMH in healthy samples are needed. The
gaps in this area have limited the ability of AMH to reliably predict reproductive
outcomes/ reproductive potential in healthy samples, thus significantly limiting the
utility of the biomarker (Steiner et al., 2017a; Zarek et al., 2015). An increased
understanding of factors associated with AMH concentrations in healthy women
will provide greater context for the clinical evaluation and interpretation of AMH
concentrations.
An integrative review was conducted with the purpose of summarizing the
evidence regarding the modifiable biobehavioral factors associated with AMH
concentrations in healthy reproductive age women. We found that various
reproductive (contraceptive use, parity), biological (obesity, cardiometabolic) and
behavioral (smoking, alcohol and caffeine consumption) factors have been
examined in association with AMH concentrations. Among the studies included in
the review, hormonal contraceptive use was most often examined. The majority
found lower AMH levels in hormonal contraceptive users compared to non-users.
Previous contraceptive use, however, was not associated with lower AMH levels
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after contraceptive use was discontinued, suggesting a reversible effect. Given
the current level of evidence, clinicians and researchers should be cautious when
interpreting AMH levels during hormonal contraceptive use. Among the other
factors examined, findings were mixed. The findings from the integrative review
demonstrate that our understanding of the modifiable biobehavioral factors
influencing AMH concentrations is incomplete and further research is needed.
Latent Class Analysis
In order to establish AMH as a reliable biomarker of the ovarian reserve, it
is vital to explore how it behaves within the context of other health parameters. In
addition to the primary study, we performed a second study exploring the
feasibility of using Latent Class Analysis (LCA) to identify subgroups based on
cardiometabolic (lipids, BMI, cortisol), psychological (depression, anxiety) and
reproductive factors (FSH, LH, E2, AMH). We used stored postpartum blood
samples of 69 women from a prospective cohort study examining mood and
weight changes in pregnant women in Edinburgh, Scotland. We were able to
identify three subgroups with unique class characteristics based on the factors
included in the LCA, specifically focusing on AMH in our discussion of class
characteristics. While the sample size was small, the findings of this exploratory
study provide the foundation for further hypothesis testing regarding the effect of
cardiometabolic and psychological parameters on reproductive health and
fertility. In addition, it demonstrates that LCA is a feasible approach for identifying
subgroups based on underlying patterns of cardiometabolic, psychological, and
reproductive factors. While the findings of the study require validation in larger
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cohorts, it demonstrates the potential of using LCA to examine AMH or other
biomarkers in the context of other significant parameters of health, including
cardiometabolic and psychological factors.
Implications for nursing practice
The findings from these studies have several important implications for
oncology and woman’s health nursing practice. Reproductive dysfunction is a
major concern for cancer survivors, and is highly correlated with quality of life in
this vulnerable population (Cherven et al., 2015; Knopman et al., 2010;
Kondapalli et al., 2014; Letourneau et al., 2013). However, studies have
demonstrated that cancer survivors are about half as likely to be treated for
infertility as their siblings (Barton et al., 2013). While the reasons for this
discrepancy are not fully understood, healthcare providers may perceive fertility
treatments to be less successful in this population. Additionally, knowledge
regarding factors that contribute to risk for post-treatment reproductive
dysfunction is incomplete (Knight et al., 2015; Letourneau et al., 2013). The
guidelines from The American Society for Clinical Oncology recommend that
options for fertility preservation be discussed with cancer patients at the earliest
opportunity (Knight et al., 2015; Letourneau et al., 2013). Oncology nurses play
an important role in advocating for cancer survivors, helping to initiate
conversations regarding future fertility as early as possible and discussing factors
that may mitigate the risk for post-treatment reproductive dysfunction. The
findings from this study also suggest that there may be modifiable factors such
as chronic stress that contribute to risk for infertility post-treatment. Oncology

77
nurses can minimize the potential burden of late effects by educating patients
regarding their risk and what actions can be taken prior to or after treatment to
reduce this risk (McClellan et al., 2013).
This research also has important implications for woman’s health nursing.
Many women seek out information regarding their fertility potential. The
integrative review provides nurses with an evidence-based summary of
modifiable biobehavioral factors associated with AMH, a biomarker of the ovarian
reserve. AMH is increasingly used in reproductive medicine as a biomarker of
fertility lifespan and reproductive potential (Didier Dewailly et al., 2014). While it
has demonstrated significant value in the context of assisted reproduction, its
value as a predictor of natural fecundity has not been established (Hagen,
Vestergaard, et al., 2012; Steiner et al., 2017a; Zarek et al., 2015). Therefore,
nurses can discuss with women the current limitations in the clinical interpretation
of AMH levels, given the present level of evidence.
Implications for nursing education and research
Understanding how to interpret biobehavioral data is vital to the nursing
role. The studies included in this dissertation demonstrate the importance of
understanding how biology and behavior interact to influence patient outcomes.
Nursing education should emphasize a biobehavioral approach to health so as to
prepare nurses to provide individualized care to patients, taking into account
biological data while also considering the ways in which lifestyle and environment
contribute to disease risk. Nursing research should continue to utilize
biobehavioral methodology to address questions related to human health and
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disease, integrating a depth of understanding regarding the pathophysiological
mechanisms of disease with a thorough comprehension of human behavior,
lifestyle and environment.
The nursing profession is tasked with health promotion and disease
prevention. For this reason, nurses need an understanding of disease risk and
the tools available to help identify or measure that risk (e.g. biomarkers). As a
biomarker of the ovarian reserve, AMH provides a window into the process of
ovarian aging. In addition to increased risk of infertility, ovarian aging is
associated with increased risk of cardiovascular disease, osteoporosis and mood
disturbances (F. J. Broekmans, Soules, & Fauser, 2009). Thus, the applications
of AMH as a biomarker of ovarian age extend well beyond reproductive health
and may provide insight into women’s’ overall health (Pal, Bevilacqua, Zeitlian,
Shu, & Santoro, 2008). Nursing education and research should continue to utilize
and improve tools such as AMH to promote reproductive health and prevent the
burden of infertility.
Future research
It is well established that stress disrupts reproductive function (Shannon
Whirledge & Cidlowski, 2013b). The proposed explanatory mechanism is HPA
dysregulation. As childhood cancer survivors are exposed to significant early life
stress and are at higher risk of infertility due to the gonadotoxicity of
chemotherapy, we sought to explore the relationship between stress, HPA
activity and ovarian function in this population. The findings of this study provide
preliminary evidence to support a negative association between perceived stress

79
and ovarian function in female childhood cancer survivors. Our findings also
provide evidence to support the role of the HPA axis in regulating reproductive
function. We found a positive association between the salivary cortisol intercept
and slope and AMH as well as a positive association between hair cortisol and
AMH, suggesting that threshold glucocorticoid levels are required to maintain
reproductive function. These findings are consistent with other studies that have
demonstrated an association between hypocortisolism and increased risk for
adverse outcomes in cancer survivors (Cuneo et al., 2017).
The HPA axis mediates resource allocation decisions and plays an
important role in determining an organism’s life history traits. In this study, we
sought to explore the association between HPA activity and the ovarian reserve
in female childhood cancer survivors in order to increase our understanding of
how pediatric cancer influences life history traits, specifically reproductive
function. Biomarkers of HPA activity may provide valuable information regarding
increased risk for infertility in this population. Additional studies with larger
samples are needed to further explore this hypothesis.
More research is also needed to examine the biobehavioral factors
associated with AMH as a biomarker of the ovarian reserve. Longitudinal studies
are needed to examine the influence of biobehavioral exposures over time. In
addition, randomized controlled trials are needed to examine the effect of lifestyle
modification (i.e. stress reduction programs, smoking cessation, weight loss) and
pharmacological intervention on the ovarian reserve and to determine whether an
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improvement in AMH concentrations is associated with subsequent improvement
in reproductive outcomes.
This dissertation examined the association between biobehavioral factors
and the ovarian reserve. The mechanisms contributing to diminished ovarian
reserve are complex, and in addition to biobehavioral factors, include
environmental and genetic factors. Further research is needed to examine how
biology, genetics and environment interact to impact reproductive lifespan and
fertility. Epigenetic changes have been proposed as the link between
biobehavioral exposures and reproductive disorders. Further research is needed
to examine epigenetic influences on the ovarian reserve in order to obtain a
better understanding of how environmental and biobehavioral exposures
contribute to infertility. Findings from this research can be used develop reliable
risk models incorporating environmental, lifestyle, and genetic factors for the
early detection of infertility. With a better understanding of the mechanisms
contributing to the ovarian reserve, nurse scientists can contribute to the
development of novel therapeutic interventions for the treatment of infertility.
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Abstract
Objective: Anti-Müllerian hormone (AMH) is an emerging biomarker of ovarian
reserve. There is inadequate understanding of the modifiable biobehavioral
factors contributing (AMH) concentrations in normo-ovulatory women. The
purpose of this integrative review was to provide a summary of the modifiable
biobehavioral factors associated with AMH concentrations.
Data Sources: An electronic literature search was conducted in PubMed using
the following search terms: “anti-Müllerian hormone” NOT “polycystic ovarian
syndrome” NOT “cancer” NOT “endometriosis” NOT “assisted reproductive
technology”.
Study Selection: Studies were included in the review if the population studied
was healthy reproductive age women (ages 19+), the exposure was a modifiable
biobehavioral factor, the outcome was serum AMH, and the biobehavioral factor
was examined in 2 or more studies.
Data Extraction: For each study, the first author, year of publication, study
design, sample size, age range, groups, covariates and main finding were
summarized and organized by factor.
Data Synthesis: A total of 39 studies were included in the final review. Studies
were published between 2007-2017. Sample sizes ranged from 20-2320. Study
designs included cross-sectional, prospective cohort, retrospective cohort, and
case-control. The main biobehavioral factors relating to AMH levels that emerged
from the review were contraceptive use (n=14), parity (n=5), BMI (n=11),
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cardiometabolic factors (n=4), smoking (n=10), alcohol consumption (n=4) and
caffeine (n=3) consumption.
Conclusion: Our understanding of the modifiable biobehavioral factors
influencing AMH concentrations is incomplete. Increased understanding of the
biobehavioral factors associated with AMH levels will improve the quality of care
for women at risk for infertility.
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Introduction
Scientists continue to search for reliable and clinically useful biomarkers in
the field of reproductive medicine (Palmer & Barnhart, 2013). The process of
ovarian aging that eventually culminates in menopause spans approximately ten
years, and there are few biomarkers that determine reproductive age. One
biomarker that has received considerable attention in the field of reproductive
medicine is anti-Müllerian hormone (AMH). A woman’s reproductive age is
determined by the size of the primordial follicle pool, referred to as the ovarian
reserve. Circulating AMH levels are recognized to reliably reflect the size of the
primordial follicle pool, making AMH a promising non-invasive marker of the
ovarian reserve (Hansen et al., 2011).
Longitudinal studies involving normo-ovulatory women have found that
serum AMH concentrations accurately predict the onset of menopause (Broer et
al., 2011; van Disseldorp et al., 2008). The hormone is ideal as a research and
clinical measure because, unlike follicle stimulating hormone (FSH)-- another
biomarker of the ovarian reserve—serum AMH concentrations remain relatively
stable across the menstrual cycle, are independent of gonadotropin levels
(Hehenkamp et al., 2006; La Marca et al., 2010; Shaw et al., 2011) and correlate
with the number of developing follicles in the ovary (Dewailly et al., 2014). Age
remains the strongest determinant of ovarian reserve, and 34% of the variation in
AMH levels can be attributed to age alone (Kelsey, Wright, Nelson, Anderson, &
Wallace, 2011). Although normative age ranges for AMH have been established,
there is considerable variation within the same age range (Konishi, Nishihama,
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Iida, Yoshinaga, & Imai, 2014; La Marca et al., 2012; Lie Fong et al., 2012;
Nelson, Messow, Wallace, Fleming, & McConnachie, 2011). To improve the
clinical application of AMH as a reliable biomarker of the ovarian reserve, further
research is needed to understand factors other than age that contribute to the
observed variations in AMH levels in healthy women.
AMH has proven utility in the field of assisted reproductive medicine
(Iliodromiti et al., 2014), but its value in predicting natural fecundability is less
clear (Hagen, Vestergaard, et al., 2012; Steiner et al., 2017b; Zarek et al., 2015).
AMH is widely used in reproductive medicine to counsel women regarding their
future fertility, and many women struggling to conceive have sought out
information regarding risk factors that contribute to a premature decline in AMH
concentrations. While several studies have examined factors associated with
AMH concentrations, the bulk of data comes from studies involving infertile
women, or women diagnosed with polycystic ovary syndrome (PCOS). It is
unclear if modifiable biobehavioral factors contribute to AMH concentrations in
normo-ovulatory women. A greater understanding of AMH levels in the healthy
female population will help to refine normative age ranges for use of this
biomarker of the ovarian reserve in clinical practice and research. The purpose of
this integrative review is to provide a summary of the modifiable biobehavioral
factors associated with AMH concentrations.
Function of AMH
Anti-Müllerian hormone (AMH), a member of the TGF-β family, is a
product of granulosa cells of pre-antral ovarian follicles. AMH plays a role in
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ovarian follicle growth, specifically in regulating the pace of follicle recruitment
and selection. AMH is expressed in granulosa cells of small growing follicles with
its strongest expression in preantral and small antral follicles between 5-8mm in
diameter (Jeppesen, Anderson, Kelsey, Christiansen, Kristensen, Jayaprakasan,
Campbell, et al., 2013). AMH is no longer expressed by granulosa cells during
FSH-dependent stages of follicle growth or by atretic follicles, degenerated
follicles that do not ovulate during the menstrual cycle (Frank J. Broekmans et
al., 2008; Didier Dewailly et al., 2014).
The role of AMH in follicle growth was first characterized in studies of
AMH-deficient mice (Visser et al., 2007). These studies demonstrated that AMH
acts as an inhibitor of primordial follicle recruitment (Durlinger et al., 1999, 2002).
AMH-deficient mice had more growing follicles and an increased rate of oocyte
degeneration and follicle atresia (Visser et al., 2007), indicating that in the
absence of AMH, primordial follicles are recruited at a faster rate, leading to a
premature depletion of the follicle pool. Another consequence of AMH absence is
an increased sensitivity of growing follicles to FSH. AMH has an inhibitory effect
on FSH and therefore plays an important role in the selection of the dominant
follicle (Durlinger et al., 2001; Sacchi et al., 2016; Visser & Themmen, 2014;
Visser, de Jong, Laven, & Themmen, 2006).
Methods
This review was conducted using the guidelines for integrative reviews
(Whittemore & Knafl, 2005). The integrative review methodology was selected
because it provides a framework for summarizing evidence from studies with
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diverse methodologies. An electronic literature search was conducted in PubMed
on January 17, 2018 using the following search terms: “anti-Müllerian hormone”
NOT “polycystic ovarian syndrome” NOT “cancer” NOT “endometriosis” NOT
“assisted reproductive technology”, using filters: females, humans, English. To
focus the review, studies conducted in the pediatric/adolescent population were
excluded. Titles and abstracts, if necessary, of all resulting citations were read.
The full text of all potentially eligible studies was read to determine whether
studies met the eligibility criteria. Reference lists of included studies were also
searched in order to identify any relevant studies missed in the primary search.
Studies were included if they met the following criteria:
1) The population studied was healthy reproductive age women. The
population was considered “healthy” if they were not identified as having
an infertility diagnosis or any other disease process that could potentially
alter AMH levels.
2) The exposure was a modifiable biobehavioral factor, involving the
interaction of biological and behavioral processes (Webster).
3) The outcome was serum AMH and was measured in all study participants.
4) The biobehavioral factor was examined in 2 or more studies.
The primary author selected and read all studies. Studies were grouped
by the biobehavioral factors that emerged from the literature search. For each
study, the first author, year of publication, study design, sample size, age range,
groups, covariates and the main finding are summarized and organized by factor
(Tables 1-7).
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Results
The search strategy resulted in 408 studies. The search strategy is
provided in Figure 1. Using the search criteria described above, fifty studies were
selected from the primary search. After reading the full text of all 50 studies, 17
were excluded for the following reasons: the factor was only examined in one
study (n=8), examined associations between AMH and non-modifiable risk
factors (n=6), examined an intervention (n=1), population with illness (1), AMH
examined as predictor (n=1). Six studies were added from the reference lists of
included studies. A total of 39 studies were included in the final review.
Studies were published between 2007-2017. Sample sizes ranged from
20-2320. Study designs included cross-sectional, prospective cohort,
retrospective cohort, and case-control. The main biobehavioral factors relating to
AMH levels that emerged from the review were contraceptive use (n=14), parity
(n=5), BMI (n=11), cardiometabolic factors (n=4), smoking (n=10), alcohol
consumption (n=4) and caffeine (n=3) consumption.
Reproductive factors
Several studies examined whether reproductive factors were associated
with a woman’s ovarian reserve trajectory (Daan & Fauser, 2015). Reproductive
factors that have been examined in relation to AMH levels are contraceptive use
(n=14) and parity (n=5).
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Contraceptive Use
Hormonal contraceptive use was examined in the greatest number of
studies (n=14). Contraceptive use suppresses ovarian follicle growth by inhibiting
gonadotropin secretion via exogenous administration of reproductive hormones.
Ten studies found a significant inverse association between AMH levels and
current hormonal contraceptive use. In a recent large retrospective cohort study,
Marsh et al. (2016) examined factors associated with AMH in 1,654 African
American women (23-34 years). In a multivariable model adjusting for BMI,
history of abnormal menstrual bleeding, history of a thyroid condition, and history
of seeking care for difficulty conceiving, current hormonal contraceptive use
(27.5%) was inversely associated with AMH levels (β = -0.290, 95% CI -0.408, 0.171), p < .0001 (Marsh et al., 2016). Five studies were cross-sectional and
examined whether there were was a significant difference in AMH levels between
users and non-users of oral contraceptives. In all five studies, oral contraceptive
use was associated with significantly lower AMH levels (Bentzen et al., 2012;
Birch Petersen et al., 2015; Dolleman et al., 2013; Kristensen et al., 2012; Shaw
et al., 2011). One study was retrospective and also found a significant inverse
association between oral contraceptive use and AMH levels (p < 0.001) (Kerkhof
et al., 2010).
Two of the studies were prospective and examined AMH levels pre- and
post- oral contraceptive use (Arbo, Vetori, Jimenez, Freitas, & Lemos, 2007;
Kallio et al., 2013). Arbo et al. (2007) examined AMH levels pre- and one month
post administration of the oral contraceptive pill (OCP) in 20 normo-ovulatory
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infertile women (male factor or tubal occlusion). AMH levels were significantly
reduced after pituitary suppression, with a median (inter-quartile range) of 3.02
ng/mL (1.21–6.39) before OCP and 2.22 ng/mL (0.9–3.11) after OCP, p < 0.04
(Arbo et al., 2007).
Kallio et al. (2013) measured AMH levels in 42 women in Finland (20–33
years) prior to contraceptive administration and at 5 and 9 weeks post
administration in three groups (OCP, transdermal patch, or vaginal ring). In
addition to examining the effect of hormonal contraceptive use on AMH levels,
the authors examined whether the effect differed depending on route of
administration. They found significant decreases in AMH levels after 9 weeks in
all groups: OCP (3.88 ± 3.0 vs. 1.91 ± 1.5 ng/mL, p < .001), transdermal (3.86 ±
3.6 vs. 1.96 ± 1.3 ng/mL, p < .001), and vaginal ring (4.27 ± 3.5 vs. 2.25 ± 1.2
ng/mL, p < 0.001). However, they found no significant difference between the
groups, demonstrating that combination (estrogen plus progestin) hormonal
contraceptive use lowers AMH levels regardless of the route of administration
(Kallio et al., 2013).
In the last study, van den Berg (2010) examined AMH levels in 25 Dutch
women in the hormone free interval (either using the standard 21-/7- day regimen
or an extended regimen) of a contraceptive cycle and two consecutive natural
cycles. There was a significant increase in AMH levels between the hormone free
interval of the contraceptive cycle and the consecutive natural cycles (p = 0.005).
The authors demonstrate that AMH levels are suppressed in the hormonal
contraceptive cycle and that levels increase after use of contraceptive is stopped.
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In contrast, four studies found no association between AMH levels and
contraceptive use. In a prospective case-control study, Deb et al. (2012)
compared the AMH levels of 34 subjects who had been using the combined OCP
(30 mcg of ethinylestradiol and 150 mcg of levonorgestrel) for more than a year
with 36 control subjects who had not used any form of hormonal contraceptive in
the last year and found that AMH levels did not differ significantly between the
two groups. However, the study did not adjust for age (18-35 years), making it
difficult to determine the strength of the evidence.
Contrary to the study by Kallio et al. (2013), Li et al. (2011) compared
AMH levels pre- and 3-4 months post- administration of five different hormonal
contraceptive types in 95 women. The five types included the (1) combined oral
contraceptive (COC) (Microgynon-30®, n=23); (2) combined injectable
contraceptive (CIC) (Cyclofem®, n=23); (3) progestogen-only contraceptive pill
(POP) (Cerazette®, n=9); (4) progestogen-only injectable (POI) (Depo-Provera®, n=20); and (5) levonorgestrel intrauterine system (LNG-IUS) (Mirena®,
n=20). There was no significant difference between pre- and post-treatment
serum AMH levels in all the treatment groups (p > .05). However, the authors
made no adjustment for age (25-50 years), and did not provide complete
statistics, making it difficult to evaluate the strength of the findings (H. W. R. Li,
Wong, Yeung, Ho, & Ng, 2011).
Similarly, Streuli et al. (2013) compared AMH levels in 24 women divided
into three groups, (1) control group; (2) 0.02 mg of ethinylestradiol (EE) plus 0.15
mg of desogestrel (DSG) orally (Mercilon); and (3) 0.015 mg of EE and 0.12 mg
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of etonogestrel, the active metabolite of DSG, through a vaginal ring (Nuvaring).
They also found no significant differences in AMH levels pre- and one month
post- administration of hormonal contraceptives (Streuli et al., 2008).
Finally, Kucera et al. (2016) compared AMH levels in females who had
used hormonal contraceptives for a period of at least 10 years and had ceased
use 1 year prior to sample collection (n=105) with females who had never used
hormonal contraceptives. The median concentration of AMH in the group of longterm users of hormonal contraceptives was 2.89 ng/ml. The median
concentration of AMH in the group of women who had never used contraceptives
was 3.37 ng/ml. There was no statistically significant difference between the
groups (p = 0.3261) (Kucera, Ulcova-Gallova, & Topolcan, 2016).
While there is contradictory evidence regarding the association between
hormonal contraceptive use and AMH levels, the majority of the studies found an
inverse association between AMH levels and hormonal contraceptive use. The
findings from several small studies (Deb et al., n=34; Streuli et al., n=24) included
in this review suggest that short-term administration of oral contraceptives (less
than 3 months) has a limited impact on AMH levels (H. W. R. Li, Wong, et al.,
2011; Streuli et al., 2008). In contrast, many studies found lower serum AMH
concentrations with long-term hormonal contraceptive use, suggesting that
hormonal contraceptive use suppresses follicle development (Bentzen et al.,
2012). However, several studies also found that AMH levels recover after
ceasing hormonal contraceptive use and that there was no significant difference
in AMH levels between those who never used hormonal contraceptives and
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those who previously used them, suggesting that the ovarian suppression
induced by long-term hormonal contraceptive use is temporary (Dolleman et al.,
2013; Kucera, Ulcova-Gallova, & Topolcan, 2016; La Marca et al., 2010; Van
Den Berg et al., 2010). More research is needed to clarify the association
between various characteristics of contraceptive use (duration, type, etc…) and
AMH levels, as well as a more precise timeline of the return to normal AMH
levels once hormonal contraceptive use is discontinued.
Parity
Several studies examined the association between parity and AMH
concentrations (n=5). In a study of 294 women, Bragg et al. found that women
with two (p < 0.05) and three or more (p < 0.01) children had significantly lower
AMH levels than those with no children. However, they were unable to exclude
women with PCOS from the study. Since PCOS is characterized by abnormally
elevated AMH concentrations and subfertility, this may have skewed the results.
In a sample of 420 women, Whitworth et al. (2015) found that women with the
highest parity had 20% lower AMH concentrations (95% CI = −39% to 6%) than
nulliparous women.
Contrary to these studies, Dolleman et al. (n = 2,320) found that higher
parity was associated with higher age-specific AMH levels (p < .02). However,
after adjusting for contraceptive use, cycle irregularity, pregnancy, and current
smoking, parity was no longer significant (Dolleman et al., 2013). In a crosssectional study of 186 women, Moini et al. (2016) found that multiparous women
had significantly higher AMH levels than nulliparous women (Moini,
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Hedayatshodeh, Hosseini, & Rastad, 2016). The mean AMH level was 2.53 ±
1.90 ng/ml in nulliparous women and 3.54 ± 1.42 ng/ml in women with children (p
< .0001), suggesting that increased parity is associated with increased AMH
levels. And finally, in a cross-sectional study of 277 women, La Marca et al.
(2010) found no association between parity and AMH levels (La Marca et al.,
2010).
Resolution of conflicting findings regarding the effects of parity on AMH
requires further studies. Higher parity may result in later age at natural
menopause by suppressing follicle recruitment and ovulation (during pregnancy),
thus preserving the follicle pool and resulting in later menopause (Gold et al.,
2001). This explanation is consistent with the findings from the studies by
Dolleman et al. and Moini et al. In contrast, studies that found lower AMH levels
in women with higher parity posit that this association may be explained by the
costly energetic investment required for pregnancy at the expense of future
reproductive potential (Bragg, Kuzawa, Ahustin, Banerjee, & McCade, 2012).
Biological factors
Obesity
Obesity inhibits reproductive function by altering the secretion of
gonadotropin releasing hormone, which disrupts the ovarian follicular
environment and leads to anovulation (Halawaty, ElKattan, Azab, ElGhamry, &
Al-Inany, 2010; Klenov & Jungheim, 2014; Moy, Jindal, Lieman, & Buyuk, 2015;
Vryonidou, Paschou, Muscogiuri, Orio, & Goulis, 2015b). Eleven studies
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examined the correlation between BMI and AMH. Six observed an association
(Bernardi et al., 2017; Bleil et al., 2014; Dafopoulos et al., 2010; Freeman et al.,
2012; Steiner et al., 2010; Su et al., 2010) and five did not (Bentzen et al., 2013;
Dolleman et al., 2013; Halawaty et al., 2010; La Marca et al., 2010; Sahmay et
al., 2012).
Bernardi et al. (2017) conducted one of the largest studies examining the
relationship between BMI and AMH in 1,654 African American women. At
enrollment, 19.8% of participants were underweight or normal, 20.7% were
overweight and 59.5% were obese. When current BMI was analyzed as a
continuous variable (15.9-79.4 kg/m2), there was a significant inverse relationship
with AMH levels in the age-adjusted and the multivariable linear regression
model, after adjusting for current hormonal contraceptive use, history of a thyroid
condition, abnormal menstrual bleeding and menstrual cycle length. When
current BMI was analyzed as a categorical variable, there was also a significant
association between AMH and BMI, with the strongest association observed in
the group with the highest BMI. This study provides convincing evidence due to
its large sample size and inclusion of participants with a wide range of BMIs.
In a prospective study of 20 women, Steiner et al. examined AMH
concentrations in obese (37.3 ± 6.0 kg/m2) and non-obese (21.9 ± 1.6 kg/m2)
women and found that AMH levels were 34% lower in the obese group (2.9 ± 2.1
vs. 4.4 ± 1.8 ng/mL, p < .05). Similarly, in a prospective study of 122 late
reproductive age women, Freeman et al. found that obese women had 65%
lower mean AMH levels than non-obese women (29.9 ± 8.6 kg/m2) (geometric
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mean: 0.016 ng/mL versus 0.046 ng/mL, p < .034). In a cross-sectional study of
947 women, Bleil et al. (2014) found that AMH decreased by 1.5% with every unit
increase in BMI after adjusting for age, smoking, parity, hormonal contraception,
age at menarche, psychological stress, educational attainment, and income (p <
0.0001) (Bleil et al., 2014). And finally, in a small comparative study (n=36), Su et
al. (2010) found that AMH levels in obese women were 77% lower on average
than in normal weight women after adjusting for age, race, smoking, and alcohol
use, (p = 0.02).
Five studies found no association between AMH and BMI. In a study of
527 Danish women, Bentzen et al. (2013) found no significant association
between BMI (median 22 kg/m2) and AMH (p = 0.53) after adjusting for oral
contraceptive use, smoking and prenatal exposure to smoking. In a comparative
study, Halawaty et al. (2010) examined differences in AMH levels between 50
women with BMI between 30-35 kg/m2and 50 age-matched controls with BMI
<30 kg/m2 and found no significant difference between the groups. In another
comparative study, Sahmay et al. (2012) found no statistically significant
difference in AMH levels between obese (>30 kg/m2) and non-obese (<30 kg/m2)
participants. However, out of the 259 participants in the study, only 37 were
obese. In the studies by Halawaty et al. and Sahmay et al., individuals were
grouped using arbitrary BMI cut points (>30 kg/m2 and <30 kg/m2). Comparing
obese women to groups that include normal and overweight women is unlikely to
detect differences in AMH levels, particularly given what we know regarding the
disruptive effects of adipose tissue on hormone metabolism (Klenov & Jungheim,
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2014). Additionally, neither of these studies adjusted for age, which has a
significant effect both on AMH and BMI. The last two studies were crosssectional. In one, the range in BMI was not reported (La Marca et al., 2012), and
in the other, the mean BMI of the sample did not cover a broad range, 24.3 ± 3.9
(Dolleman et al., 2013).
There are several theories that may explain the relationship between AMH
and obesity. Obesity is characterized by alterations in adipocyte-hormone
secretion and insulin resistance (Crujeiras & Casanueva, 2015). Leptin, an
adipokine required for activation of gonadotropin releasing hormone secretion, is
present in high concentrations in obesity, and may directly inhibit gonadal
functions and contribute to lower AMH levels (Crujeiras & Casanueva, 2015).
Adinopectin, an adipokine that contributes to oocyte maturation and granulosa
cell proliferation, is decreased in obesity and may contribute to lower AMH levels.
Insulin resistance may contribute to granulosa cell dysfunction and alter AMH
concentrations (Bernardi et al., 2017; Park et al., 2010). Another possibility is that
AMH metabolism is altered in obese women (Freeman et al., 2007). Decreased
levels of AMH in obese women may point to impaired follicular function; however,
the association between AMH and BMI was not observed in all studies (Freeman
et al., 2007). More research is needed to examine the association between BMI
and AMH levels and to clarify the explanatory mechanisms behind this
association.
Cardiometabolic
Four studies examined the association between AMH and cardiometabolic
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factors (Bleil, Gregorich, McConnell, Rosen, & Cedars, 2013; Park et al., 2010;
Tehrani, Erfani, Cheraghi, Tohidi, & Azizi, 2014; Zhu, Wang, Chen, Ji, & Xiong,
2017). In a study of 951 women, Bleil et al. (2013) observed that the number of
cardio-metabolic risk factors was higher in women with low compared to high
AMH levels and that women with low AMH levels had increased risk of highdensity lipoprotein (HDL) <50 mg/dL, increased waist circumference, and
hypertension. However, associations were no longer significant after controlling
for BMI (Bleil, Gregorich, et al., 2013).
In a longitudinal study of 1,015 women by Tehrani et al. (2014),
cholesterol and low-density lipoprotein (LDL) profiles were less favorable in
women with lower age-specific AMH levels. While there were no significant
differences in baseline cardiovascular risk factors, during the follow-up period,
total cholesterol increased for those with the lowest age-specific AMH levels,
while it decreased for those with the highest age-specific AMH levels (p < .001);
the average decrease in LDL for those with the lowest age-specific AMH levels
was less than for those with the highest age-specific AMH levels (p < .004)
(Tehrani et al., 2014). And last, in a prospective study of 120 healthy women,
Park et al. used the Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR) to examine the association between insulin resistance and ovarian
reserve and found an inverse association between HOMA-IR and AMH levels (r =
-0.343, p < .001) (Park et al., 2010).
While numerous studies have found evidence of increased cardiovascular
disease risk with advancing gynecological age (Tehrani, Behboudi-Gandevani,
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Ghanbarian, & Azizi, 2014), few studies have examined potential associations
between premenopausal cardiovascular risk factors and the process of ovarian
aging (de Kat, Broekmans, Laven, & van der Schouw, 2015). The studies
included in this review provide preliminary evidence that variability in
reproductive aging may be related to cardiometabolic risk factors in premenopausal women, however more research is needed to examine this
association (Maria E Bleil, Gregorich, et al., 2013).
Behavioral factors
Smoking
Toxins from smoking may have detrimental effects on the ovarian follicle
pool and increase rates of follicle atresia, leading to decreased antral follicles and
alterations in ovarian hormones (Schuh-Huerta et al., 2012). The association
between smoking and AMH levels was examined in 10 studies. Two observed an
inverse association (Dolleman et al., 2013; Plante, Cooper, Baird, & Steiner,
2010), one observed higher AMH levels in smokers vs non-smokers (SchuhHuerta et al., 2012) and seven observed no association (Bentzen et al., 2013;
Dafopoulos et al., 2010; Hawkins Bressler et al., 2016; J. Kline, Tang, & Levin,
2016; Lambert-Messerlian, Plante, Eklund, Raker, & Moore, 2016; Waylen,
Jones, & Ledger, 2010).
In a cross-sectional study of 284 women, Plante et al. (2010) examined
AMH levels in current smokers (defined as actively smoking within the previous
two years), past smokers (defined as a history of smoking with cessation
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occurring at least two years before the study), and passive smokers (defined as
currently living with someone who smoked in their home). They found that
current smokers, but not past smokers, had 44% lower AMH levels than the
reference group (participants with neither active nor former or passive smoke
exposure), p = 0.04. They also found that within current smokers, those who
smoked 15 cigarettes or more per day tended to have lower AMH levels than
those who smoked fewer than 15 cigarettes per day, but this difference was not
statistically significant (p = 0.08). Dolleman et al. (2013) also found lower AMH
levels in current smokers in comparison to never smokers (p = 0.02), and no
association with previous smoking. When examining duration of smoking, they
found an inverse association between AMH levels and 10+ pack-years (β = -7.0,
P = .003).
Of the studies that found no association, Hawkins Bressler et al. was one
of the largest with 1,654 African American participants. This study provided one
of the most in depth analyses of various characteristics of smoking including age
at initiation, cessation and duration. Most women (73%) never smoked regularly,
7% formerly smoked, and 19% were current smokers. Among current smokers,
only 4% smoked a pack or more a day. The average age of smoking initiation
was 18 (±4) years, cessation was 25 (±4) years, and the average duration of
smoking was 6 (±5) years, none of which were associated with AMH levels (p >
.05) (Hawkins Bressler et al., 2016). In another study of 137 women, of which 59
(43%) smoked 8.6 ± 5.9-pack years (range 2–20 pack years), Dafoupoulos et al.
found an inverse association between smoking and AMH levels; this association
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was no longer significant after adjusting for age, BMI, and reproductive hormones
(Dafopoulos et al., 2010).
Waylen et al. examined the association between AMH and smoking in 335
women. Of these, 202 were non-smokers, 86 were ex-smokers and 47 were
current smokers. No statistically significant difference was observed in serum
AMH concentrations in women with a history of smoking compared with those
that had never smoked. However, a trend towards a decrease in both previous
and current smokers was observed (Waylen et al., 2010). Several other crosssectional studies examined the association between smoking and AMH levels
and also found no association (Bentzen et al., 2013; J. Kline et al., 2016;
Lambert-Messerlian et al., 2016; Shaw et al., 2011). Contrary to these studies,
Schuh-Huerta et al. (2012) found higher AMH levels in a sample of 947 smokers
vs nonsmokers, 33.5 ± 2.4 versus 27.4 ± 1.7 pM (p = 0.038) and found that
neither current nor previous smoking was associated with overall lower ovarian
follicle counts. It is unclear why AMH levels would have been elevated in
smokers in this study.
While a greater number of studies found no association between AMH and
smoking, the two studies that included smoking duration in the analyses of
smoking did observe an association between the duration of smoking and AMH
levels. More research is needed to clarify the association between smoking and
AMH levels.
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Alcohol consumption
Four studies examined the association between alcohol consumption and
AMH levels. In a cross-sectional study of 420 women, Whitworth et al. (2016)
found lower AMH levels among women who drank alcohol (−21%, 95% CI=−36%
to −3%) (Whitworth et al., 2016). In another cross-sectional study of 1654
women, Hawkins Bressler et al. (2016) found that those who binge drank twice a
week or more had 21% lower AMH levels compared with those who never drank
(95% CI= -41% to 7%), but found no association between drinking alcohol and
AMH levels in non-binge drinkers (Hawkins Bressler et al., 2016). Hawkins
Bressler et al. hypothesized that the association between binge drinking and
lower AMH levels may be due to alcohol-induced alterations in hepatic
catabolism of estradiol or gonadotropins and the subsequent impact on
hypothalamic-pituitary axis signaling. Alternatively, they also hypothesized that
repeated large-volume alcohol exposures may overwhelm the protective
mechanisms of the granulosa complex and contribute to lower AMH levels
(Hawkins Bressler et al., 2016). Two studies found no association between
alcohol consumption and AMH levels (Dolleman et al., 2013; J. Kline et al.,
2016).
Caffeine consumption
Three studies examined the association between caffeine consumption
and ovarian reserve. Whitworth et al. (2016) found lower AMH levels among
women who drank coffee (−19%, 95% CI −31% to −5%). Two studies of 2320
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and 477 women found no association between caffeine consumption and AMH
levels (Dolleman et al., 2013; J. Kline et al., 2016). In a review of epidemiologic
evidence concerning the association between caffeine consumption and
reproductive health, Peck et al. (2010) concluded that there was insufficient
evidence to support a relationship between caffeine intake and reproductive
outcomes (Peck, Leviton, & Cowan, 2010).
Discussion
This integrative review provides a summary of the evidence regarding the
association between modifiable biobehavioral factors and anti-Müllerian hormone
levels in reproductive age women. Various reproductive (contraceptive use and
parity), biological (obesity, cardiometabolic) and behavioral (smoking, alcohol
and caffeine consumption) factors have been examined in association with
serum anti-Müllerian hormone concentrations.
Among the studies included, most often examined was hormonal
contraceptive use (n=14). While several studies found no association, the
majority (n=10) found lower AMH levels in hormonal contraceptive users
compared to non-users. Previous contraceptive use, however, was not
associated with lower AMH levels after contraceptive use was discontinued.
These findings suggest that if contraceptive use affects serum AMH levels, the
effect is reversible. Given the current level of evidence, clinicians and
researchers should be cautious when interpreting AMH levels during
contraceptive use; and it is important that future researchers examine how long
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after discontinuing hormonal contraceptive use AMH returns to age-adjusted
normal levels.
Among the biological factors examined, obesity was examined the most
(n=11). However, the evidence regarding the association between BMI and AMH
is contradictory. Six observed an association between increased BMI and lower
AMH levels, and five found no association. There was considerable variation in
the way BMI was measured and categorized. Several of the studies examined
BMI as a continuous variable and several examined it as a categorical variable.
The studies examining BMI as a categorical variable used different cut-points
making it difficult to compare the findings (Bentzen et al., 2013; Freeman et al.,
2007; Steiner et al., 2010).
There is insufficient evidence regarding the association between AMH
levels and cardiometabolic risk factors; however, the studies included in this
review suggest that women with lower AMH levels are more likely to have less
favorable cardiometabolic profiles. And finally, the evidence regarding the effect
of lifestyle factors (smoking and alcohol/caffeine consumption) is inconclusive.
However, studies that observed an association between smoking and AMH
levels found lower AMH levels in current smokers but no association with
previous smoking, suggesting a reversible effect.
In order to facilitate direct comparison between studies and increased
precision in determining effect sizes, there is a need to incorporate standardized
and consistent measures of biobehavioral exposures. There was significant
variation in how exposures were defined and measured (i.e. duration, quantity,
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categorization, etc…). In addition, greater consistency in adjustment for
covariates is needed, as this will improve our understanding of the combined
effect of multiple factors as well as their total contribution to variation in the
process of ovarian aging. Chronic disease risk is best explained by the
synergistic effect of multiple factors, and this is likely also the case with the
process of ovarian aging. The studies included in the review were all cohort,
cross-sectional or case-control studies. These study designs limit the ability to
detect effects and conclusions drawn are based only on associations.
Longitudinal studies are needed to account for fluctuations in biobehavioral
exposures over time, and to permit an examination of the mechanisms behind
the associations between biobehavioral exposures and AMH levels.
The focus of this integrative review was to summarize the evidence
regarding modifiable biobehavioral factors associated with AMH levels in women
of reproductive age. While age at menopause is highly heritable, the rate of
change in AMH levels improves the precision of estimates of time to menopause
(Freeman et al., 2012). Therefore, it is helpful to also consider the evidence
regarding these same biobehavioral factors and onset of menopause. In a large
multi-ethnic study examining factors associated with age at natural menopause
(n=14,620), Gold et al. found that ever using hormonal contraceptives was
associated with later age at natural menopause (Gold et al., 2001). However, in
another study that examined more specific characteristics of hormonal
contraceptive use in relation to age at natural menopause, de Vries et al. found
that long-term (>3 years) use of high dose oral contraceptives and long-term

123
(>11 years) overall oral contraceptive use were associated with an earlier age at
menopause (adjusted HR = 1.12; 95% CI 1.03–1.21 and HR = 1.13;
respectively). The use of lower dose oral contraceptives had no influence on
menopausal age (de Vries et al., 2001). As regards parity, Gold et al. reported
that higher parity was associated with later age at menopause (Gold et al., 2001).
The evidence regarding the relationship between BMI and age at
menopause has been conflicting. In the study by Gold et al., in unadjusted
models, women with lower BMI were more likely to be pre-menopausal, and
women with higher BMI were more likely to be surgically amenorrheic (Gold et
al., 2001). However, in adjusted models, BMI was not a significant predictor of
age at menopause. The relationship between cardiometabolic factors and age at
menopause has also proven complex to unravel. While it is widely accepted that
postmenopausal status is associated with increased risk for cardiovascular
disease, recent studies have demonstrated that premenopausal CVD risk factors
may play a more important role in determining postmenopausal risk than
previously thought (de Kat et al., 2017). It has been hypothesized that the
processes of ovarian aging and cardiovascular disease risk have a synergistic
relationship (de Kat, Verschuren, Eijkemans, van der Schouw, & Broekmans,
2016).
In a systematic review examining the association between smoking and
age at menopause, a reduction in age at menopause was greater among current
smokers than among former smokers, suggesting that the detrimental effect of
smoking on ovarian follicles may be salvageable (Parente, Faerstein, Keller, &
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Werneck, 2008). And in a recent systematic review and meta-analysis examining
the association between alcohol consumption and age at menopause, Taneri et
al. (2016) found that low and moderate alcohol consumption (more than one
drink per week (RR = 0.60; 95% CI 0.49–0.75) and three or fewer drinks per
week (RR = 0.75; 95% CI 0.60–0.94) were associated with later menopause
onset, compared to non-drinkers. They suggest that low to moderate alcohol
intake may reflect moderate lifestyle habits, which could explain the positive
association between moderate intake and age at menopause (Taneri et al.,
2016).
Many of the factors shown to influence AMH levels may also influence age
at menopause. More research is needed to better understand the effects of
these factors on AMH and whether serum AMH concentrations accurately predict
the onset of menopause (Broer et al., 2011; van Disseldorp et al., 2008).
Conclusion
It is clear from this integrative review that our understanding of the
modifiable biobehavioral factors influencing AMH concentrations is incomplete.
Increased understanding of the biobehavioral factors associated with AMH levels
will improve the quality of care for women at risk for infertility. Many reproductive
age women seek evidence-based information regarding their fertility status There
is a great need for a reliable biomarker to improve early detection of infertility risk
and address gaps in reproductive healthcare. Greater understanding of factors
affecting AMH levels will aid in the development of evidence-based information
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for improved patient education as well the development of effective interventions
for the prevention and treatment of infertility.

Inclusion
criteria:
1. Reproductive
age (19+)
2. AMH as
outcome
3. Healthy
females
4. Human
5. English

408 Records
identified
through
Pubmed

50 records

6 added from
references lists
of included
publications

39 included in
the final review

Figure 1: Search Strategy

17 excluded:
1. Only one
study (n=8)
2. Interventio
n (n=1)
3. Nonmodifiable
(n=6)
4. Illness
(n=1)
5. AMH
outcome
(n=1)
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Table 1: Hormonal Contraceptive Use
Inverse association (n=10)
Author et
al. (date)
Bentzen
(2012)

Desig
n
CC

N (age)

BirchPeterson
(2015)

CC

887
(19-46)

Dolleman
(2013)

CC

2,320
(37.3 ±
9.2)

732
(21-41)

Race/
Ethnicity
Denmark

Groups

Covariates

Finding

228
users,
504 nonusers

Age

•

AMH 29.8% lower in OCP users
(p < .001, 95% CI 19.8%; 38.5%)

Denmark

244
users,
643 nonusers

Age, smoking,
BMI, maternal
age at
menopause,
preterm birth,
maternal
smoking

•

AMH 20% lower in OCP users
(p < 0.001, 95% CI 8.4%; 30.3%).

The
Netherlands

1194
previous,
908
current,
218
never

Age, cycle
regularity,
OCP use, age
at menarche,
parity

•

Current OCP users had
significantly lower AMH levels
than women who had never used
OCP
(β = -9; p < .0001)
Previous OCP use was not
associated with lower AMH levels
(β = -0.3; p = .9)

•

Arbo
(2007)

PC

20
(29.1 ±
4.1)

Brazil

Pre and
post
OCP use
(1 month)

No

•

AMH levels were significantly
reduced with OCP use
Median (inter-quartile range)
3.02 ng/mL (1.21–6.39) before
OCP and 2.22 ng/mL (0.9–3.11)
after OCP (p < .04)

Shaw
(2011)

CC

135
(41 ±
2.48)

USA

14 Users,
121 nonusers

Age

•

Median AMH level in OCP users
was 3.00 pmol/L (95% CI, 2.07–
3.86), compared with 4.57 pmol/L
(95% CI, 3.86–5.21) in nonusers
(p < .001)

Kristensen
(2012)

CC

256
(19-20)

Denmark

180
users, 76
nonusers

No

•

Median AMH in users was 2.5
ng/mL (95% CI, 1.5–3.5),
significantly lower than the median
AMH level in nonusers 2.9 ng/mL
(95% CI, 1.8–4.3), (p < .01)

Kallio
(2013)

PC

42
(20-33)

Finland

13 OCP,
15
transder
mal, 14
vaginal

No

•

Significant decreases in serum
AMH levels after 9 weeks in all
groups: OCP (3.88 ± 3.0 vs. 1.91
± 1.5 ng/mL, p < .001),
transdermal (3.86 ± 3.6 vs. 1.96 ±
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ring

1.3 ng/mL, p < .001), and vaginal
ring (4.27 ± 3.5 vs. 2.25 ± 1.2
ng/mL, p < .001)

van den
Berg
(2010)

PC

25
(26.3 ±
6.2)

The
Netherlands

Hormone
free
interval,
natural
cycle

Age

•

Significant increase in AMH in
natural cycle vs. hormone free
interval of contraceptive cycle, (p
= .005)

Kerkhof
(2010)

RC

279
(18-24)

The
Netherlands

Users,
nonusers

Age, birth
weight, fat
mass, age at
menarche and
SES

•

OCP use inversely associated
with AMH in each model (p <
0.001)

Marsh

RC

1654
(23-34)

USA:
African
American

Current
users,
nonusers

Age, BMI

•

Current OCP use (27.5%)
inversely associated with AMH
levels (β = -0.290 (-0.408, -0.171),
(p < .0001)

No association (n=4)
Author
et al.
(date)
Deb et al.
(2012)

Desig
n

N (age)

Race/
Ethnicity

Casecontrol

70
(18-35)

UK

Li et al.
(2011)

PC

95
(26-50)

Hong Kong

Streuli
(2008)

PC

24
24.1
(3.5)

Kucera
(2016)

CC

149
(23-34)

Groups

Covariates

Finding

34 Use for
≥1 year;
36 no use
for ≥1
year
Pre and 3
months
post
contracept
ive use (5
types)

No

•

No significant difference between
groups (p = .44)

No

•

No significant difference pre and
post contraceptive use in all
treatment groups (p >
.05)(statistics not provided)

Switzerland

OCP,
vaginal
ring,
control

No

•

No significant difference between
groups. Mean AMH levels for
controls, 4.4 (SD ± 1.2) and 4.2
(SD ± 1.4) ng/mL for first and
second cycles; for OC, 5.0 (SD ±
2.0) and 6.2 (SD ± 3.0) ng/mL;
and for vaginal ring, 4.9 (SD ±
3.3) and 5.5 (SD ± 4.1) ng/mL.

Czech
Republic
(23-34)

Long-term
users,
non-users

No

•

No significant difference between
groups. Median for users 2.89
ng/mL, for non-users 3.37 ng/mL
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(p = .3261).
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; RC, Retrospective cohort; OCP, Oral
Contraceptive Pill; BMI, Body Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval; OR, Odds
Ratio; SD, Standard Deviation

Table 2: Parity
Lower AMH associated with higher parity or no association (n=3)
Author et al.
(date)
Bragg (2012)

Design

N (age)

Race/
Ethnicity
Philippines

Groups

Covariates

Finding

PC

294

1, 2, 3+
children

Age, BMI,
smoking
status

•

The overall
association with parity
was significant (F
(3,286) = 4.25, p <
0.01). Women with 2
or 3+ pregnancies had
50% of a SD decrease
in AMH.

Whitworth
(2015)

CC

420
(20-30)

South Africa

Nulliparous,
1, 2
children

Age, BMI,
parity,
education

•

Compared with
nulliparous women,
women with one
previous birth had
21% lower AMH
concentrations (95%
CI −36 to −3%), and
women with two or
more previous births
had 30% lower AMH
concentrations (95%
CI −46% to −10%).

La Marca
(2010)

CC

277
(18-50)

The
Netherlands

Nulliparous,
1+

Age

•

No significant
association between
parity and AMH levels.

Higher AMH associated with higher parity (n=2)
Author et al.
(date)
Dolleman
(2013)

Design

N (age)

CC

2320
(37.3 ±
9.2)

Moini (2016)

CC

186
(20-35)

Race/
Ethnicity
The
Netherland
s

Groups

Iran

Nulliparous
,
multiparous

Continuous
variable

Covariat
es
Age,
cycle
regularity,
HC use,
age at
menarche
Age, BMI,
age at
menarche
, cycle
regularity,

Finding
•

Higher parity
associated with 2
percentiles higher
AMH.

•

Higher AMH in
multiparous women.
The mean of AMH was
2.53 ± 1.90 ng/ml in
nulliparous women and

129
duration
of
menses

3.54 ± 1.42 ng/ml in
women with children,
which showed a
significant difference
between the groups (p
< 0.0001).

Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval; SD, Standard Deviation

Table 3: BMI
Inverse association (n=6)
Author et al.
(date)
Steiner (2010)

Design

N
(Age)
20
(18-35)

Race/
Ethnicity
USA

Groups

Covariates

Finding

<25 kg/m2
(n=10), >30
kg/m2
(n=10)

No

•

AMH levels were 34%
lower in the obese group
(2.9 ± 2.1 vs. 4.4 ± 1.8
ng/mL, p < 0.05)

Bleil (2014)

CC

947
(25-45)

USA

Continuous
variable

BMI,
smoking,
parity, HC,
age at
menarche,
psychologica
l stress,
education,
and income

•

With every unit increase
in BMI, AMH decreased
by 1.5% (p < .0001)

Dafoupoulos
(2010)

PC

137
(20-49)

Greece

Continuous
variable

Age, BMI,
reproductive
hormones

•

BMI and AMH associated
without adjusting for age
(r = -0.345, p < 0.05)

Freeman (2007)

PC

122
(45.8 ±
5.2)

USA

≤30 kg/m2,
>30 kg/m2,
continuous
variable

BMI, age,
menopausal
status and
race

•

Obese women had mean
AMH levels that were
65% lower than AMH
levels of non-obese
women (geometric mean:
0.016 ng/mL versus
0.046 ng/mL; geometric
mean ratio = 0.35; 95%
CI 0.13, 0.92; p < .034)

Bernardi (2017)

RC

1654
(23-34)

USA:
African
American

<18.5kg/m2
=
underweight
, ≥18.5 to
24.9 kg/m2
= normal,
25 to 29.9

Current HC,
history of a
thyroid
condition,
abnormal
menstrual
bleeding,

•

When current BMI was
analyzed as a continuous
variable, there was a
significant inverse
relationship with AMH in
the age-adjusted and the
multivariable linear

PC

130

Su (2010)

CC

kg/m2=
overweight,
≥30 kg/m2=
obese
Continuous

and
menstrual
cycle length

<25 kg/m2
(n=18)
>30 kg/m2
(n=18)

Age, BMI,
race,
smoking,
alcohol use

regression models.
When current BMI was
analyzed as a categorical
variable, the beta
coefficients for each BMI
group increased with
increasing BMI, with the
strongest association
between AMH and BMI
being observed among
those with the highest
BMI.

36
(40-52)

USA

Race/
Ethnicity
Danish

Groups

Covariates

Finding

<18 kg/m2,
18-25
kg/m2, >25
kg/m2, >30
kg/m2

HC, BMI,
smoking
habits and
prenatal
exposure to
smoking

•

No significant
association found
between BMI and
serum AMH (p = 0.53).

AMH levels in obese
women were 77% lower
on average than in
normal weight women (p
= 0.02)

•

No association (n=5)
Author et al.
(date)
Bentzen (2013)

Design

N (Age)

CC

527
(32.7 ±
4.1)

Dolleman
(2013)

PC

2320
(37.3 ±
9.2)

The
Netherlands

Continuous
variables

Age, cycle
regularity,
HC use, age
at menarche,
parity

•

No significant
association between
BMI and AMH (β = 0.2; p = 0.16) or waist
circumference and
AMH (β = -0.09, p =
0.12)

La Marca
(2012)

CC

416
(18-50)

Italy

Continuous
variable

Age

•

AMH levels and BMI
were significantly and
negatively correlated
(r = -0.1; p = 0.03), but
not correlated after
adjusting for age

Sahmay (2012)

CC

259
(27-45)

Turkey

<30 kg/m2
(n=222),
>30 kg/m2
37

No

•

AMH levels were 3.46
± 2.79 ng/ml in nonobese participants and
3.79 ± 2.93 ng/ml in
obese participants. No
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significant correlation
was found between
the levels of AMH and
BMI (p > 0.05).
Halawaty
(2010)

CC

100
(40-48)

Egypt

<30 kg/m2,
30-35
kg/m2

No

•

There was no
correlation between
BMI and serum AMH.

•
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval;

Table 4: Smoking
Inverse association (n=2)
Author et al.
(date)

Design

Dolleman
(2013)

CC

Plante (2010)

CC

Sample
size
(Age)
2320
(37.3 ±
9.2)

Race/
Ethnicity

Groups

Covariates Finding

The
Netherlands

Current,
previous,
never

Age, cycle
regularity,
OC use,
age at
menarche,
parity

•

Current smoking was
associated with 3.6
percentiles lower agespecific AMH values (p =
.02) in comparison to never
smokers. Significant effect
of duration of smoking on
AMH levels seen after 10+
pack-years (β = -7.0, p =
.003). No significant effect
of previous smoking.

284 (3850)

USA

Current,
previous,
passive,
never

Age, BMI

•

Current smokers, but not
past smokers, had 44%
lower AMH values than did
the reference group
(participants with neither
active nor former or
passive smoke exposure);
p = 0.04.

No association (n=8)
Author et al.
(date)
Dafoupoulos
(2010)

Design Sample
CC

137
(20-49)

Bentzen

CC

527

Race/
Ethnicity
Greece

Groups

Covariates

Finding

Smokers,
nonsmokers

Age, BMI,
reproductive
hormones

•

Pearson’s correlation
showed that AMH
levels were negatively
correlated with smoking
(r = -.807, p < .001), not
significant in multiple
linear regression.

Denmark

Current,

Age

•

No significant effect of

132
(2012)

(21-41)

previous,
never

current or previous
smoking on AMH
values (p = .9).

Waylen
(2010)

RC

335
(24-48)

UK

Current,
previous,
never

Age

•

A decreasing trend was
observed, but not
significant: Geometric
mean: Never: 1.074
(0.925–1.245),
Previous: 0.955
(0.760–1.199), Current:
0.869 (0.638–1.183).

Kline (2016)

CC

477
(19-45)

USA

Current,
previous,
never

Age

•

Neither current nor
former smoking was
associated with AMH
levels.

Hawkins
Bressler
(2016)

RC

1654
(23-34)

USA
African
American

Current,
previous,
never

Age, BMI,
current HC
use

•

AMH not associated
with current or previous
smoking, age at
initiation, duration, or
passive exposure (p >
.05)

Lambert
Messerlian
(2016)

PC

45
(18-45)

USA

Current
Not
smoking

Age, BMI

•

AMH not associated
with smoking

Schuh-Huerta
(2012)

CC

432
(25-45)

USA

Smokers,
nonsmokers

Age, HC
use

•

AMH was significantly
higher in smokers than
non-smokers AMH
levels were 33.5+2.4
versus 27.4+1.7 pM (p
< 0.038) in Caucasians.

Shaw (2011)

CC

135
(41 ± 2.5)

USA

Current,
Previous,
never

Age

•

No significant
association between
age and smoking status

Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; RC, Retrospective cohort; HC, Hormonal
Contraceptive; BMI, Body Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval
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Table 5: Cardiometabolic
Inverse association (n=4)
Author et
al. (date)
Tehrani
(2014)

Design

Sample

Race/
Ethnicity
Iran

Groups

Covariates

Finding

PC

1015
(20-50)

Continuous
variables

Age, BMI,
menopause
status

•

Total cholesterol net
changes per year
were higher in
women with the
lowest age-specific
AMH but not in
women with the
highest age-specific
AMH (p < 0.001).
Over time,
cholesterol and LDL
profiles were less
favorable in women
with lower agespecific AMH levels.

Park
(2010)

PC

120
(37.24 ±
5.48)

Korea

HOMA-IR

Age

•

There was a
significant
association between
HOMA-IR and AMH
levels, increase of
HOMA-IR
associated with
decrease in AMH
levels (r = -0.343, p
< .001)

Zhu
(2017)

CC

109
(23-41)

Chinese

>30, <30
years old

NA

•

In women 30 years
or older, increases
in triglycerides were
associated with
increased AMH
level; however, the
effect of triglycerides
vanished with
adjustment for
testosterone level.

Bleil
(2013)

CC

951
(25-45)

USA

Categorical
:
number of
cardiometabolic
risk factors

Age, smoking,
race/ethnicity,
age at
menarche,
past use HC,
and parity

•

The number of
cardio-metabolic risk
factors was 52.1%
higher among
women with low
compared to high
AMH levels and
46.0% higher among
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women with mid
compared to high
AMH levels.
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body
Mass Index; AMH, Anti-Müllerian hormone

Table 6: Alcohol
Inverse association (n=2)
Author et al.
(date)
Whitworth
(2016)

Design

Hawkins
Bressler
(2016)

RC

CC

N
(Age)
420
(20-30)

Race/
Ethnicity
South
Africa

Groups

Covariates

Finding

Yes/No
Alcohol
drinker

Age, BMI,
parity,
education

•

AMH levels were
significantly lower
among women who
drank alcohol
(−21%, 95% CI
−36% to −3%).

1654
(23-34)

USA:
African
American

Drinkers,
nondrinkers,
binge
drinkers

Age, BMI,
current HC

•

Those who binge
drank twice a week
or more had 21%
lower AMH levels
compared with those
who never drink
(95% CI, -41 to 7).

No Association (n=2)
Author et al.
(date)

Design

Kline (2016)

CC

Dolleman
(2013)

CC

Sample
size
(Age)
477
(19-47)

Race/
Ethnicity

Groups

Covariates

Finding

USA

Days/week
drink
alcohol

Age

•

2320
(37.3 ±
9.2)

The
Netherlan
ds

Daily,
drinks per
day

Age, cycle
•
regularity, HC
use, age at
menarche,
parity

No significant
association between
alcohol consumption
and AMH levels
No significant
association between
alcohol consumption
and AMH levels (β=-.4;
p = .74)

Note: Abbreviations: CC, Cross-sectional; RC, Retrospective cohort; HC, Hormonal Contraceptive; BMI, Body
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval
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Table 7: Caffeine
Inverse association (n=1)
Author et
al. (date)

Design

N
(Age)

Whitworth
(2016)

CC

420
(20-30)

Race/
Ethnicit
y
South
Africa

Groups

Covariates

Finding

Yes/No
regular
coffee
consumption

Age, BMI,
parity,
education

•

Lower AMH levels
among women who
drank coffee (−19%,
95% CI −31% to
−5%)

No Association (n=2)
Author et
al. (date)
Kline
(2016)

Design

Dolleman
(2013)

CC

CC

N
(Age)
477
(19-47)

Race/
Ethnicity
USA

Groups

Covariates

Finding

Amount of
caffeine

Age

•

No significant
association between
caffeine consumption
and AMH levels

2320
(37.3 ±
9.2)

The
Netherlands

Daily,
drinks per
day

Age, cycle
regularity,
OCP use,
age at
menarche,
parity

•

No significant
association between
caffeine consumption
and AMH levels

Note: Abbreviations: CC, Cross-sectional; OCP, Oral Contraceptive Pill; BMI, Body Mass Index; AMH, AntiMüllerian hormone; CI, Confidence Interval
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Abstract
The process of ovarian aging is influenced by a complex and poorly
understood interplay of endocrine, metabolic and environmental factors. The
purpose of this study was to explore the feasibility of using Latent Class Analysis
to identify subgroups based on cardiometabolic, psychological and reproductive
parameters of health and to describe patterns of anti-Müllerian hormone levels, a
biomarker of the ovarian reserve, within these subgroups. Sixty-nine lean (BMI ≤
25kg/m2) and severely obese (BMI ≥ 40kg/m2) postpartum women in Edinburgh,
Scotland were included in this exploratory study. The best fitting model included
3 classes; Class 1, n = 23 (33.5%); Class 2; n = 30 (42.2%); Class 3; n = 16
(24.3%). Postpartum women with lower ovarian reserve had less favorable
cardiometabolic and psychological profiles. Examining the ovarian reserve within
distinct subgroups based on parameters of health that affect ovarian aging may
facilitate risk stratification in the context of ovarian aging.
Key Words: Ovarian reserve, latent class analysis, cardiometabolic,
psychological
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The ovarian reserve--the number of remaining ovarian follicles--declines
gradually over a women’s reproductive lifespan and natural menopause occurs
when the ovarian reserve is depleted (Daan & Fauser, 2015). Anti-Müllerian
hormone (AMH) plays a role in ovarian follicle growth, specifically in regulating
the pace of follicle recruitment and selection (Visser et al., 2007). Plasma levels
of AMH reflect the continuous non-cyclic growth of small ovarian follicles, and
therefore mirror the size of the remaining follicle pool (Dewailly et al., 2014;
Jeppesen et al., 2013). Considerable variation in the age at natural menopause
suggests that factors other than chronological age contribute to the depletion of
the ovarian follicle pool over time (van Disseldorp et al., 2008).
While numerous studies have examined the effect of biobehavioral factors
on AMH concentrations (Dolleman et al., 2013; La Marca et al., 2012b), few have
explored patterns within and between women with proven fertility as a means of
identifying subgroups. Accurate group classification would improve the clinical
interpretation of serum AMH concentrations and facilitate risk stratification in the
context of ovarian aging (Pal et al., 2010). As cardiovascular, metabolic, and
psychological factors have each been shown to have an effect on the ovarian
reserve (Balkan, Cetin, Usluogullari, Unal, & Usluogullari, 2014; Bleil et al., 2012;
Bleil et al., 2012; de Kat, Broekmans, Laven, & van der Schouw, 2015), we
hypothesized that latent class analysis (LCA) could be used to develop subgroup
classifications using these factors and that these subgroups would provide a
useful context within which to examine the complex interplay of variables
involved in the process of ovarian aging.
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LCA is a clustering method used to identify patterns in factor
configurations and has been effectively used to examine co-occurrence patterns
of risk factors in chronic disease development (Dewailly, Alebić, Duhamel, &
Stojanović, 2014; Leventhal, Huh, & Dunton, 2014). Rather than providing
prescriptive clinical guidelines regarding the nature of class structures, we sought
to elucidate the complex process of ovarian aging by exploring AMH within the
context of cardiometabolic, psychological and reproductive factors (Henry,
Dymnicki, Mohatt, Allen, & Kelly, 2015; Leventhal et al., 2014). As the underlying
mechanisms contributing to premature ovarian aging are not well understood,
LCA may be a useful method for clarifying how co-occurrence patterns of risk
factors contribute to subtle changes in ovarian functioning over time (Leventhal et
al., 2014). We conducted an exploratory study with the purpose of testing the
feasibility of this hypothesis in a sample of postpartum women in whom
cardiovascular, metabolic, and psychological factors had been measured during
pregnancy and postpartum.
Methods
Sample
This study used data from a prospective cohort study conducted in
Edinburgh, Scotland from 2008-2013 examining associations between mood and
weight changes in lean (BMI ≤ 25kg/m2) and very severely obese (BMI ≥
40kg/m2) women with singleton pregnancies (Mina et al., 2015). In the parent
study, cardiovascular, metabolic, and psychological measures were recorded
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during pregnancy and 3 months postpartum. For this exploratory cross-sectional
study, only data collected during the study visit three months postpartum were
used. This time point was selected to avoid the ovarian suppression that occurs
during pregnancy and to coincide with the expected recovery of AMH levels
(Köninger et al., 2015). Women diagnosed with gestational diabetes or polycystic
ovary syndrome were excluded as these conditions are known to influence AMH
levels (Iliodromiti et al., 2013; Łebkowska et al., 2016). All samples and data
were collected with ethical approval (references 08/S1101/39 and 13/ES/0126),
and with fully informed and written consent from all women.
Measures
Cardiometabolic risk factors included fasting lipids (total cholesterol, high
density lipoprotein, triglycerides), fasting glucose, fasting morning cortisol and
BMI (Mina et al., 2015). BMI was used to group women as lean (BMI ≤ 25kg/m2)
or severely obese (SO) (BMI ≥ 40kg/m2).
Psychological measures included the Hospital Anxiety and Depression
Scale (HADS), the State-Trait Anxiety Index (STAI) and the General Health
Questionnaire (GHQ). The HADS evaluates anxiety and depression symptoms
(range: 0–21) and has been reported to help in differentiating transient and
enduring stress during pregnancy (Matthey & Ross-Hamid, 2012). The STAI
evaluates both state and trait anxiety (range: 20–80 each), and has been
previously validated in severely obese pregnant women (Gunning et al., 2010).
The GHQ-12 uses binary scoring (range: 0–15) and has been shown to reliably
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differentiate stress levels between pregnant and non-pregnant controls
(Goldberg, 1973; van Bussel, Spitz, & Demyttenaere, 2006).
Reproductive measures included LH, FSH, estradiol (E2), AMH and
breastfeeding status. Serum levels of LH, FSH, E2 and AMH were measured in
stored serum samples in a single batch by electrochemiluminescence
immunoassay using the Roche Elecsys assay system (West Sussex, UK)
(reference numbers: 11732234122, 11775863122, 06656021190 and
06331076190 respectively). The intra-assay coefficients of variation were 6.26.9% for LH, 7.3-8.1% for FSH, 1.5-3.2% for E2, and 5.8-6.9% for AMH..
Breastfeeding status at both time points was assessed with a single yes/no
question: ‘Are you breastfeeding your baby now?’. A ‘yes’ answer included both
exclusive and non-exclusive breastfeeding.
Data Analyses

To describe the data, means and standard deviations were calculated for
clinical and demographic variables in the whole sample. A one-way ANOVA was
used to explore differences in variables between lean vs. very severely obese
women, and in breastfeeding vs. non-breastfeeding women. The ANOVA was
conducted to control for the parent study’s primary research questions and to
identify meaningful differences present in the data. Bonferroni adjustment was
used, dividing α of 0.05 by the number of variables (n= 12), to account for
multiple statistical testing with only differences resulting in a p-value lower than
0.004 considered statistically significant.
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AMH levels were log-transformed for parametric analysis. Anxiety and
depression were analyzed using the methods outlined in Mina et al. (2015).
Briefly, maternal mood outcomes were grouped into ‘anxiety symptoms’ and
‘depression symptoms’. Anxiety symptoms were represented by Hospital Anxiety
(HA from the HADS) and both the state and trait components of the STAI.
Depression outcomes were represented by Hospital Depression (HD, from the
HADS) and the GHQ. To avoid multiple testing and the need to include a
Bonferroni correction, the z-score was calculated for each outcome and
averaged z-scores were used for each symptom group in the analysis.
Latent Class Analysis (LCA) was used to classify the subjects of the whole
sample (heterogeneous) into smaller homogeneous classes/groups in which
members are similar to each other and differentiated from subjects in other
groups using cardiometabolic, psychological and reproductive factors. The
objective is to identify groups naturally occurring in the data, when the number of
underlying groups is unknown (DiStefano, 2012; Kaplan, 2014). LCA assumes
that the data comes from a mixture of populations that have different probability
distributions and that the population consists of homogeneous subgroups, in
which the groups are discrete and mutually exclusive (DiStefano, 2012). The
results of LCA provide probabilities for the proportion of the population expected
in each group. Groups are not defined a priori but are rather probabilistic
(Dewailly, Alebić, Duhamel, & Stojanović, 2014); individuals are allocated to
groups based on observed values in the indicator variables used to determine
class membership. Individuals of the same group are similar such that their
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observed values are assumed to come from the same probability distribution
(Tein, Coxe, & Cham, 2013). Conditional probabilities describing the mean or
likelihood of each indicator variable are provided for each class (Henry et al.,
2015). LCA has demonstrated the ability to accurately determine class
membership in samples as small as 50 (Henry et al., 2015). As this was an
exploratory study to examine the feasibility of using LCA to identify subgroups,
we used a small sample. The LCA model included the following indicator
variables: age, fasting lipids (triglycerides, cholesterol, and HDL), fasting glucose,
fasting cortisol, lean/obese, breastfeeding status, anxiety, depression, FSH, LH,
E2, and AMH levels. All variables were continuous with the exception of
lean/obese and breastfeeding status; LCA is capable of reliability identifying
class structures using variables with mixed scales (DiStefano, 2012).
All analyses were conducted using R 3.3.3 (Core Team, 2017), with the
package flexmix (Leisch, 2004). This software allowed us to estimate LCA with
different numbers of classes and compare the fit of each number of classes to
identify how many classes should be estimated. The LCA was estimated for 1 to
10 classes, comparing the models with the Bayesian Information Criterion (BIC)
and Integrated Completed Likelihood Criterion (ICL) (Burnham & Anderson,
2003). These information criteria penalized the log-likelihood of the model. The
BIC and ICL are used to select the model from a set of candidate models that
provides the best balance of model fit, complexity and parsimony, where models
with lower BIC and ICL present better fit (Burnham & Anderson, 2003). Once the
number of classes was defined, we looked at the characteristics of each class
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and the patterns of the variables of interest relative to the ovarian reserve. As the
primary focus of this study was to establish the feasibility of using LCA to identify
subgroups, we provide only a brief discussion of class characteristics.
Results
Sixty-nine lean (n=38) and severely obese (n=31) postpartum women with
mean age 33.97 (SD = 4.1) years were included in the analysis. Forty-seven
women were breastfeeding and 22 were not breastfeeding. Clinical and
demographic data and group differences (lean/very severely obese and
breastfeeding/non-breastfeeding) are summarized in Table 1. As expected, there
was a significant negative correlation between age and logAMH (r = -0.312, p =
0.002).
Information criteria (BIC and ICL) and entropy were used to compare the
LCA solutions from a different number of classes (Table 2). As the number of
classes increases, the log-likelihood decreases, and entropy increases. The BIC
and ICL decreased from 1 to 2 classes, increased minimally from 2 to 3 classes,
and clearly increased from 4 or more classes. Given that the difference in
information criteria between the 2 and 3 classes solution was small, we
examined the parameter estimates for each of these solutions to identify which
one presented results that were more theoretically fitting.
The best fitting LCA model with meaningful parameter characteristics for
each class included 3 classes (Table 3). For the 3-class LCA, 33.5% (n=23) of
the sample was in Class 1, 42.2% (n=30) of the sample was in Class 2, and
24.3% (n=16) of the sample was in Class 3. Table 4 shows the variable
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characteristics for each class. For the continuous variables, the characteristic is
presented as the average score of that variable within each class, for the binary
variables (breastfeeding status and lean/obese), the characteristic is presented
as the probability of presenting that characteristic. Comparisons between the
classes by cardiometabolic, psychological and reproductive health parameters
are shown in Table 3. For the 3-class solution, the entropy is 0.93. Entropy is a
measure of uncertainty in the classification procedure, indicating how well the
model predicts membership, with values close to 1 representing better prediction.
The high entropy (0.93) for this LCA solution shows that the model accurately
predicts membership. Each class is summarized briefly below:
Class 1: Highest mean AMH levels, lowest probability of breastfeeding,
lowest mean cholesterol levels, lowest mean HDL levels, lowest
probability of being lean, lowest mean fasting morning cortisol levels,
lowest mean anxiety scores, lowest mean FSH and LH levels, and highest
mean E2 levels
Class 2: Highest probability of breastfeeding, lowest mean triglyceride
levels, highest mean HDL levels, highest probability of being lean, lowest
mean depression score, highest mean FSH and LH levels, and lowest
mean E2 levels
Class 3: Lowest mean AMH levels, highest mean triglyceride and
cholesterol levels, highest mean anxiety and depression scores, and
highest mean cortisol levels
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Discussion
In this study, we used latent class analysis to explore possible subgroups
of cardiometabolic, psychological and reproductive parameters of health in
relation to ovarian reserve in a convenience sample of post-partum women.
Three subgroups were identified. As expected, there was a negative correlation
between age and AMH; however, age was not a strong determinant of class
membership in the LCA. The subgroups identified through LCA provide insight
into the complex interactions of various health related parameters in relation to
ovarian reserve and contribute to our understanding of factors other than age
involved in the process of ovarian aging. LCA offers a feasible approach for
examining risk factors in the context of ovarian aging.
Class 1 had the highest mean AMH levels and the lowest mean
cholesterol levels. Class 3 had the lowest mean AMH levels and the highest
mean cholesterol and triglyceride levels. Several studies have observed the trend
toward a less favorable cardiovascular risk profile in women with lower agespecific AMH levels (Bleil, Gregorich, McConnell, Rosen, & Cedars, 2013;
Tehrani, Erfani, Cheraghi, Tohidi, & Azizi, 2014). Cardiovascular disease risk
factors have been suggested to accelerate the process of ovarian aging by
impairing vascularization of the ovaries and accelerating ovarian decline (de Kat
et al., 2015). It may be that these processes occur simultaneously and share
similar underlying mechanisms, such that accelerated ovarian aging increases
cardiovascular disease risk and increased cardiovascular disease risk
accelerates ovarian aging (de Kat et al., 2015; Kok et al., 2006).
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In the present study, the probability of being lean or severely obese did
not demonstrate a strong class trend in relation to AMH. Given the strong class
trend of cardiovascular risk factors in relation to AMH, this was an unexpected
finding since severe obesity is a well-defined risk factor for early onset
cardiovascular disease. This finding may be explained by the lack of variability in
cardiometabolic factors observed in the sample, irrespective of BMI. Despite their
obesity, these women are still relatively young and display a narrow range of
variability in cardiometabolic factors. This lack of class trend may also be
explained by the use of a postpartum sample of women; breastfeeding has been
shown to have a protective effect on cardiovascular health regardless of preconception risk factors (McClure, Catov, Ness, & Schwarz, 2012).
The suppressive effect of obesity on reproductive function is well
established (Klenov & Jungheim, 2014; Nelson, Stewart, Fleming, & Freeman,
2010; Vryonidou, Paschou, Muscogiuri, Orio, & Goulis, 2015). Obesity alters the
ovarian follicular environment and contributes to anovulation (Klenov &
Jungheim, 2014; Moy et al., 2015). The effect of obesity on ovarian reserve is
less well understood (Moy et al., 2015; Sahmay et al., 2012) with conflicting
results (Malhotra et al., 2013; Moy et al., 2015; Sahmay et al., 2012; Steiner,
2013). Whether obesity also accelerates follicle loss and perhaps contributes to
diminished ovarian reserve remains unclear (Klenov & Jungheim, 2014).
Class 1 had the lowest mean fasting morning cortisol levels and was the
only class to have cortisol levels within the normal range. Both the mean cortisol
levels in class 2 and class 3 were higher than normal. Class 2 had the highest
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probability of breastfeeding. While few studies have examined hypothalamic
pituitary adrenal (HPA) activity in breastfeeding, one study found that morning
salivary cortisol levels were higher in women who predominantly breastfed (Ahn
& Corwin, 2014). Class 3 had the highest fasting morning cortisol levels. This
finding may be explained by the increased mean anxiety and depression scores
as well as less favorable lipid profiles observed in this class (Veen et al., 2009).
Dysregulation of the HPA axis impairs reproductive function by suppressing
steroidogenesis and inhibiting gonadotropin release (Schliep et al., 2015). The
effect of HPA activity on ovarian reserve is less well understood, however
preliminary studies suggest associations between cortisol and abnormal AMH
levels (Hardy et al., 2016).
In addition to the lowest mean AMH levels and a less favorable
cardiovascular risk profile, class 3 also had the highest mean depression and
anxiety scores (z-scores). Few studies have examined the association between
psychological factors and biomarkers of the ovarian reserve (Bleil et al., 2012;
Pal et al., 2010). Psychological disorders such as depression and anxiety are
associated with impaired reproductive function (Williams, Marsh, & Rasgon,
2007) and are also associated with greater cardiovascular and metabolic disease
risk (Bleil, Bromberger, et al., 2013; Lamers et al., 2012; Nikkheslat et al., 2015).
Class 2 had the highest probability of breastfeeding and of being lean, the
lowest mean triglyceride levels, and the highest mean HDL levels. This is
consistent with a protective effect of breastfeeding on cardiovascular health
regardless of pre-conception risk factors (McClure et al., 2012). The probability of
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breastfeeding did not, however, demonstrate a strong class trend in relation to
AMH. Several studies have reported a suppressive effect of pregnancy on the
ovarian reserve (Gerli et al., 2015; Köninger et al., 2013; Nelson et al., 2010).
The effect of breastfeeding is not previously described, although AMH was not
reduced in women with hyperprolactinaemia-induced amenorrhea (Li, Anderson,
Yeung, Ho, & Ng, 2011). In this study, there was no significant difference in AMH
concentrations between breastfeeding and non-breastfeeding postpartum
women.
Consistent with this class also having the highest probability of
breastfeeding, class 2 had the lowest E2 levels (McNeilly, 1993). Class 2 also
had the highest gonadotropin levels, a finding that was unexpected and the basis
for which is unclear. Class 1 had the highest E2 levels and the lowest FSH and
LH levels. Class 1 also had the highest AMH levels. While AMH does not
fluctuate significantly across the menstrual cycle, levels are at their highest in the
late follicular phase, corresponding with rising estradiol levels (Wunder,
Bersinger, Yared, Kretschmer, & Birkhäuser, 2008). Reproductive hormone
levels were not able to be timed according to menstrual cycle phase in our
postpartum sample, so these findings should be interpreted with caution.
This was an exploratory study with a small sample size. However, this was
appropriate given that the study was exploratory in nature, it was the first to use
latent class analysis to explore subgroups of risk profiles for ovarian reserve, and
was meant to determine the feasibility of this type of analysis for this population.
It is important to note that the sample consisted of a population of postpartum
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women with known fertility; most studies examining factors associated with AMH
concentrations have been conducted in infertile populations.
While preliminary, the findings from this study can be used as the
foundation for future analyses of subgroups in relation to the ovarian reserve.
The findings from this exploratory study should be replicated in larger samples to
allow for independent validation, as well as in different reproductive contexts to
examine how these variables behave in other populations. Current evidence
suggests that the rate of change in AMH concentrations improves the accuracy
of the biomarker to predict age at menopause (Freeman et al., 2012). Thus,
longitudinal studies will be necessary to identify additional factors contributing to
variation in the process of ovarian aging.
The process of ovarian aging spans many years, and at present, there are
few clues, other than chronological age, that indicate where a woman is in her
reproductive lifespan (Ottinger, 2011). In this study, we explored patterns in
cardiometabolic, psychological and reproductive factors in relation to ovarian
reserve and found less favorable cardiometabolic and psychological profiles in
women with lower ovarian reserve. The findings from this study demonstrate that
LCA is a feasible and useful approach for examining subgroups based on various
parameters of health, and sheds light on factors that may contribute to variation
in serum AMH concentrations, providing a window into what may be the earlier
stages of ovarian aging. With validation in larger samples, this information could
be used to develop reliable subgroup classifications to aid in the early detection
and prevention of premature ovarian aging.
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Table 1: Clinical and Demographic Data
Overall
(n = 69)

Lean
(n = 38)

Obese
(n = 31)

p-value

Breastfeeding
(n = 47)

Not
Breastfeeding
(n = 22)

p-value

Age (years)

33.97 ± 4.1

34.54 ± 3.64

33.27 ± 4.56

0.203

34.6 ± 3.93

32.66 ± 4.24

0.07

Anxiety

0.04 ± 1.08

-0.2 ± 1.04

0.33 ± 1.06

0.039

-0.05 ± 1.07

0.24 ± 1.08

0.302

Depression

-0.08 ± 0.95

-0.38 ± 0.86

0.29 ± 0.94

0.003

-0.2 ± 0.91

0.17 ± 1.01

0.132

FSH (mIU/ml)

7.02 ± 3.56

7.79 ± 3.35

6.08 ± 3.64

0.046

7.4 ± 3.34

6.19 ± 3.95

0.188

LH (mIU/ml)

5.19 ± 3.93

4.9 ± 4.12

5.53 ± 3.73

0.513

5.21 ± 4.39

5.14 ± 2.82

0.952

40.02 ± 38.06

31.02 ± 26.6

51.04 ± 46.71

0.029

27.9 ± 26.12

65.91 ± 46.52

<0.0001*

2.79 ± 2.5

3.19 ± 2.81

2.3 ± 2.0

0.143

2.98 ± 2.57

2.4 ± 2.36

0.375

855.7 ± 556.5

963.7 ± 587

742.5 ± 504.9

0.168

867.88 ± 537.53

758.96 ± 577.62

0.446

5.28 ± 1.47

5.57 ± 1.51

4.92 ± 1.36

0.064

5.29 ± 1.36

5.26 ± 1.71

0.937

1.57 ± 0.46

1.68 ± 0.46

1.44 ± 0.43

0.027

1.62 ± 0.4

1.46 ± 0.56

0.196

1.12 ± 0.81

1.01 ± 0.77

1.25 ± 0.85

0.234

1.01 ± 0.79

1.34 ± 0.82

0.115

E2 (pg/ml)
AMH (ng/ml)
Serum cortisol
(nmol/L)
Cholesterol
(mmol/L)
HDL
(mmol/L)
Triglycerides
(mmol/L)

•
Alpha level ≤ .0004 considered significant
Note: Anxiety and depression are z-scores. Abbreviations: AMH, Anti-Müllerian Hormone; HDL, High-Density Lipoprotein; FSH,
Follicle Stimulating Hormone; LH, Luteinizing Hormone; E2, Estradiol
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Table 2: Latent Class Analysis: Three-class model characteristics
Class 1 (32.2%)
(n=22)

Class 2 (43.4%)
(n=30)

Class 3 (24.3%)
(n=17)

AMH
(ng/ml)

3.83

2.88

1.86

Age

33.25

35.01

33.08

Breastfeeding
(Yes)

0.47

0.94

0.49

Triglycerides
(mmol/L)

1.04

0.64

1.85

Cholesterol
(mmol/L)

4.1

5.05

6.53

HDL
(mmol/L)

1.22

1.77

1.56

4.73

4.48

4.61

0.29

0.73

0.51

Anxiety
(z-score)

-0.18

-0.05

0.33

Depression
(z-score)

0.02

-0.26

0.1

Cortisol
(nmol/L)

437.15

955.91

974.67

FSH
(mIU/ml)

5.1

8.13

6.99

LH
(mIU/ml)

4.34

5.9

4.85

E2
(pg/ml)

74.19

22.85

37.04

Glucose
(mmol/L)
Lean

Note: For the continuous variables, the characteristic is presented as the mean of that variable within each class, for the binary
variables (breastfeeding status and lean/obese), the characteristic is presented as the probability of presenting that
characteristic. Abbreviations: AMH, Anti-Müllerian Hormone; HDL, High-Density Lipoprotein; FSH, Follicle Stimulating
Hormone; LH, Luteinizing Hormone; E2, Estradiol
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Table 3: Comparisons between classes by health parameters
Class
(mean AMH level)
Cardiometabolic

Class 1
(3.83 ng/mL)

Class 2
(2.88 ng/mL)

•

•
•

Lowest cholesterol
and HDL
Lowest probability
of being lean
Highest glucose
Lowest cortisol

Psychological

•

Reproductive

•
•

•
•

•
•

Class 3
(1.86 ng/mL)

•

•

Lowest
triglycerides
Highest HDL
Highest probability
of being lean
Lowest glucose

Lowest anxiety

•

Lowest depression

•

Highest anxiety
and depression

Highest AMH
Lowest probability
of breastfeeding
Lowest FSH and LH
Highest E2

•

Highest probability
of breastfeeding
Highest FSH and LH
Lowest E2

•

Lowest AMH

•
•

•
•

•

Highest
triglycerides and
cholesterol
Highest cortisol
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Abstract
Background: Few predictors of post-treatment reproductive function in
childhood cancer survivors (CCC) have been identified. CCS report high levels of
psychological stress. The association between stress and ovarian function has
not been explored in this population.
Purpose: The purpose of this exploratory study was to explore the relationship
between perceived stress, biomarkers of HPA activity, gonadotropin levels, and
anti-Müllerian hormone (AMH) in female CCS.
Methods: Perceived stress was measured using the Perceived Stress Scale-10.
HPA activity was measured using salivary and hair cortisol. Ovarian function was
measured using serum gonadotropin levels and serum AMH levels. Latent
Growth Modeling was used to determine diurnal cortisol slope and intercept.
Bayesian Structural Equation Modeling was used to explore the relationship
between perceived stress, biomarkers of HPA activity and ovarian function.
Results: Twenty-four female (mean age 21.79 ± 5.68) CCS were included in the
study. We found an inverse association between perceived stress and ovarian
function and a positive association between biomarkers of HPA activity and
ovarian function.
Conclusion: The findings from this study provide the foundation for further
research examining factors that contribute to risk for post-treatment reproductive
dysfunction in female CCS.
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Background
An estimated one in 1000 adults under the age of 35 is a survivor of
childhood cancer (Blumenfeld, 2012). Due to significant advances in the
treatment of pediatric cancer, the five year survival rate now exceeds 80% in the
United States (Barton et al., 2013) with similar statistics worldwide (Reinmuth et
al., 2013). With an increasing number of survivors, there has been growing
recognition of the potential late effects of cancer treatment (Kremer et al., 2013).
Among these, reproductive dysfunction is a major concern for cancer survivors,
and is highly correlated with quality of life in this population (Cherven et al., 2015;
Knopman et al., 2010; Kondapalli et al., 2014; Letourneau et al., 2013). Among
female childhood cancer survivors (CCS), 6.3% suffer from acute ovarian failure
and another 22.6% suffer from a significant reduction in ovarian function (Salih et
al., 2015). Female CCS are at risk for persistent chemotherapy-related
amenorrhea and early menopause; however, not all premenopausal CCS
experience these effects (Abusief et al., 2012).
The American Society for Clinical Oncology recommends that providers
discuss fertility preservation options with cancer patients at the earliest
opportunity; however, it remains challenging for providers to predict individual
risk of post-treatment reproductive dysfunction because of the limited knowledge
of factors associated with this late effect (Knight et al., 2015; Letourneau et al.,
2013). While the etiology of reproductive dysfunction in cancer survivors has
been discussed (El-Shalakany, Ali, Abdelmaksoud, Abd El-Ghany, & Hasan,
2013; Letourneau et al., 2013), few predictors of this effect of treatment have
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been identified (Dewailly, et al., 2014, Anderson et al., 2015). Further research is
warranted to develop reliable biomarkers to help clinicians accurately identify
cancer survivors at increased risk for reproductive dysfunction (Abusief et al.,
2012).
In clinical practice, post-treatment ovarian function is assessed using a
profile of the hormones follicle-stimulating hormone (FSH) and luteinizing
hormone (LH), plus the presence or absence of menses. However, neither FSH
nor menstrual cyclicity post-cancer treatment are reliable predictors of future
fertility (Knight et al., 2015). Because risk of infertility related to premature
ovarian failure is directly associated with the size of the ovarian follicle pool
(ovarian reserve), a biomarker which more closely reflects the number of
remaining follicles in the ovary would have significant clinical potential.
Anti-Müllerian hormone (AMH) is one such recently identified biomarker of
ovarian reserve. Plasma levels of AMH reflect the continuous non-cyclic growth
of small follicles, and therefore mirror the size of the remaining follicle pool
(Jeppesen, Anderson, Kelsey, Christiansen, Kristensen, Jayaprakasan,
Campbell, et al., 2013). Kelsey et al. (2011) developed and validated the first
model of AMH, mapping out the chronological trajectory of the hormone from
conception to menopause (Kelsey, Wright, Nelson, Anderson, & Wallace, 2011).
La Marca et al. then established normative age-ranges to aid in the clinical
interpretation of AMH values (La Marca et al., 2012).
Ovarian reserve declines naturally with age; however, recent research
demonstrates that chronological age alone is not an accurate indicator of

172
reproductive age and that other factors affect the depletion of the ovarian follicle
pool over time (Dolleman et al., 2013). AMH is prematurely reduced in CCS
(Anderson & Wallace, 2013; Charpentier et al., 2014; Miyoshi et al., 2013), and
may be an early marker of significant gonadotoxicity post treatment (Brougham
et al., 2012; Lie Fong et al., 2009). Several studies have demonstrated the utility
of pre-treatment AMH concentrations to predict risk of post treatment ovarian
dysfunction in cancer survivors (Anderson & Wallace, 2013; Lunsford et al.,
2014). However, the predictive value of AMH in cancer survivors is limited due to
incomplete knowledge of factors that influence AMH concentrations (Abusief et
al., 2012; Van Dorp et al., 2014).
One of the primary regulators of reproductive function is the hypothalamicpituitary-adrenal (HPA) axis. Cancer survivors have high rates of psychological
stress and hypothalamic-pituitary-adrenal (HPA) dysregulation (Oancea et al.,
2014; Taylor et al., 2012; Zeltzer et al., 2009). It is well established that
psychological stress impairs reproductive function by activating the HPA axis,
which suppresses hypothalamic-pituitary gonadal function (Kalantaridou et al.,
2010; Louis et al., 2011; Lynch, Sundaram, Maisog, Sweeney, & Buck Louis,
2014; Whirledge & Cidlowski, 2013). Increased HPA activity is associated with
elevated levels of glucocorticoids, such as cortisol. Precise levels of
glucocorticoids are required for proper ovarian function (Whirledge & Cidlowski,
2010). At homeostatic levels, cortisol contributes to steroid biosynthesis and
maintenance of gonadotropin release; at elevated levels, it suppresses
gonadotropin-releasing hormone secretion, reduces pulsatile LH secretion, and
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increases rates of follicle atresia (Breen & Mellon, 2014; Whirledge & Cidlowski,
2010; Whirledge & Cidlowski, 2013). As both higher rates of psychological stress
and reproductive dysfunction are observed in cancer survivors, this study
explored the relationship between psychological stress and biomarkers of
ovarian function in young cancer survivors. The purpose of this study was to
explore relationships between perceived stress, HPA activity, and ovarian
function in a sample of female survivors of childhood cancer.
Theoretical Framework
Life history theory was the framework used to guide this study (Whirledge
& Cidlowski, 2013). Rooted in evolutionary biology, life history theory was
developed to explain variation in resource allocation strategies adopted by
organisms to optimize survival and reproduction throughout the life course and
across varying environmental conditions. The task of all organisms is essentially
the same, to distribute material and energy resources to competing life functions:
bodily maintenance, growth and reproduction. Life history theory posits that the
allocation of biological resources is a trade-off between survival and
reproduction.
Because resources are limited, an organism must make trade-offs,
prioritizing their use in one domain at the expense of other competing domains
(Ellis et al., 2009). Life history traits, characteristics that determine rates of bodily
maintenance, reproduction, and growth, are the primary units of analysis in life
history theory. Both individually and collectively, life history traits provide a
window into an organism’s life history strategy and the developmental continuum
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that results from a chain of resource allocation decisions (trade-offs). The main
life history traits are age and size at maturity, reproductive investment,
reproductive lifespan, and aging (Stearns, 2000).
Early evolutionary biologists were able to demonstrate that organisms
make tradeoffs in response to changing environmental conditions and that these
tradeoffs influence the life course of an organism, but they struggled to identify
the biological mechanisms that allow organisms to make tradeoffs. Identifying
these mechanisms is vital to understanding the sources of variation in life history
strategies (Stearns, 2000). One of the primary mechanisms by which an
organism responds to changing environmental conditions is the hypothalamicpituitary-adrenal (HPA) axis (Ellis, 2013). Environmental challenges or stressors
activate the HPA axis and increase glucocorticoid secretion, directing resources
to vital physiological activities such as energy mobilization, cardiac output, and
cognition, and away from less vital functions. Because reproduction is
energetically costly, when resources are limited, an organism is likely to prioritize
survival over reproduction, delaying fertility until environmental conditions are
more ideal. The HPA axis, as a primary mediator of resource allocation
decisions, plays an important role in determining an organism’s life history traits.
The HPA axis plays a prominent role in the regulation of the hypothalamicpituitary-gonadal (HPG) axis through glucocorticoids, which have both supportive
and suppressive effects on reproductive function. This complex and
synchronized neuroendocrine cross talk between the HPA and HPG axes allows
tradeoffs to occur (Whirledge & Cidlowski, 2010). At homeostatic levels,
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glucocorticoids contribute to steroid biosynthesis and maintenance of
gonadotropin release. During acute stress, endogenous glucocorticoids
counteract the suppressive effects of prostaglandins on reproductive function,
thus protecting gonadotropin secretion. This suggests that threshold
glucocorticoid levels are necessary to maintain adequate gonadotropin release
(Whirledge & Cidlowski, 2010). Elevated glucocorticoid levels suppress
reproduction at multiple levels along the HPG axis. Increasing glucocorticoid
levels down-regulate gonadotropin releasing hormone (GnRH) synthesis and
decrease GnRH pulsatility, inhibiting the LH surge and delaying ovulation, and
increasing the rate of ovarian follicle atresia (Whirledge & Cidlowski, 2010, 2013).
In this study, we hypothesized that chronic stress, operationalized
as perceived stress (Perceived Stress Scale), and HPA activity,
operationalized as hair cortisol and diurnal salivary cortisol patterns, would
be associated with AMH, gonadotropin and reproductive hormone levels.
This study had the following aims:
Aim 1: Describe the relationship between perceived stress and biomarkers
of HPA activity in female cancer survivors.
Aim 2: Explore the relationship between perceived stress, biomarkers of
HPA activity, AMH and gonadotropin levels in female cancer survivors.
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Methods
Sample and Settings
The sample for this exploratory cross-sectional study consisted of female
childhood cancer survivors between the ages of 16 and 35 who were previously
treated for cancer at the Edinburgh Children’s Cancer Centre, Royal Hospital for
Sick Children (RHSC). This was an exploratory study; sample size calculations
are challenging in an exploratory model of potential predictors, due to the fact
that one is not aware of predictor effects, and cannot put forth anticipated effect
sizes.
Cancer survivors are seen annually for follow up at the Royal Hospital for
Sick Children (RHSC) (Wallace et al., 2014). The inclusion criteria were: female
patients treated for cancer (including leukemia and brain tumors) at the
Edinburgh Children’s Cancer Centre, younger than 18 years of age at cancer
diagnosis and between 16-35 years of age at the time of the study visit, at least
one year out from completing treatment, and signed written informed consent. In
the UK, research subjects aged 16 and older are able to provide informed
consent.
This inclusion age range of 16-35 was selected because subjects are
likely to be post-pubertal and in the most fertile window of their reproductive
lifespan. Cancer survivors seen for long-term follow-up at the Royal Hospital for
Sick Children (RHSC) in Edinburgh, Scotland were selected because of Dr.
Anderson’s current research on reproductive function and fertility preservation in
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cancer survivors (Wallace et al., 2014). This collaboration minimized burden to
subjects and maximized potential findings. The exclusion criteria were a positive
pregnancy test, ovarian surgery in the past 6 months, hormonal therapy in the
preceding 3 months (GnRH agonists, recFSH), alcohol or drug
abuse/dependence according to ICD-10 criteria, and having received an
investigational drug in the past 3 months (90 days).
Instruments
Ovarian function: Assessment of ovarian function included serum
gonadotropin levels (luteinizing hormone (LH), follicle-stimulating hormone
(FSH)), estradiol (E2) and AMH. Serum levels of these hormones are
routinely measured during the annual follow-up appointment as part of
standard care at NHS affiliated clinics. The laboratory results were retrieved
from participants’ medical records. Serum AMH levels were analyzed using
the Beckman Coulter AMH GEN II ELISA (Beckman Coulter Inc., Brea, CA).
The AMH Gen II ELISA has a sensitivity of 0.57 pmol/l. The validated model
of serum anti-Müllerian hormone by Kelsey et al. (2011) and the nomogram
with normative values for age published by La Marca et al. (2012) was used
to interpret AMH levels (Kelsey et al., 2011b; La Marca et al., 2012b).
HPA activity was determined using measures of salivary cortisol and
hair cortisol. Salivary cortisol has been used to measure diurnal HPA activity
in cancer survivors and other populations (Du et al., 2013; Ho et al., 2013;
Sephton et al., 2013). Chronic stress is associated with alterations in the
cortisol awakening response (Dedovic & Ngiam, 2015; Révész et al., 2013),
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and blunting of the morning-evening diurnal slope (Garland et al., 2014; Ho
et al., 2013; Schrepf et al., 2015). A commercially available Enzyme-Linked
Immuno-Sorbent Assay (ELISA) kit was used for the quantification of
cortisol in saliva (Salimetrics, Suffolk, UK KIT 1-3002). This cortisol assay kit
has a lower detection limit of 7 ng/dl. The mean intra-assay coefficient is
5.7% and the mean inter-assay coefficient is 10%. Analysis of salivary
cortisol was conducted at the Queen’s Medical Research Institute in
Edinburgh, Scotland under the supervision of Dr. Richard Anderson.
Chronic stress has also been associated with elevated levels of
cortisol in hair (Russell et al., 2012; Wells et al., 2014a). Hair has a
predictable growth rate of 1 cm/month; the most proximal 1 cm segment to
the scalp approximates the last month’s cortisol production, the second
most proximal segment the month prior to that, and so on (Russell et al.,
2012). Hair (3 cm) was processed for extraction of cortisol in the laboratory
of Clemens-Kirschbaum in Dresden, Germany as previously described
(Kirschbaum et al., 2009).
Perceived Stress was measured using the Perceived Stress Scale
(Cohen et al., 1983). The PSS is a 10 item (PSS-10) self-report of life stress
over the past 4 weeks, and is the most widely used measure of this concept.
The PSS-10 was designed for use in community samples of subjects with
education as low as junior high. Good to excellent reliability has been
observed with the PSS-10 in varied populations (Cohen et al., 1983) with a
Cronbach’s alpha ranging from .78-.91 (E.-H. Lee, 2012). The measure has
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been demonstrated to reliably measure stress appraisal in cancer survivors
(Golden-Kreutz et al., 2009).
Data Collection
Recruitment was conducted by sending letters of invitation to female
cancer survivors in long-term follow-up two weeks prior to their annual
review appointment. After consenting to be contacted, patients were
interviewed over the phone to determine eligibility to participate in the study.
If eligibility requirements were met and the patient agreed to participate, a
30-minute study visit at the RHSC was scheduled at a mutually agreed upon
time. Written consent was obtained from participants at the study visit. Each
subject was assigned a unique study ID and data was entered into an SPSS
file on an encrypted computer in a locked office.
Data was collected in this order: saliva, demographic and PSS-10
questionnaires, hair. Salivette collecting devices and detailed instructions for
collection of samples were provided to participants at their annual review
appointment. Participants were instructed not to eat, smoke, consume
caffeine or exercise for 30 minutes prior to sample collection (Schrepf et al.,
2015). Participants provided three timed saliva samples for the analysis of
salivary cortisol: the first sample was collected before going to bed on the
night prior to the study visit, the second immediately upon awakening the
morning of their visit before getting out of bed, and the third was collected
30 minutes after the second sample. Participants were instructed to record
the time of saliva collection on their salivette collecting devices and to keep
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the saliva samples refrigerated until coming in for their study visit to
preserve sample integrity. Participants brought the three saliva samples to
their study visit. Samples were labeled with a unique subject study ID and
stored at the RHSC at -20 C; within a week of collection, a research nurse
picked them up and brought them to the QMRI, where they were centrifuged
and stored at -80 C.
During the study visit, participants provided demographic information
including age, ethnicity/race, level of education, marital status and employment
status. Participants then completed the PSS-10 (Cohen et al., 1983). Lastly,
participants provided a sample of hair for measurement of hair cortisol. A small
sample of hair, 20mg (100-150 strands), was taken from the vertex posterior of
the participant’s scalp using a new pair of thinning shears (Hoffman et al., 2014;
Van Uum et al., 2008). Hair length was recorded and proximal ends of the hair
samples were marked. Hair samples were stored in aluminum foil for protection
before processing (Hoffman et al., 2014) and labeled with a unique subject study
ID.
During data collection, it was discovered that many subjects travel a great
distance to the hospital for clinic visits. Therefore, to reduce the burden of
participation, subjects were given the option to receive a research packet in the
mail if they were unable to return to the RHSC for a separate study visit because
of the travel distance. Since the current methods already required subjects to
collect saliva samples at home, the main change was that subjects who decided
to receive a research packet in the mail also self-collected a hair sample. They
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were instructed on how to collect the hair sample when they consented to
participate in the study. They were also asked to complete the PSS-10 at home.
Biological samples and questionnaires were labeled with the subject’s study ID
so as to ensure confidentiality. No identifying information was included in or on
the research packet. The research packet included prepaid return packaging and
an ice pack so that subjects could return samples and questionnaires to the
Royal Hospital for Sick Children for processing.
The following clinical characteristics were retrieved from participants’
medical records: cancer diagnosis, age at cancer diagnosis,
chemotherapy/radiation received (yes/no) and age at menarche.
Reproductive hormone levels (AMH, FSH, LH and E2), measured as part of
routine care at the annual review visit, were also retrieved from participants’
medical records.
Data Analysis and Interpretation
Means and standard deviations or frequency distributions, as appropriate,
for all demographic and clinical variables were reported to describe the sample
and reveal distributional characteristics.
Latent Growth Curve Modeling was used to examine diurnal cortisol
patterns. Bayesian Structural Equation Modeling was used to explore the
relationship between perceived stress and HPA activity and to explore
relationships between perceived stress, biomarkers of HPA activity, gonadotropin
levels, and AMH.
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Latent Growth Curve Modeling
Latent Growth Curve Modeling was used to define diurnal cortisol change
over time (three time points). Growth curve modeling (GCM) examines change
as a trajectory and assumes that trajectories vary across participants (Barker et
al., 2013). This method was selected since chronic stress is characterized by a
persistent and unstable trajectory of HPA activity (Hellhammer et al., 2009).
Change processes are determined by combining the underlying pattern of growth
(slope) with the initial or baseline measurement (intercept). The intercept and
slope of this trajectory were then incorporated into the structural equation model
as independent predictors of ovarian function. GCM was selected instead of
more commonly utilized methods of analyzing diurnal cortisol (e.g. area under
the curve, cortisol awakening response) because it permits a robust examination
of change in small samples.
GCM was evaluated as yit = λintηint + λslpηslp + et, where yit represents the
observations for each subject i at each time t. λint represents the vector of fixed
values that define the latent intercept, this is λint = [1,1,1], while λslp represents the
vector of fixed values that define the linear slope, this is λslp = [0, 9.3, 9.8]. This
represents the average time between the first observation to the second (9.3
hours), and from the first observation to the third observation (9.8 hours). ηint
represents the latent intercepts, while ηslp represents the latent slope, for which
we estimate the respective mean and variance. The means represent the
average starting point and average change over time, while the respective
variance represents how much the subjects vary from the respective mean.
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Lastly, et represents the residual variance at each time point t, this indicates that
the GCM is estimated without the assumption of homogeneity of variance over
time, the residual variance is allowed to differ over time.
Bayesian analysis
In Bayesian analysis, statistical inferences are drawn from parameter
values that could give rise to the observed data (Scheines et al., 1999). The term
prior is used to refer to the expected parameter distribution based on theory or
previous research. The posterior distribution is the parameter distribution that
results from multiplying the prior distribution by the likelihood (as observed in the
sample data). The posterior distribution describes the behavior of the parameters
conditional on the data. Because the Bayesian framework makes inferences from
the posterior distribution, it allows researchers to make direct inferences about
the parameters given the observed data. The posterior distribution describes
both the best estimate given the data, and the level of uncertainty about the
respective parameter by the width of it, typically represented by the credible
interval (Yuan & MacKinnon, 2009).
The Bayesian framework is an appropriate method for small sample sizes.
Frequentist methods rely on the asymptotically correct estimation methods,
basing the inference in function of the null hypothesis (Wagenmakers, Lee,
Lodewyckx, & Iverson, 2008). Bayesian inference bases the inference on the
observed data, which allows estimation of parameters with small samples in
conditions where frequentist estimation fails (Lee & Song, 2004).
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The Bayesian approach requires specification of prior distributions for
each of the model parameters (Palomo et al., 2007). The selection of the prior
distribution is important because the posterior distribution is informed by the prior
distribution and the likelihood of the data (Palomo et al., 2007). The prior
distribution incorporates information drawn from previous empirical studies or
theory regarding the model parameters. Given the exploratory nature of this
study, we first examined the model parameters using weakly informed priors.
Weakly informed priors are not intended to guide the parameters, but instead
provide information to delimitate the most likely data space for the parameters.
Means/intercepts have a prior µ~N(0,100); the standard deviations have a prior
δ~half-cauchy(0,2.5); the regressions have a prior β~N(0,50); and the
correlations have a prior ρ~U(-1,1).
Strong hypotheses are tested by model comparison. A model without
constraints was compared to a model with constraints in the regressions (β),
constraining if the β is positive or negative (according to theory). These
constraints are set by specifying the respective β prior as a truncated normal
(e.g: β~N(0,50)T(0,)) not allowing β to be above/below 0. Model comparison
allowed us to evaluate if the model with directional constraints fit the data better
than the unconstrained model. If the directional constraint model fit better, it is
evidence that the β should be directional. The models were compared with
Information Criteria Leave-One-Out (LOO), and Widely Applicable (WAIC)
(Gelman et al., 2013; Kass & Raftery, 1995; Raftery, 1992; Vehtari, Gelman, &
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Gabry, 2015, 2016). The theoretical model including the hypothesized
directionality of the associations is presented in Figure 1.
Bayesian Structural Equation Modeling
Structural Equation Modeling (SEM) provides a broad framework for
modeling relationships with multivariate outcomes (Palomo et al., 2007). The
purpose of SEM is to test a theory by specifying a model that represents
predictions about the theory’s constructs measured with appropriate observed
variables (Kline, 2015). The outcome of SEM is a set of model parameters for
hypothesized effects given the data. From these parameters, a set of logical
implications result about the nature of the relationship or non-relationship
between the variables (Kline, 2015). While SEM typically includes an
approximation of unobserved or latent constructs as well as an estimation of the
structure of the relationships among these observed constructs, in this study we
used a special case of SEM called path analysis. In path analysis, every variable
in the model is directly measured or observed (Bryan et al., 2007). While latent
variables account for unreliability of measures and uncertainty in the model, they
can also complicate a model, especially when the sample size is small. Path
analysis was selected instead of multiple linear regression because it allowed us
to test multiple relationships between variables, with multiple outcomes,
conforming to the hypothesized model in this study. Establishing relationships
including multiple paths and outcomes allowed us to test the presence of
relationships accounting for the relationships with other variables of interest
(Kline, 2015).
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Bayesian SEM was selected because it facilitates greater precision in
estimating the posterior distribution of the parameters for small samples.
Additionally, Bayesian SEM offers the advantage of incorporating previous
knowledge about the model’s parameters through the use of priors. Thus,
Bayesian SEM provided an excellent framework for exploring the relationships
between this study’s variables, allowing for an appropriate degree of uncertainty
when estimating the model’s parameters (Scheines et al., 1999). We ran a series
of path analysis models with salivary cortisol intercept and slope, PSS, Hair
cortisol, BMI, Age, Age at diagnosis, and Age at menarche as predictors and with
AMH, E2, FSH, and LH, as outcomes.
Because the aim of the study was to explore relationships between
variables, the analysis was not strictly confirmatory. If the data did not fit the
model specified, alternative models were tested. The purpose of exploring
various models was to provide additional information about the plausible
relationships between the variables of interest and make recommendations for
future model testing. Data augmentation was used to account for missing data.
Missing data was treated simultaneously as a parameter and data, filling any
missing data points with the most likely value given the posterior distribution. At
each iteration of the estimation, likely values were imputed for the missing data.
These likely values were drawn from the posterior distribution estimated at that
point in the iterations. In later steps of the estimation, the likely values were used
as data in the path analysis, and this process continued until the model had
converged (Merkle, 2011).
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Data analysis was conducted in R (Core Team, 2017). Bayesian path
analysis was run with the R package blavaan (Merkle & Rosseel, 2016) which
estimates the model with the general Bayesian software JAGS (Plummer, 2003).
Convergence of the Markov chains was determined using the potential scale
reduction factor (PSRF), also known as univariate R-hat (Gelman & Rubin,
1992). It was determined that the model converged when R-hat was lower than
1.10 for every parameter (Brooks & Gelman, 1998). The models were run with 3
chains, keeping the last 5000 iterations from each chain to build the posterior
distributions. Model comparison with LOO and WAIC were done with loo R
package (Vehtari et al., 2015); smaller values for LOO and WAIC represent a
better fit.
Results
Twenty-four female childhood cancer survivors (mean age 21.79 ± 5.68)
participated in the study. The majority had at least a high school education
(62.5%) and was unmarried (79.2%). Childhood cancer diagnoses varied
considerably and included: Osteosarcoma (n=1), Rhabdomyosarcoma (n=5),
Wilms Tumor (n=1), Optic Chiasmal Glioma (n=1), Non-Hodgkin's Lymphoma
(n=3), Ewing’s Sacrcoma (n=2), Immature teratoma L ovary (n=1), B-cell
lymphoma (n=1), Hodgkin's Lymphoma (n=4), Right temporal lobe pilocytic
astrocytoma (n=1), Pilocytic astrocytoma of the conus (n=1), Left renal tumor
(n=1), Undifferentiated sarcoma of posterior sacral region (n=1), and Acute
lymphoblastic leukaemia (n=1).
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Latent Growth Curve results
The three measures of cortisol were standardized in function of the first
time point. For each time point, we subtracted the mean from the measure at the
first time point, and divided that number by the standard deviation of the measure
at the first time point. This standardization sets the metric in function of the
standard deviation from cortisol at the first time point (SD = 74.67) (Figure 2).
Due to the standardization, the mean of the intercepts is 0.
The GCM found that ηint ~ N(0.00, 0.65), indicating that the average
starting point is at the average of the first time point (M = 105.25 ng/dL), and the
variance is 0.65*74.67 = 48.53 ng/dL, in function of the standard deviation. For
the other parameter of interest, ηslp ~ N(0.324, 0.126), indicating that on average,
the participants’ cortisol levels increased about 0.324*74.67 = 24.19 ng/dL/hour,
and the variance across the sample was 0.126*74.67 = 9.41 ng/dL. The residual
variances indicate that the variance increases over time; at the third time point,
the variability of cortisol is greater (Table 1). We found that the salivary cortisol
intercept and slope were not correlated (r = 0.09).
Path analysis results
The first model included weakly informative priors, which did not constrain
the directionality of the regressions. The second model constrained the direction
of the regressions for the outcome AMH, the third constrained the direction of the
regressions for E2, the fourth model constrained the direction of the regressions
for FSH, the fifth model constrained the direction of the regressions for LH, the
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sixth model constrained the direction of the regressions for all the outcomes, the
seventh model constrained the direction of the regressions for all the outcomes in
the opposite direction to the sixth model. These models allowed us to test if the
data fit better with some constraints. The seventh model allowed us to do a
sensitivity test; if the original theory driven constraints are meaningful the seventh
model should decrease the fit.
Table 2 shows the seven models and their fit comparison. Models 2 to 7
were compared with model 1. For model 2 and model 5, the model fit is
functionally the same. For models 3, 4, and 6 the model fit improved slightly. And
for model 7, the fit decreased slightly. The model comparison demonstrates that
the theory driven constraints do not decrease the fit of the model, and in some
cases improve it. It also indicates that the opposite direction constraints do harm
the fit of the model. Although model 6 improved the fit over model 1, this change
in fit was not meaningful, as its change was within the margin of the respective
standard errors. Functionally, model 1 and model 6 were equivalent. We chose to
keep model 1 as the model from which to interpret the results.
The results for model 1 are presented in Tables 3 to 9. We found that the
predictors explained 33.2% of the variance of AMH, 41.8% of FSH, 39.2% of LH,
and 0.0% of E2. Overall effects indicate that these predictors were less sensitive
to E2. The standardized regression coefficients allowed us to compare the effect
of different predictors for each outcome. For AMH, Age, Age at diagnosis, and
Perceived Stress Scale (PSS) were the strongest predictors. As PSS increased 1
SD, AMH decreased 0.287 SD. In the case of FSH, PSS was the strongest
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predictor, followed by the intercept of salivary cortisol, and age at menarche. As
PSS increased 1 SD, FSH decreased 0.53 SD. For LH, we found that the 3
predictors related to cortisol (intercept, slope of salivary cortisol, and hair cortisol)
and age at diagnosis were the strongest predictors. As the intercept of salivary
cortisol increased by 1 SD, LH increased by 0.387 SD. In the case of E2, all the
predictors were equivalent around 0.0, demonstrating that these predictors did
not characterize the behavior of E2.
The correlations between predictors and the residual correlation between
outcomes are presented in tables 8 and 9. The residual correlation represents
the relationship between the outcomes after some variance has been explained
by the model. For both sets of correlations, the variables have either a correlation
functionally equal to 0, or a weak correlation (r < 0.2).
Discussion
Aim 1: Description of perceived stress and HPA activity in female cancer
survivors.
In this small sample of female childhood cancer survivors, the mean
perceived stress scale (PSS) score was 16.43 ± 6.73; this is higher than the
mean threshold for stress in the general population, which is 13.7 for
women (Cohen et al., 1983). Surviving a life-threatening illness such as
pediatric cancer represents a major early life stressor (Laufer et al., 2012)
and several studies have demonstrated that childhood cancer survivors
report higher levels of stress than healthy controls (Brown, Madan-Swain, &
Lambert, 2003; Oancea et al., 2014). Keir et al. demonstrated that long-term
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cancer survivors are just as likely as cancer patients to report high levels of
stress, suggesting that the time since diagnosis and treatment does not
mitigate the stress effects of cancer (Keir et al., 2007).
The average salivary cortisol intercept (corresponding to the PM
timepoint) was 105.25 ng/dL with a variance of 48.53 ng/dL. On average, salivary
cortisol levels increased 24.19 ng/dL per hour with a variance of 9.41 ng/dL. The
latent growth curve demonstrated heterogeneity of variance over time (as shown
in Figure 2), with wider variability observed at the later time points. Some slopes
were positive and others were flat, creating an over-dispersion at the later time
points. Both higher night salivary cortisol concentrations (>100 ng/dL) and
flattened diurnal cortisol slopes have been observed in studies examining HPA
activity in cancer survivors, a population at risk of experiencing high levels of
psychological stress (Cuneo et al., 2017; Garland, Beck, Lipschitz, & Nakamura,
2015; Schrepf et al., 2015; Sephton et al., 2013). It is hypothesized that these
abnormal diurnal patterns induce systemic inflammation, which is associated with
increased incidence of adverse long-term health outcomes for cancer survivors
(cancer recurrence, chronic symptom experience, etc…) (Schrepf et al., 2015).
To our knowledge, no studies have yet examined hair cortisol levels
in childhood cancer survivors. In our small sample of 24 CCS, we found a
wide range of hair cortisol concentrations (1.08-211.70 pg/mg, mean 19.94
± 43.23 pg/mg), a finding which is consistent with other studies that have
examined hair cortisol concentrations in the general population (Russell et
al., 2012; Stalder & Kirschbaum, 2012). However, the median hair cortisol
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concentration in our sample was 7.01 pg/mg with 16/24 (67%) having
concentrations lower than 10 pg/mg (see Figure 3). This is lower than the
median concentrations reported in healthy samples (Stalder & Kirschbaum,
2012). In a meta-analysis of chronic stress and HPA activity, Miller et al.
(2007) report that patterns of HPA activity in response to chronic stress vary
by time since onset. When the eliciting stimulus of a chronic stressor first
begins, there is an initial activation of the HPA axis, which results in
elevated concentrations of cortisol. As time passes, this activity lessens,
and cortisol secretion rebounds to below normal (Miller, Chen, & Zhou,
2007). This may explain the lower median hair cortisol concentrations
observed in our sample of childhood cancer survivors. As both
hypocortisolism and hypercortisolism are associated with adverse health
outcomes, the finding of lower median hair cortisol concentrations in this
sample is notable and requires further investigation (Miller et al., 2007).
Correlation between perceived stress and HPA activity in cancer survivors
In this exploratory study, perceived stress levels, salivary cortisol intercept
and slope and hair cortisol concentrations were not correlated in childhood
cancer survivors (Table 8). These findings are consistent with previous studies
that have examined the relationship between self-reported measures of stress
and measures of HPA activity (Miller et al., 2007; Stawski, Cichy, Piazza, &
Almeida, 2013). Wells et al. (2014) used a pooled database from diverse
community samples to examine the association between hair cortisol
concentrations (HCC) and measures of perceived stress. Correlations of HCC
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with self-reported stress were small and both were non-significant after
controlling for confounders (Wells et al., 2014).
Correlation between biomarkers of HPA activity in cancer survivors
We also found no correlation between hair and salivary cortisol in our
sample of CCS. Sauve et al (2007) examined correlations between hair cortisol
and concentrations of cortisol in urine, saliva, and serum in 39 non-obese
subjects. Hair cortisol and saliva cortisol were not correlated (r = 0.306, p =
0.119). One explanation for the lack of correlation between hair cortisol and
salivary cortisol is the difference in time frames reflected by the measurements:
salivary cortisol represents cortisol secretion at one time point during the day,
whereas hair cortisol represents average cortisol secretion during 1-3 months
(Sauvé et al., 2007). Since hair cortisol reflects long-term cortisol secretion, the
association between hair and salivary cortisol would be expected to strengthen
with an increasing number of accumulated shorter-term cortisol samples (Stalder
& Kirschbaum, 2012) and this was recently confirmed in a study by Short et al.;
HCC was most strongly associated with 30-day integrated cortisol production
(average salivary cortisol AUC) and there were no significant associations
between HCC and the 30-day summary measures using cortisol awakening
response or diurnal slope (Short et al., 2016).
Aim 2: To explore the relationship between perceived stress, HPA activity and
gonadotropin and reproductive hormone levels and AMH in female cancer
survivors
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For each outcome, the overall R2 will be discussed as well as the highest
standardized regression coefficients for that outcome.
Perceived stress, HPA activity and AMH
In this study of 24 CCS, we found that the model predictors explained 33%
of the variation in AMH levels, with the highest standardized regression
coefficients observed for age, age at diagnosis, perceived stress and hair cortisol
(Table 4). With an increase of one standard deviation in age, age at diagnosis
and perceived stress, AMH declined 5.66 pmol/L, 5.19 pmol/L, and 5.02 pmol/L
respectively. The inverse association between age and AMH is well established
in the literature (Kelsey et al., 2011). Barton et al. (2013) also found that older
age at diagnosis increased risk of post-treatment infertility in childhood cancer
survivors, but only in unadjusted models (Barton et al., 2013). The association
between perceived stress, HPA activity and the ovarian reserve has not been
examined in childhood cancer survivors. However, Pal et al. (2010) examined
associations between acute (serum cortisol) and chronic (history of abuse and/or
drug use) psychosocial stress and Müllerian-Inhibiting-Substance (MIS), now
referred to as AMH, in 89 pre-menopausal infertile women. Those with chronic
stress demonstrated significantly lower MIS (AMH) levels (p = 0.034), and were
three times more likely to be diagnosed with diminished ovarian reserve (p =
0.025). However, no association was observed in their study between serum
cortisol levels and diminished ovarian reserve. The authors concluded that
chronic, but not current stress, was associated with diminished ovarian reserve.
They proposed HPA dysregulation as a plausible explanation for this association;
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because a biomarker of chronic stress was not included in the study, the authors
were unable to provide evidence supporting this theory (Pal et al., 2010).
In this study, we found that with an increase of one standard deviation in
hair cortisol concentrations, AMH increased 3.76 pmol/L. And while the
standardized regression coefficients of the diurnal cortisol intercept and slope
were lower, they were also positively associated with AMH levels. Taken together
(positive associations between hair cortisol concentrations, diurnal cortisol slope
and intercept and AMH levels), these findings suggest a positive association
between cortisol concentrations and the ovarian reserve, and support the
hypothesis that threshold glucocorticoid levels are necessary to sustain ovarian
function (Whirledge & Cidlowski, 2013). As stated earlier, we found lower median
hair cortisol concentrations in our sample than reported in healthy populations
(Stalder & Kirschbaum, 2012).
Over half of the subjects in our sample exhibited flattened diurnal cortisol
slopes. Lower daily cortisol output and flattened diurnal cortisol slopes have been
observed in cancer survivors. Our findings are consistent with prior studies
linking hypocortisolism with increased risk of experiencing the late effects of
cancer treatment (Bower et al., 2005; Cuneo et al., 2017; Ho et al., 2013; Schrepf
et al., 2015; Sephton et al., 2013).
Perceived stress, HPA activity and Gonadotropin levels
In this study, we found that the model predictors explained 42% of the
variation in FSH levels, with the highest standardized regression coefficients
observed for salivary cortisol intercept, perceived stress and age at menarche
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(Table 5). The model predictors explained 39% of the variation in LH levels, with
the highest standardized regression coefficients observed for salivary cortisol
intercept and slope, hair cortisol and age at diagnosis (Table 6). We also found
that perceived stress was inversely associated with FSH and LH levels and was
not associated with E2 levels.
Because we were unable to time the collection of reproductive hormone
levels according to menstrual cycle phase, we did not anticipate a strong
association between perceived stress and FSH and LH levels. There are several
possible explanations for the strong inverse association we observed irrespective
of menstrual cycle phase. It may be that perceived stress has a significant effect
on ovarian function, regardless of menstrual cycle phase.
Schliep et al. (2015) found that daily stress (measured using the
Perceived Stress Scale-4) was inversely associated with E2 and LH but
positively associated with FSH levels in 259 healthy women aged 18-44 years,
after adjusting for age, race, percent body fat, depression score, time-varying
hormones and vigorous exercise (Schliep et al., 2015). These contradictory
findings regarding stress and FSH may be due to the younger age range
included in our study (16-35), in which extreme levels of FSH were less likely.
Another explanation may be that stress perception varies across the menstrual
cycle, such that the degree to which a woman perceives her life to be stressful is
in part influenced by fluctuations in gonadotropin levels (Duchesne & Pruessner,
2013).
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While perceived stress was inversely associated with FSH and LH, we
found that HPA activity (hair, salivary cortisol intercept and slope) was positively
associated with FSH and LH levels. Similar to perceived stress, HPA activity was
not associated with E2 levels. Our findings support the role of glucocorticoids in
regulating the hypothalamic-pituitary-gonadal axis. In our sample, we observed
lower median hair cortisol levels than those reported in healthy samples; thus,
the positive association we observed suggests that threshold glucocorticoid
levels are needed to sustain reproductive function (Whirledge & Cidlowski, 2013).
Another explanation is that cortisol levels may fluctuate across the menstrual
cycle as has been suggested by others (Kirschbaum, Kudielka, Gaab, &
Schommer, 1999; Nepomnaschy et al., 2011; Stephens et al., 2016; Wolfram,
Bellingrath, & Kudielka, 2011). While preliminary, the findings from our small
sample support an association between perceived stress, HPA activity and
gonadotropin levels in female cancer survivors. More research is needed to
clarify the mechanism behind this association and to determine whether it varies
depending on the temporal nature of the stressor and menstrual cycle phase.
Limitations
This exploratory study has several limitations. Due to the small
sample, we were unable to adjust for hormonal contraceptive use in the
overall model. Hormonal contraceptive use is associated with increased
production of corticotropin-binding-globulin and subsequent decreases in
unbound cortisol levels (Stephens et al., 2016). In addition, due to the wide
variety of pediatric cancer diagnoses in this small sample, we could not
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adjust for cancer diagnosis and treatment-related factors in the model.
Several studies have found a significant effect of diagnosis and treatmentrelated factors on post-treatment ovarian function, including the cancer
pathology itself (Van Dorp et al., 2014), the therapeutic regimen
(Charpentier et al., 2014) and the length of exposure (El-Shalakany et al.,
2013; Reinmuth et al., 2013). Another limitation is that due to the great
distance that many of the participants needed to travel, we were unable to
time study visits to coincide with a specific menstrual cycle phase. For this
reason, we were unable to adjust gonadotropin and reproductive hormone
levels to account for menstrual cycle phase. And last, the study design was
cross-sectional and relied on a convenience sample.
Conclusions
In this exploratory study, we sought to examine the association
between chronic stress and ovarian function in survivors of childhood
cancer. The effects of chronic stress on the ovarian reserve are poorly
understood. The findings from this study provide preliminary evidence to
suggest that perceived stress is negatively associated with ovarian function,
and that biomarkers of HPA activity are positively associated with ovarian
function in female childhood cancer survivors. Few studies have examined
predictors of the ovarian reserve in childhood cancer survivors other than
diagnosis and treatment-related factors. Pre-treatment planning and the
ability to provide individualized fertility prognoses depends on increased
understanding of factors associated with the ovarian reserve in this
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population (Anderson et al., 2013; Knopman et al., 2010). The findings from
this study provide the foundation for further research examining the risk for
post-treatment reproductive dysfunction in female CCS. Due to the small
sample size, this study’s findings require validation in larger longitudinal
studies. Given that our current understanding of the ovarian reserve is
limited, the findings from this exploratory study can be used to clarify
relationships between variables and propose a model for future hypothesis
testing in experimental research.

200
Table 1: Clinical and Demographic Descriptive Statistics
N
Age
Age diagnosed
Age at Menarche
BMI (kg/m2)
PSS Total
PM CORT (ng/dL)
AM CORT (ng/dL)
AM + 30 (ng/dL)
HAIR CORT (pg/mg)
FSH (U/L)
LH (U/L)
Estradiol (pmol/L)
AMH (pmol/L)

24
24
22
20
23
20
21
21
24
24
24
24
23

Minimum

Maximum

17
1
10.0
19.96
6
18.92
32.63
26.24
1.08
0.7
0.5
50
2.4

34
16
15.0
34.38
32
262.66
644.01
850.89
211.70
9.8
10.7
685
79.5

Mean
21.79
10.38
12.27
24.57
16.43
105.26
318.74
392.93
19.94
4.93
4.53
197.88
23.28

SD
5.68
5.22
1.19
3.81
6.727
74.68
203.46
263.68
43.23
2.34
3.12
175.04
17.94

Note: Abbreviations: BMI, Body Mass Index; PSS, Perceived Stress Scale; PM CORT,
Night cortisol; AM CORT, Morning cortisol; AM + 30, Morning cortisol plus 30 minutes;
HAIR CORT, Hair cortisol; FSH, Follicle Stimulating Hormone; LH, Luteinizing Hormone;
AMH, Anti-Müllerian Hormone
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Diurnal Cortisol
intercept

Diurnal Cortisol
slope

Perceived Stress
Scale

Anti-Müllerian
Hormone
R2 = 0.332

Follicle
Stimulating
Hormone
R2 = 0.418
Luteinizing
Hormone
R2 = 0.392

Hair Cortisol
Estradiol
R2 = 0.000

Figure 1: Bayesian Path Analysis Model

Covariates
1. Age
2. BMI
3. Age at
menarche
4. Age at
diagnosis
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Figure 2: Graph of Diurnal Cortisol slopes including three time points

Figure 3: Boxplot of hair cortisol concentrations
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Table 2: Latent Growth Curve
Parameter

Estimate

95% CI

Standardized
estimate

Intercept mean

0.00

-0.45, 0.46

0.00

Intercept variance

0.65

0.09, 1.39

1.00

Slope mean

0.32

0.16, 0.49

0.91

Slope variance

0.12

0.06, 0.22

1.00

Covariance

0.03

-0.12, 0.17

0.09

Residual T1

0.482

0.00, 1.26

0.42

Residual T2

0.86

0.00, 3.42

0.07

Residual T3
4.06
0.00, 7.29
0.23
Note: Estimate: mean of the posterior distribution; CI: Credible Interval

Table 3: Path analysis model fit comparisons
LOO (pd)
WAIC (pd)
ΔLOO (SE)

ΔWAI (SE)

Model 1

1474.0 (58.5)

1463.0 (53.1)

Model 2

1475.3 (58.1)

1463.7 (52.3)

-0.6 (2.0)

-0.3 (1.7)

Model 3

1466.5 (55.2)

1457.3 (50.5)

3.8 (2.4)

2.9 (1.3)

Model 4

1469.0 (55.7)

1460.2 (51.3)

2.5 (2.1)

1.4 (1.7)

Model 5

1474.8 (55.3)

1464.5 (50.1)

-0.4 (3.1)

-0.7 (2.8)

Model 6

1471.5 (51.4)

1464.9 (48.1)

1.3 (4.5)

-1.0 (4.4)

Model 7

1487.1 (49.4)

1479.6 (45.6)

-6.6 (5.4)

-8.3 (5.3)

Note: LOO: leave one out information criteria; WAIC: Widely Applicable Information
criteria; pd: effective number of parameters; SE: standard error; Δ: change

Bayesian Path Analysis results by outcome
Table 4: AMH
Predictor

β

95% CI

Standardized
estimate
SC Intercept
4.138
-10.39, 18.81
0.133
SC Slope
5.260
-7.14, 18.28
0.082
PSS
-5.020
-10.93, 1.58
-0.287
Hair Cortisol
3.757
-2.43, 10.57
0.214
BMI
1.955
-4.65, 8.29
0.112
Age
-5.664
-12.37, 1.18
-0.312
Age at diagnosis
-5.187
-11.86, 1.86
-0.289
Age at menarche
2.996
-3.77, 9.32
0.172
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval
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Table 5: FSH
Predictor

β

95% CI

Standardized
estimate
SC Intercept
1.040
-6.31, 8.45
0.233
SC Slope
0.286
-5.60, 6.61
0.031
PSS
-1.332
-2.47, -0.05
-0.530
Hair Cortisol
0.381
-0.93, 1.65
0.151
BMI
0.294
-0.99, 1.54
0.117
Age
0.153
-1.22, 1.51
0.058
Age at diagnosis
0.113
-1.32, 1.52
0.044
Age at menarche
0.571
-0.77, 1.70
0.228
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval

Table 6: LH
Predictor

β

95% CI

Standardized
estimate
SC Intercept
2.259
-8.73, 13.95
0.387
SC Slope
2.802
-7.85, 10.18
0.233
PSS
-0.537
-2.08, 1.04
-0.164
Hair Cortisol
0.814
-0.88, 2.87
0.247
BMI
-0.384
-2.40, 1.65
-0.117
Age
-0.430
-2.48, 1.46
-0.126
Age at diagnosis
0.857
-1.34, 2.87
0.254
Age at menarche
-0.091
-1.67, 1.55
-0.028
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval

Table 7: E2
Predictor

β

95% CI

Standardized
estimate
SC Intercept
0.140
-13.51, 14.35
0.000
SC Slope
1.065
-13.37, 14.36
0.001
PSS
0.749
-12.59, 14.75
0.003
Hair Cortisol
-0.535
-14.05, 13.34
-0.002
BMI
0.589
-13.15, 13.94
0.002
Age
-0.100
-14.03, 13.36
-0.000
Age at diagnosis
-0.960
-14.56, 12.92
-0.004
Age at menarche
-1.115
-14.54, 12.86
-0.005
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval
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Table 8: Correlation between predictors
SC Int

SC Slp

PSS

Hair C

BMI

Age

Age dx

Age Mn

SC Inte 1
SC Slp

0.045

1

PSS

0.021

0.082

1

Hair C

0.054

-0.035

0.006

1

BMI

0.001

-0.067

0.081

-0.051

1

Age

0.036

0.155

-0.027

-0.019

0.055

1

Age dx

-0.052

0.002

-0.083

0.111

0.023

0.120

1

Age Mn -0.011
0.043
0.002
0.009
-0.100
0.064
0.010
1
Note: Abbreviations: SC Inte, salivary cortisol intercept; SC Slp, salivary cortisol slope;
PSS, Perceived Stress Scale; Hair C, Hair cortisol; BMI, Body Mass Index; Age dx: Age
at diagnosis; Age Mn, Age at menarche; CI, credible interval

Table 9: Residual correlation between outcomes
AMH

E2

AMH

1

E2

-0.069

1

FSH

-0.186

-0.108

FSH

LH

1

LH
0.173
0.192
0.059
1
Note: Abbreviations: AMH, Anti-Müllerian Hormone; E2, Estradiol; FSH, Follicle
Stimulating Hormone; LH, Luteinizing Hormone
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APPENDIX D: INSTRUMENTS

Study Checklist
Please write the name of person completing and the date completed:
Item
Consent form
Minimum data set
Saliva Cortisol 1
Saliva Cortisol 2
Saliva Cortisol 3
Saliva IL-6
Hair Sample
Demographic Sheet
Perceived Stress Scale

Name of person completing

Date
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DEMOGRAPHIC QUESTIONAIRRE
(Please check or fill in the answer)
1. What is your age? _____________
2. What is the highest level of education you have completed?
o Primary school
o Secondary school
o University
o Postgraduate studies
3. What is your ethnic origin?
o Asian
o Indian
o Pakistani
o Black
o White
o Mixed
o Other
o Prefer not to say
4. What is your country of origin?
_____________________________
5. What is your current marital status?
o Married
o Living with someone
o Divorced
o Separated
o Single
o Widowed
o Prefer not to say
6. What is your sexual orientation?
o Heterosexual
o Bisexual
o Gay woman/lesbian
o Other
o Prefer not to say
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7. What best describes your current employment status?
o Employed full time
o Employed part time
o Homemaker
o Unemployed
o Student
o Other
8. Which of the following best describes the area you live in?
o Urban
o Suburban
o Rural
9. What is your current household income in GBP?
o Under £10,000
o £10,000-£19,999
o £20,000-£29,999
o £30,000-£39,999
o £40,000-£49,999
o £50,000-£59,999
o £60,000-£75,999
o £76,000-£99,999
o £100,000-£150,000
o Above £150,000
o Prefer not to say
10. How many people besides you live in your household?
o None
o 1
o 2
o 3
o 4 or above
11. Do you have any children?
o Yes
o No
o Prefer not to say
12. If you have children, how many do you have?
o N/A
o 1
o 2
o 3
o 4 or more
o Prefer not to say
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Perceived Stress Scale-10
Instructions: This set of questions is about your feelings, thoughts, and activities
over the last month. Please give one answer for each question. Possible
responses are never, almost never, sometimes, fairly often, and very often.
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Perceived Stress Scale Scoring
PSS-10 scores are obtained by reversing the scores on the four positive items, e.g.,
0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4,5, 7, and 8 are the
positively stated items.
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Saliva Collection Instructions:
1. General: Please avoid sample collection within 60 minutes after eating a
major meal or within 12 hours after consuming alcohol. Ten minutes
before the sample is collected, please rinse your mouth thoroughly with
water.
2. You will have four saliva collecting tubes. Three are for cortisol (marked
with an orange sticker) and one is for IL-6 (marked with a blue sticker).
3. Saliva tubes marked with an orange sticker will also be numbered. The
numbers indicate the order in which the samples should be collected:
a. Orange #1: This sample should be collected on the night prior to
the study visit just before you go to bed.
b. Orange #2: This sample should be collected on the morning of the
study visit immediately after waking up, before getting out of bed.
c. Orange #3: This sample should be collected 30 minutes after the
second sample.
d. Blue: This sample should be collected immediately after the third
sample.
4. To collect the sample, unwrap the oral cotton swab and place it
underneath your tongue.
5. After collecting the samples, write your study ID, date, and time of
collection on each tube.
6. Double-bag the samples in the sealable plastic bags that are provided and
place them in the refrigerator until you come in for your study visit.
7. Bring the samples to the study visit and give them to the research nurse.

221

Subject ID:

Saliva Sample Handling
Saliva Sample

Date collected

Time collected

Cortisol 1
D D M

M

Y

Y

Y

Y

H H M M

D D M

M

Y

Y

Y

Y

D D M

M

Y

Y

Y

Y

H H M M

D D M

M

Y

Y

Y

Y

H H M M

Cortisol 2
Cortisol 3
IL-6

H H M M

Time sample spent at 40c awaiting centrifuge processing
prior to freezing

Days

Handing by Queen’s Medical Research Institute
Add contact info
Total volume of saliva sample after centrifuge
Cortisol 1

mL

Cortisol 2

mL

Cortisol 3

mL

IL-6

mL

Date and time into -80ºC
D D M

Number of Freeze-thaw cycles:

M

Y

Y

Y

Y

H H M M

Reason:…………………………………
……………………………………………
……………………………………………
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Hair collection instructions
1. Collect approximately 1cm width hair section from posterior vertex region.
Place scissors as close to the scalp as possible.
2. Secure hair sample with thread provided (indicating proximal end).
3. Place hair sample in aluminum foil provided with the proximal end of the
sample on the side of the foil marked “top”.
4. Fold the aluminum foil to ensure sample is covered.
5. Place sample wrapped in aluminum foil in the plastic bag provided.

Figure 1. Hair sampling from posterior vertex region.
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Hair Sample Handling
Date collected
Hair Sample
Length of sample

D D M

M

Y

Y

cm

Has subject ever dyed hair (yes or
no)

YES / NO

If so, how recently?

_________________

Time collected
Y

Y

H H M M
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Minimum Data Set: Please ensure the following clinical data is collected if not
already available in the participant’s medical records.
1. Diagnosis ___________________________
2. Age at diagnosis ____________________
3. Treatment Type: ___________________
a. Chemotherapy: YES / NO
b. Radiotherapy: YES / NO
4. Age at completion of treatment: _________________
5. Comorbidities
a. ____________________
b. ____________________
c. ____________________
d. ____________________
6. Chronic symptoms (post treatment)
a. ____________________
b. ____________________
c. ____________________
d. ____________________
7. Prescription medications
a. ____________________
b. ____________________
c. ____________________
d. ____________________
8. Age at menarche: _____________________
9. Average menstrual cycle length before treatment: __________________
10. Average menstrual cycle length after treatment: ____________________
11. Date of last menstrual period: ______________________________
D D/ M

12. Parity: ________________
13. Weight: _______________
14. Height: ________________
15. BP: ________________

M / Y

Y

Y

Y
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APPENDIX E: PATIENT INFORMATION SHEET

Dear _______________ (name of patient),
You are receiving this letter because you may be eligible to participate in a
research project examining the effect of Chronic Stress on Reproductive
Function (CSRF) in female cancer survivors. Our knowledge of factors that
contribute to reproductive problems in cancer survivors is incomplete. We know
that stress inhibits reproductive function, and we would like to examine the extent
to which it may contribute to reproductive problems in cancer survivors. In this
way, if we find that stress contributes to reproductive problems, we can integrate
stress reduction techniques into reproductive heath care in cancer survivors.
Thank you in advance for taking the time to read through the study description.
Feel free to contact us to discuss it further or request more information before
making your decision. If you agree to be contacted regarding the study, please
return the reply slip at the bottom of this letter, either electronically or by using
the stamped envelope provided.
Yours sincerely,
Richard A Anderson
Principal Investigator
-----------------------------------------------------------------------------------------------------------I have read the enclosed patient information sheet explaining the study, “Effect of
Chronic Stress on Reproductive Function in Female Cancer Survivors.”
I am interested in taking part: please contact me with further
information
Please do not contact me with further information about the study
Signature: ________________________ Date: _________________
Name:
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Effect of Chronic Stress on Reproductive Function in Female Cancer
Survivors
Participant Information Sheet
What is the purpose of this study?
The main purpose of this study is to explore the influence of chronic stress on
reproductive function in females following treatment for childhood cancer.
Reproductive function is measured by a blood test, and this is done as part of
your normal care. Chronic stress will be measured by a brief questionnaire
assessing perceived stress over the past month and hair and saliva samples to
assess cortisol levels (a hormone released as part of the body’s stress response)
and IL-6 levels (released as part of the body’s inflammatory response to stress).
Do I have to take part?
It is entirely your decision whether you would like to take part in this study or not.
If you decide to take part, we will ask you to sign a consent form and we will ask
you to keep a copy of this leaflet.
If you decide not to take part, it will not affect your medical care. Even after you
have decided to take part, you are free to withdraw and you need not give us a
reason for withdrawal.
What will happen to me if I decide to take part?
If you decide to take part, we will schedule a brief 30-minute visit to collect study
data.
Before the study visit, you will receive a saliva collection kit with detailed
instructions on how to collect the saliva samples. We will ask you to collect four
saliva samples in total. We will ask you to collect one sample on the night before
the study visit and the remaining three on the morning before you come in for
your visit. We will ask you to bring the saliva samples to the study visit.
During the visit, we will ask you some short questions about your medical history
and collect a small hair sample from the back of your head. We will also ask you
to fill out a brief questionnaire about your stress over the past month. The whole
visit should take no more than half an hour.
No drugs or extra blood tests are involved in this study.
What do I need to do?
If you agree to participate in this study, we will arrange a suitable date for your
visit.
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What are the side effects of any treatment when taking part?
Collecting hair and saliva samples can be a little uncomfortable; any discomfort
will be minimized as much as possible.
What are the possible disadvantages and risks of taking part?
We do not expect any disadvantages or risks from taking part in this study.
What are the possible benefits of taking part?
By taking part in this study, you may learn more about your current reproductive
status and your stress levels.
What if new information becomes available?
We will continue to look at emerging studies from across the world in this field. If
any new information that is relevant to this study becomes available, we will
review the study in consultation with the Ethics Committee.
What if something goes wrong?
If you have a concern about any aspect of this study, you should ask to speak
with the researchers who will do their best to answer your questions. If you
remain unhappy and wish to complain formally, you can do this through the NHS
Complaints Procedure. Details can be obtained from the hospital.
In the event that something does go wrong and you are harmed during the
research study there are no special compensation arrangements. If you are
harmed and this is due to someone's negligence then you may have grounds for
a legal action for compensation against The University of Edinburgh but you may
have to pay your legal costs. The normal National Health Service complaints
mechanisms are available to you.
Will my taking part in the study be kept confidential?
With your permission, we will let your GP know that you are taking part in this
study. If we find any abnormalities, we will discuss this with you and if necessary,
refer you to your GP or a specialist.
We will keep your participation in this study and all related information
confidential. All information that is recorded or sent to our colleagues (e.g:
laboratory staff) will be labeled with a unique reference number. Your name,
address and any other identifying information will be removed.
If at any point during the study you should lose the capacity to provide consent,
you will be withdrawn from the study and no further data will be collected from
you. Data already collected while you were able to provide consent will be
retained.
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What will happen to the results of the research study?
Once we have analysed all the results, we will write one or more papers, which
will be submitted to medical research journals for publications. Your personal
details will not be included in any of these. After completion of the study, a lay
summary of the study’s findings will be available upon request from the clinical
team looking after you.
What will happen to my saliva and hair samples after the study is
completed?
Samples will be stored for up to 5 years in the Queen’s Medical Research
Institute at the University of Edinburgh for use in further research studies, which
would require additional ethical approval. It is possible that we may work with a
commercial organization in analyzing your samples, but you will not receive
compensation should the samples have commercial value.
Who is organizing and funding the research?
This study is funded by the Medical Research Council, a publicly funded UK
organization.
Who has reviewed this study?
The study has been reviewed by the South East Scotland Research Ethics
Committee
Contacts
Research team:
Professor Richard Anderson
MRC Centre for Reproductive Health
University of Edinburgh
47 Little France Crescent
Edinburgh EH16 4TJ
Phone: 0131 2426386
E-mail: richard.anderson@ed.ac.uk
Professor Hamish Wallace
Paediatric Oncologist
Royal Hospital for Sick Children
9 Sciennes Road
Edinburgh EH9 1LF
If you wish to speak to someone not involved in the study, please contact:
Dr Angela Edgar,
Consultant Paediatric Oncologist
Royal Hospital for Sick Children
17 Millerfield Place
Edinburgh EH9 1LF
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Tel: 0131 2420425
NHS complaints contact:
NHS Lothian Complaints Team
2nd Floor
Waverley Gate
2-4 Waterloo Place
Edinburgh
EH1 3EG
Tel: 0131 465 5708
Email: craft@nhslothian.scot.nhs.uk
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APPENDIX F: CONSENT FORM

CSRF

Consent Form
Patient Identification Number:
Effect of Chronic Stress on Reproductive Function in Female Cancer Survivors
Please initial to confirm
1. I confirm that I have read and understand the information sheet dated 16 July 2015
(version 2) for the above study.
2. I have had the opportunity to consider the information, ask questions and have had these
answered satisfactorily.
3. I understand that I will provide saliva and hair samples and answer some questions
regarding my stress level over the past month as part of the research study.
4. I understand that relevant sections of my medical notes and data collected may be looked
at by individuals from the regulatory authorities and from the Sponsor(s) (NHS Lothian and
the University of Edinburgh) or from the/other NHS Board(s) where it is relevant to my taking
part in this research. I give permission for those individuals to have access to my records.
5. I agree to my GP being informed of my participation in the study.
6. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, without my medical care or legal rights being affected.
7. I consent to hair, and saliva being stored in a secure facility for use in future related
ethically approved studies, which may include transfer to other academic or commercial
collaborators. I understand that a unique number will identify all samples to ensure
confidentiality.
__________________________ ______________ __________________________
Name of Participant
Date
Signature
________________________
______________ __________________________
Name of Person taking consent Date
Signature
(if different from researcher)
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Original (x1) to be retained in site file. Copy (x1) to be included in patient notes. Copy
(x1) to be retained by the participant.

